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Prevalence and Prediction of Serious Bacterial Infection in
Febrile Children: A Role for Cytokines?
Background: To date, no consensus has been reached regarding the evaluation and
management of young febrile children, and no single laboratory test has been shown to
reliably identify young children at high or low risk of having serious bacterial illness.
Knowing the local prevalence of SBI is essential in formulating management strategies
because extrapolation from studies done elsewhere is difficult.
Aims: i) To determine the prevalence of SBI in young febrile children served by a
paediatric hospital. Ii) To evaluate the role of cytokines in predicting SBI in these
children.
Hypothesis: IL-6, IL-8 and sICAM-1 can accurately predict SBI in young febrile
children.
Methodology: The study population was children seen at the emergency department of
the Edinburgh Royal Hospital for Sick Children. All children <5 years old with a
temperature of >38.5°C were studied over a 12-month period. Demographic, clinical and
laboratory data were collected prospectively. Serum IL-6, IL-8 and sICAM-1 were
measured by ELISA. The performance characteristics of the cytokines in predicting SBI
were compared to those of the traditional tests (WBC, ANC, CRP, ESR).
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Results: 618 patients fulfilled the study criteria of age and temperature. 26.7% of the
patients had a SBI. The commonest SBI was pneumonia. 2.7% of blood cultures were
positive, over half were streptococcus pneumoniae. 40% of positive blood cultures were
from patients discharged with an apparently benign illness. The modest gain in the post-
test probability of SBI was comparable between the cytokines and the traditional tests.
Serum IL-6 and IL-8 was elevated in all patients with bacteraemia or meningitis. A
model based on the respiratory rate, CRP, and sICAM-1 correctly identified 70% of SBI.
Conclusion: The prevalence of SBI, and bacteraemia, in young febrile children is still
high in spite of the decline in immunizable diseases. Highly febrile young children
should continue to be evaluated with a blood culture and close follow up, and UTI
should be excluded in all infants. IL-6 and IL-8 appear to be sensitive markers for
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A study of the prevalence of serious bacterial infection in young
febrile children and the role of cytokines in its prediction.
Issues pertaining the management of febrile young children have been reviewed in
this thesis, which has been written in three parts. The first part discusses the prevalence
of serious bacterial infection (SBI) and the controversy surrounding the management of
febrile children. The clinical evaluation and laboratory tools used to identify serious
illness in these patients are outlined. The inflammatory cytokines and their potential role
as markers of illness in febrile children are discussed in the second part. The third part is
a study of the prevalence of serious infection in febrile children seen in the emergency
department of a paediatric teaching hospital. The performance of three cytokines in
predicting serious illness is tested and compared with the conventional markers of
infection.
Hypothesis:
Plasma interleukin-6, interleukin-8 and sICAM-1 can accurately predict SBI in
febrile young children.
Aims:
1. To determine the prevalence of SBI in children <5 years of age attending
A&E with a temperature >38.5 °C.
2. To determine the utility of cytokines (IL-6, IL-8 and sICAM-1) in predicting








Prevalence of Serious Bacterial Infection in Febrile Children
1.1. Febrile illness in children
Clinicians differ in the magnitude of temperature by which they define the
presence of fever in children (Zerr et al. 1999). The upper limit of normal body
temperature has been agreed to be 37.7°C (99.9°F) in adults and 37.9°C (100.2°F) in
children. The lowest and highest (99th percentile) temperature varies with the time of
the day, with the lowest occurring at 6 am and the highest at 6 pm. A temperature of
38.0°C (100.4°F) or greater in the infant or child represents abnormal temperature
elevation or fever (McCarthy, 1995). Paediatric patients experience approximately 4-6
episodes of infectious disease per year during the first 5 years of life (Procop et al.
1997). Of these, fever is one of the most frequently encountered complaints and
accounts for as many as 20% of paediatric emergency department visits (Nelson et al.
1992, Henretig et al. 1996). A similar proportion of total sick child visits in general
practice is also for a febrile illness (Pantell et al. 1980, Wright et al. 1981). In England
and Wales, between 2 and 3 million children attend accident and emergency (A&E)
annually, representing 25% of all A&E attendance. A third of these children present with
an infectious illness (Simons et al. 1999). The highest rate (98%) of GP consultation, the
percentage of registered individuals consulting their GP, in England and Wales is for the
under fives and the commonest reason for these consultations is for infectious diseases
(Polnay, 1993).
Episodes of fever in the first 3 months of life are less common than in the age
range of 3 to 36 months. At times, a young infant may not mount a fever response to an
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acute infection and may even be hypothermic. In one study of 575 patients in the first 2
months of life who were being followed for primary care, only six (1%) developed
fever. In the same clinic, 55 of 390 children (14%) between 9 and 12 months of age
developed a fever (Baker et al. 1993). Furthermore, it appears that young infants react
with lesser degrees of fever than older patients. In another report, only 2 of 149 (1.3%)
consecutive febrile young infants (0-2 months old) had fevers of 40°C (104°F) or more
compared with 26 of 332 (8%) consecutively seen febrile children aged 3 to 36 months
from the same institution {Baker et al. 1989). An increase in the occurrence of fever is
seen between November and March in children aged 3 to 36 months of age, coinciding
with the circulation within the community of acute infections caused by respiratory and
gastrointestinal viral pathogens such as respiratory syncytial virus and rotavirus. There is
also an increase in the frequency of febrile illness in infants younger than 90 days of age
during this period. However, 40% of febrile episodes in these younger patients occur in
July through September, due to the circulation of enteroviruses at that time of the year.
This could also be due to immature thermoregulation predisposing infants to elevated
body temperatures at high ambient temperatures during summer months (McCarthy et
al. 1995).
Acute fever of unknown origin (AFUO) is used to describe a child who develops
high fever of relatively sudden onset, but who displays no localizing signs of infection or
other cause discernible by history. This type of illness accounts for 2-4% of infections in
outpatients of all ages and is an important diagnostic problem especially in young
children {Murray et al. 1981). The majority of children presenting with a febrile illness,
however, have symptoms and/or signs of respiratory tract disease and a virus can be
identified in a third to a half of these patients {Martin et al. 1978). Acute otitis media,
URTI, and viral syndrome are the most common diagnoses made, accounting for more
than 70% of febrile episodes seen in a paediatric accident and emergency department. In
this group of patients a viral aetiology can be implicated in up to 86% of cases, when
investigated thoroughly, with aseptic meningitis being the commonest diagnosis {Krober
et al. 1985, Nelson, 1992). Nevertheless, up to 25% of febrile illnesses show no
localizing signs or symptoms {Wright, et al. 1981) and a significant proportion of these
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patients will have a serious bacterial infection (McCarthy et al. 1982, Dagan et al.
1985, Bonadio et al, 1994, Berger et al. 1996, Kuppermann et al. 1998) (Table 1). It
has been demonstrated that nearly half of serious bacteraemic illnesses are diagnosed as
viral illness when first seen (Forman, 1991).
1.2. Definition of serious bacterial infection
Studies varied widely in what constituted a serious bacterial infection. The
definitions used depend to some extent on the objectives and methodology of the study.
Some authors define SBI as a positive culture of urine, blood or CSF (Pantel et al. 1980,
Bachur et al. 2001). Other studies put more emphasis on the pathophysiology involved
and potential for serious complications {Dagan et al 1985). Bonadio et al, studying
infants aged 8-12 weeks, define SBI as bacterial meningitis, Salmonella enteritis, and
UTI, (positive tests of urinalysis were considered indicative of UTI) excluding
pneumonia {Bonadio et al. 1994). In an earlier study of older children, the same authors
also exclude pneumonia from the definition of SBI {Bonadio et al. 1990). Other authors
also omit pneumonia from their definition of SBI (Anbar et al. 1986). Dagan et al
consider culture-positive purulent otitis media to be SBI, while excluding radiologically
diagnosed pneumonia {Dagan et al. 1988). In an appraisal of the Rochester criteria for
the detection of SBI in febrile infants, Jaskiewicz et al consider pneumonia to be serious
bacterial infection. They define bacterial pneumonia as a focal infiltrate on chest
radiogram in association with a bacterial pathogen isolated from the blood or the
presence of capsular polysaccharide in the urine detected by countercurrent immuno-
electrophoresis {Jaskiewicz et al. 1994). Baker et al consider pneumonia to be SBI only
if cultures of blood or respiratory secretions grow a known respiratory bacterial
pathogen {Baker et al. 1999). The authors of the practice guidelines for the
"Management of Fever without Source in Infants and Children" define SBI as
meningitis, sepsis, bone and joint infections, UTI, pneumonia, and enteritis. No
bacteriological proof of pneumonia is required {Baraff. 1993).
In the era of wide vaccination coverage of previously dreaded infections, such as
those caused by Haemophilus influenzae type B, some meningococcal strains, and more
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recently pneumococci, less emphasis has been placed on bacteraemia while the concept
of systemic inflammatory response syndrome (SIRS) has attracted more attention (Table
2). It is important, nevertheless, to have a specific bacteriological diagnosis in order to
effect prompt and targeted treatment and thus reduce cost and discomfort and also
implement evidence-based preventive measures. Definitive identification of SBI requires
a positive culture of CSF, blood or urine or an identifiable bacterial focus by physical
examination or radiographic testing. However, the reality of clinical practice dictates
that establishing a causative agent for many apparently infectious illnesses is difficult to
achieve and is not always accomplaished. Illnesses managed as bacterial infections
include meningitis with clinical and cytological indicators of a bacterial pathogen,
urinary tract infection, cellulitis, epiglottitis, sinusitis, and osteomyelitis. Other illnesses
are clearly viral, for example measles, varicella, roseola, erythema infectiosum,
herpangina, hand/foot/mouth syndrome, croup, bronchiolitis, and hepatitis. There are,
however, syndromes in which a number of agents may be causative: bacteria, viruses,
mycoplasmas, chlamydiae, or fungi. These include pharyngitis, pneumonia, infectious
diarrhea, and fever in the young child with no focus of infection. In evaluating these
syndromes, epidemiologic and clinical features may be used more frequently than
laboratory testing.
In daily clinical practice, a specific microbiologic diagnosis may not be pursued,
whether an antibiotic is prescribed or not, except perhaps in the highly or persistently
febrile child. Instances when a viral diagnostic evaluation may be worthwhile include; i)
infants at risk for serious disease from RSV or influenza A, where antiviral therapy is a
consideration; ii) infants taking antibiotics where bacterial cultures and antigen detection
tests are negative and demonstration of a viral aetiology might allow earlier
discontinuation of antibiotics; and iii) where knowing the etiology is of prognostic
importance. In an emergency room setting, when it comes to ordering investigations and
deciding upon disposal of the patient, clinical judgment is frequently subjective and
following a standard of management based on evidence-based guideline, if one is
available, is not always straightforward. It is impractical to obtain a precise
bacteriological diagnosis in each and every febrile patient presenting to a busy
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emergency department. To study the incidence of serious bacterial infections, it will not
suffice to obtain blood cultures only, as these will reveal only the minority (2-5%) of
patients who are bacteraemic. Even for hospitalized patients the diagnosis recorded at
discharge is often non-specific and does not necessarily reflect the true status of the
patient. Many such diagnoses are presumptive and the causative organism may not be
mentioned. Diagnoses such as otitis media, tonsillitis and chest or lower respiratory tract
infection, are usually made to reflect the site of symptoms or signs without any
indication of a possible causative organism. These infections can be potentially serious
but are not considered so unless a local or remote septic or reactive complication has
occurred. The middle ear is part of the secretory immune system, where antigens react
with immune cells in its lamina propria to produce local, and systemic, immune
response. Immunoglobulins and chemical mediators of inflammation can be found in
middle ear effusion. Otitis media is associated with elevated levels of circulating
cytokines, and this response can vary among different causative micro-organisms. It has
been demonstrated that the immunologic response and cytokine profile differ between,
for instance, viral and bacterial otitis media (Heinkkinen et al, 1998). Unless
microbiologic diagnosis has been made by myringotomy, which is not routinely
practiced, the inclusion of patients with otitis media can adversely affect the
performance characteristics of any marker of infection that is sought to differentiate
between viral and bacterial causes of infection. Moreover, the clinical diagnosis of otitis
media can on occasion be questioned, as redness of the tympanic membrane can be part
of a simple upper respiratory catarrh or due to excessive crying.
Otitis media is one of the most frequent causes for medical consultations in
children. Up to 40% of clinic visits by children below 5 years are due to acute otitis
media with effusion (AOME) and 5% to 10% of all well child visits result in a diagnosis
of either acute otitis media or otitis media with effusion {Klein et al. 1994). AOME is a
clinically identifiable suppurative disease of the middle ear and is characterized by an
opaque and/or bulging tympanic membrane. Bacterial pathogens can be isolated from
middle ear fluid in approximately two thirds of patients who have AOME. Streptococcus
pneumoniae is found in approximately 30% to 50% of infected middle ears.
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Haemophilus influenzae causes 20% to 27% of all cases of AOME. The majority of
these cases are caused by non-typeable strains, but up to 36% have been caused by type
b, and a quarter of these could be associated with bactaeremia or meningitis. Moraxella
catarrhalis is isolated in approximately 7% to 23% of cases of AOME {Del Beccaro et
al. 1992). Other bacteria reported to cause AOME include: group A Streptococcus,
Staphylococcus aureus, alpha-haemolytic Streptococcus and Pseudomonas aeruginosa.
The rate of bacteraemia in patients with isolated clinical otitis media is comparable to
those in children with no clinically identifiable focus of infection {Shutzman et al. 1991,
Lee et al. 1998). Therefore, it has been advised that otitis media should not be
considered a cause of fever and febrile infants and children with otitis media should be
evaluated for an occult infection {Luszczak et al. 2001). Viruses have also been
associated with AOME and have been cultured or detected by antigens in up to 42% of
children with AOME. The virus isolated most commonly is rhinovirus, followed by
respiratory syncytial virus. Other causative viruses include adenovirus, parainfluenza,
coronavirus, influenza, and enteroviruses {Arola et al. 1990). The microbioligical
diagnosis of AOME rests on obtaining purulent middle ear fluid for culture by needle
tympanocentesis. The most specific symptom of otitis media is otalagia, and clinical
diagnosis is based on the presence of a retracted, dull or bulging tympanic membrane.
Pneumatic otoscopy, tympanometry, and acoustic reflectometry can add objective
evidence to the status of the middle ear but are not available to a physician working in a
busy paediatric emergency room where diagnosis of AOME largely depends on the
appearance of a red tympanic membrane.
The clinical distinction between viral and bacterial pharyngitis is also difficult as
all can cause fever, sore throat, pharyngitis with or without exudate, and enlarged
cervical nodes. Group A beta-hemolytic streptococcus (GABHS) is the major cause of
bacterial pharyngitis, while EBV, adenovirus, the coxsackie A viruses, and HSV are the
major causes of viral pharyngitis. Infections which can be detected by more specific and
easily obtained tests, such as urinalysis and chest radiograph, can also impose
considerable difficulty and confusion in interpretation. Because bacterial aetiology can
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be difficult to establish, the serious nature of the infection is sometimes determined by
the need for interventions such as hospitalization or specific treatment.
1.3. Prevalence of serious bacterial infection
The incidence of all infectious diseases peaks in children in the first four years of
life, and serious infections have the highest rates in the same age group (Van den Bruell,
2006). The prevalence of serious bacterial infections varies between different
populations and universal extrapolation of findings from local studies is therefore
difficult. Comparison between different studies is further complicated by the varying
definitions of SBI between studies, as detailed above. The disease patterns vary between
and within populations with changing demographic characteristics and the continuing
implementation of varied preventive measures, such as newly introduced vaccines. With
elimination of H. influenzae type b and vaccine-serotype pneumococcal invasive
diseases, the incidence of serious bacterial infections in febrile children is likely to
decrease, to the extent that some experts predict current strategies of testing and empiric
antibiotic therapy will become obsolete (Baraff, 2000). However, the current vaccine is
only 90% effective in preventing invasive pneumococcal disease (Black et al. 2000), and
the number of children with fever seen in emergency rooms or in general practice is
unlikely to change (.Klein et al. 2002). Infections caused by pneumococcal serotypes not
in PCV7, Neisseria meningitides, Salmonella spp., group A Streptococcus,
Staphylococcus aureus and gram-negative enteric bacteria will continue to occur,
together with those occurring due to vaccine failure. It follows that infectious disease
presenting as acute febrile illness will continue to be a common cause for hospitalising
children. It is widely realised that a high proportion of such children are unnecessarily
admitted and subjected to stressful and expensive treatment and tests. Therefore, the
challenge of distinguishing the febrile child with invasive bacterial disease, who requires
aggressive therapy, from the febrile child who has a viral infection and requires only
symptomatic therapy, will persist.
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1.3. a. Occult bacteraemia
Occult bacteraemia, defined as a febrile state in which a major pathogen
circulates in the blood for hours to days in temporary balance with the body's immune
defenses {Baron, 1980), occurs in 3-12% of febrile illnesses in young children showing
no focal signs {Schwartz et al. 1982, Anbar et al.l986). Bacteraemia also frequently
occurs in association with the common focal bacterial infections of young children, such
as otitis media {Schutzman et al. 1991). It has been estimated that 10-15% of children
with bacteraemia, if not promptly treated, will develop more serious illness such as
septicaemia, meningitis, pneumonia, osteomyelitis, and septic arthritis {Dagan et al.
1985). The potential for bacteraemia evolving into a serious illness largely depends on
the causative organism {Table 3).Before the introduction of Haemophilus infulenzae
type b (Hib) vaccine, Hib accounted for 25% of occult bacteraemia in young children (3-
36 months) and it caused 42% of the complications identified at follow up {McGowan et
al. 1973, Teele et al. 1975, McCarthy et al. 1976, Hoekelman et al. 1979, Wood et al.
1990, Forman et al. 1991). Hib also caused most cases of bacterial meningitis in this age
group {Barraf 1993, Shapiro et al. 1993). Streptococus pneumoniae caused around 65%
of bacteraemic infections {Forman et al. 1991). In areas where Hib immunisation rate is
high, this once dreaded organism is now almost completely eliminated {Lee et al. 1998).
In Finland {Peltola et al. 1992) and the USA {Lee & Harper, 1998), where Hib
vaccination was introduced in 1986 and 1990 respectively, a large reduction of invasive
Hib disease has been documented. A similar decline has also been witnessed in the UK
after Hib vaccination was introduced in 1992 {Booy et al. 1995). However, meningitis
and other serious illnesses due to Haemophilus influenzae continue to occur in areas and
individuals not completely covered by the vaccine {Luca et al. 2004). Furthermore,
concerns are raised of possible resurgence of invasive disease in the same age group
targeted by vaccination programmes. This has been blamed partly on incomplete
vaccination coverage and partly on the considerable lot-to-lot variation in both the
composition and the immunogenecity of conjugate vaccines. There are also concerns
about the ability of the available conjugate vaccines to provide long-term protection and
the possibility of an increase in the proportions of older children and adults who are
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susceptible to Hib infections due to the reduction in the prevalence of colonization with
Hib in the population. In the United Kingdom, invasive Haemophilus influenzae type b
disease has been increasing since 1998 despite high levels of immunization. Low levels
of protective Hib IgG were found in children, especially those born prematurely, who
had a full primary course of immunization with combined conjugate Hib vaccine
(.Steinhoffet al. 2003).
In the post Hib vaccine era, Streptcoccus pneumoniae accounts for more than
90% of all cases of occult bacteraemia, while Salmonella, Neisseria meningiditis, group
A streptococcus, and group B streptococcus are responsible for the rest (Lee et al. 1998)
(Table 4). The incidence of invasive pneumococcal infections has been estimated as 10
per 100,000 children under 16 years of age and 45.3 per 100,000 children less than age
2, and an increase has recently been observed in some parts of the western world after
the wide use of Hib vaccine (Baer et al. 1995). It has been speculated that this surge
could be related to the disappearance of Haemophilus influenzae type b disease and
changes in the pneumococcal carriage rates among recipients of Hib vaccine. It is
biologically more plausible, however, to suppose that non-serotype b H. influenzae
would be likely to replace Hib in the nasopharynx and cause more frequent invasive
disease. No such change has been recorded in the rate of invasive pneumococcal disease,
or that of non-type-able and type-able Haemophilus influenzae infections (other than
type b) in areas of the United Kingdom where Hib has largely been eradicated (Booy et
al. 1995). The prevalence of invasive pneumococcal disease continues to change with
the recent introduction of conjugated heptavalent pneumococcal vaccine (PCV7).
O'Brien et al reported on the epidemiology of invasive pneumococcal disease before the
introduction of a conjugate heptavalent vaccine. The estimated incidence in children
below 5 years of age was 272 infection episodes per 100,000 child years, with the
highest rate in the 6-11 month old children. Only 60% of isolated pneumococci were
serotypes contained in the pentavalent vaccine (OBrien et al. 2004). Following the
introduction of heptavalent pneumococcal vaccine, a study of highly febrile young
children (2-36 months of age) who were well enough to be discharged from the
emergency department, reported an incidence of occult pneumococcal bacteraemia of
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0.91% {Stoll et al. 2004). Nonetheless, another study has shown a shift in pneumococcal
colonization towards non-vaccine serotypes and an increase in infections with other
virulent organisms after vaccination (Bogaert, et al, 2004). More worrying is the
demonstrated increased prevalence of very-high-level resistant pneumococci (Schrag et
al. 2001).
The incidence of bacteraemia varies among different age groups (Table 5). No
racial, geographic, or socio-economic predictors of bacteraemia have been demonstrated
(Dershewitz et al 1983). Nevertheless, there are many important confounding factors
that affect the reported incidences of occult bacteraemia. Changes in the size of
population, paediatricians' criteria (temperature and age) for ordering blood cultures in
febrile children, culture techniques and the coverage rates of Hib and other vaccines are
some examples. Hospitalized patients may have higher rates of bacteraemia than
outpatients, because hospitalized children may look more ill and often have serious
diseases that are more likely to be associated with bacteraemia. Bacteraemia is rarely
seen in a primary care setting because of the relative infrequency of the condition, the
treatment with antibiotics at the onset of the illness, the policy of obtaining blood
cultures judiciously, and the referral of sick children to emergency rooms hours after
being seen. Thus, findings from studies based in primary care might underestimate the
prevalence of bacteraemia in children seen at hospital emergency departments where a
selected population is represented. The importance of bacteraemia as a cause of acute
fever of unknown origin will diminish as effective vaccines are developed and
effectively used.
1.3. b. Bacterial meningitis
Bacterial meningitis, the most dreaded serious bacterial infection, has the highest
incidence in children younger than 5 years, with over 70% of cases occurring in those
below 2 years of age. The incidence of neonatal meningitis, 0.25-1 case/1000 live births,
remains relatively stable. 30% of newborns with clinical sepsis will have associated
bacterial meningitis (Kumar et al. 2003). S. agalactae, L. monocytogenes and gram
negative organisms cause most of these infections. In children older than 2 months, H.
33
influenzae, S.pneumoniae, and N. meningiditis, account for 90% of bacterial meningitis
(.Baraff, 1993). Meningitis caused by organisms other than these in a child over two
months should prompt a search for an immunological or anatomical abnormality. In
Western Europe, half cases of meningitis are due to S. pneumoniae, a third are caused by
N. meningiditis , while Hib accounts for less than 3% of the cases (Perrocheau et al.
2004). In Eastern Europe, where vaccination with conjugate Hib and meningococcal C
vaccines is not widespread, meningococcal meningitis accounts for two thirds of cases
and Hib causes about a quarter of meningitis in children below 5 years of age (Luca et
al. 2004). In developing countries, where the high cost of the vaccine is a major obstacle
to its mass application, Hib meningitis is still an important public health problem
{Gomez et al. 1998). Before the advent of Hib vaccine, the average annual incidence of
meningitis in the Western countries was 30 to 70 per 100000 {Wenger et al. 1990). H.
influenzae was the most common organism. Currently, the likelihood of Hib meningitis
occurring in a child who has received at least two doses of Hib vaccine approaches zero
{Kaplan et al. 1997). Since the introduction of Hib vaccine, S. pneumoniae has become
the most common cause of bacterial meningitis in this age group. The annual incidence
of meningitis in children under 5 years of age in the United States has been relatively
stable for N. meningiditis (4-5/100,000) and S. pneumoniae (2.5/100,000) since 1980.
Seven of the 84-pneumococcal serotypes (4, 6B, 9, 14,18F, 19F, and 23F) account for
80% of invasive disease in children. The universal use of the heptavalent conjugated
pneumococcal vaccine (PCV7) will certainly have an impact on the prevalence of
meningitis in this age group. Group B and C are the most common serogroups of N.
meningiditis causing meningitis in the Western World {Kaplan et al. 1997).
Meningococcal bacteraemia has the highest propensity to cause meningitis {Table 3).
The mortality and morbidity of bacterial meningitis vary with the etiologic
organism. For instance, the estimated mean probability of mortality for H.influenzae is
3.8%, for N.meningditis 7.5% and for S.pneumoniae 15.3% {Baraff and Schringer
1993). Pneumococcal meningitis has a particularly high rate of neurological
complication. In a multi-centre surveillance involving eight children's hospitals in the
United State, Arditi et al reported 25% and 32% incidence of motor deficits and
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moderate to severe hearing loss, respectively, among the survivors of pneumococcal
meningitis (Arditti et al. 1998). The most common serotypes of S.pneumoniae recovered
from children with meningitis were the same as those isolated from children with other
systemic infection, many of which are not included in the heptavalent pneumococcal
vaccine. There was also a high rate of resistance to penicillin (19.3%) and ceftriaxone
(7.2%). Because of this organism-specific variation in sequelae, the substantial reduction
in H.influenzae infections may not lead to as striking a reduction in the incidence of
neurologic sequelae of this disease.
1.3. c. Urinary tract infection
UTI is the most common occult SBI in young febrile children seen in a paediatric
emergency unit occurring in between 7% and 11% of the patients (Roberts et al. 1983,
Krober et al. 1985, Bauchner et al. 1987, Pulliam et al. 2001), and is frequently seen
with associated bacteraemia; especially in young infants (Crain et al. 1990, Jaskiewicz
et al. 1994, Craig et al. 1998). In spite of its frequency and potential severity, UTI is
often felt to be a simple problem. It is important to identify children with UTI among
those who present with fever to institute early treatment and evaluate their renal tract
and watch for recurrence of infection, because the risk of renal damage increases as the
number of recurrences increase. Up to 50% of young children with their first episode of
UTI can be expected to have an underlying urinary tract abnormality (Rickwood et al.
1992, Zamir et al. 2004). Proper evaluation of UTI will provide the opportunity to
prevent kidney damage and consequent complications. On the other hand, it is critically
important to use proper criteria to diagnose UTI to avoid the risks of over-diagnosis;
repeated patient visits, use of antimicrobials, exposure to radiation, and excessive costs.
The prevalence of UTI varies by age and sex. In the newborn period,
approximately 1-2% of both girls and boys can be expected to develop UTI. In young
febrile infants <2 months old, the prevalence of UTI is similar in infants evaluated for
sepsis, those suspected of UTI and infants with other illnesses and no suspected UTI
(.Hoberman et al. 1993). The prevalence of UTI in children younger than 2 years of age
with fever without source is high, around 5%. The prevalence in girls younger than one
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year of age (6.5%) is twice that in boys (3.3%). Between one and two years, the
prevalence in girls is 8.1%, and in boys it is 1.9%. The rate in circumcised boys is low,
0.2%-0.4%, but it is 5 to 20 times higher in uncircumcised boys (.Bergman et al. 1999).
UTI in children younger than 2 years warrants special attention because they are at
higher risk for UTI, they show no symptoms referable to the urinary tract, are more
likely to have factors predisposing them to renal damage, and they are at higher risk of
developing renal scarring from an episode of UTI. The incidence and severity of VUR
are greater in this age group, with the most severe form (intrarenal reflux or pyelotubular
backflow) virtually limited to infants (Woodard et al. 1976).
Although the management of UTI is seemingly straightforward, there exists a
considerable variation in the methods of diagnosis, treatment and evaluation of children
with UTI. UTI has been defined, variably, as urethritis, cystitis, or pyelonephritis.
Urethritis is dysuria, frequency or enuresis with pyuria, but colony count of <104 /ml of
urine. Cystitis is as above, with a colony count of > 104 /ml of urine. Haematuria may be
present, but no casts, flank pain, fever, or systemic toxicity. Pyelonephritis is febrile
UTI, often with flank pain and symptoms of cystitis. The colony count may be <105 /ml
of urine. No diagnostic test except the radionuclide renal scan has been shown to
distinguish cystitis conclusively from pyelonephritis. Indirect tests for localisation of the
site of UTI, such as a reversible defect in the renal concentrating ability and high levels
of antibody titres to the infecting E. coli, and non-specific tests of inflammation, such as
elevated WBC or CRP, do not provide confirmatory evidence that the febrile young
child with UTI has pyelonephritis. Fever as a marker of pyelonephritis (defined by a
positive scan) provides a wide range of sensitivity (53% to 84%) and specificity (44% to
92%) (Bergman et al. 1999). Nevertheless, the presence of fever in a child with
bacteruria and pyuria has been accepted as a marker of renal parenchymal involvement
(pyelonephritis) (Johnson et al. 1999) and indicates an increased frequency of
underlying urinary tract abnormalities (.Roberts et al. 1983, Woodard et al. 1976).
The symptoms and signs of UTI are usually non-specific in young children and
vary with age. In the newborn, late-onset jaundice, hypothermia, signs of sepsis, failure
to thrive, vomiting, and fever are possible signs of UTI. In infants and preschool
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children, additional findings include diarrhoea and strong-smelling urine. The school-
age child is more like the adult in terms of signs and symptoms of UTI, but enuresis,
strong-smelling urine, and vomiting may be holdover features from the younger age
group. Other historic findings that should be sought include voiding problems and
family history of UTI or proven vesico-ureteric reflux.
Laboratory tests useful in diagnosing UTI include urinalysis and urine culture but
it is important to focus on the technique of urine collection (The Royal College of
Physicians, 1991). Commonly used methods of urine collection in young children
include clean catch specimen (Ramage et al. 1999), sterile adhesive bags (Waddington et
al. 1997), urine collection pads (Feasey et al. 1999, Macfarlane et al. 1999), and urine
collection from disposable nappies (Ahmed et al.l991) and sanitary towels (Vernon et al.
1992). These methods have been reported with variable parental acceptance, success and
contamination rates (Lewis et al. 1998, Vernon et al. 1995, Roderck et al. 1997, Liaw et
al. 2000, Giddens et al. 1998). In children, clean-catch midstream specimens are often
contaminated, especially in girls by some vaginal reflux of urine. Midstream specimens
in circumcised males are more reliable. Bag urine specimens are frequently
contaminated in both males and females and are not recommended for use in the
diagnosis of symptomatic patients who may have UTI. The combination of a 5%
prevalence of UTI and a high rate of false positive results from bag urine (specificity of
70%) results in a positive culture of urine collected in a bag to be a false-positive result
in 85% of the time {Bergman et al. 1999). The false-positive rate would be 93% in
febrile boys and 99% in circumcised boys, who have 2% and 0.2% respective prevalence
of UTI. If taken, bag urine specimens are useful only when negative, provided no prior
antimicrobial treatment has been received. Transurethral catheterization does not
eliminate completely the possibility of contamination in girls and uncircumcised boys.
SPA has been considered the gold standard for obtaining urine. However, technical
expertise and experience are required, with a variable success rate (23% to 90%), and
many parents and physicians perceive the procedure as unnecessarily invasive. Decision
analyses and cost-effectiveness studies based on different age and gender prevalence of
UTI have shown that it is cost-effective to pursue the diagnosis of UTI by invasive
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means and to perform imaging studies in girls and uncircumcised boys younger than 2
years of age. The evidence is equivocal for circumcised boys younger than one year, but
it is generally held that they deserve the same diagnostic evaluation. Invasive diagnostic
procedures are not justified in circumcised boys older than 1 year with unexplained
fever. Analysis of bag urine is a reasonable screening test in these boys, as long as they
do not appear so ill as to warrant the initiation of antimicrobial treatment. Those who
will be given antimicrobials on clinical grounds should have a specimen obtained for
culture that is unlikely to be contaminated (.Bergman et al. 1999).
Commercial test strips are used for rapid urine testing for infection. These utilize
colour indicators that detect nitrite, leucocyte esterase, and blood. The nitrate test is the
most specific for UTI and is based on the principle of nitrate being converted to nitrite in
the bladder by bacteria. Therefore, it is best done on first-morning or concentrated urine
specimens where the bacteria have had sufficient opportunity (4 to 6 h) to metabolize the
nitrate to nitrite in the bladder. Urine analysis is the best tool to identify patients who
might need treatment and further investigation and, in practice, most clinicians would
treat any febrile child who has positive findings on urinalysis, before culture results are
available. However, the sensitivity of the test is so low that the risk of missing UTI is
unacceptably high (Table 6). Microscopic examination of unspun urine is a simple, rapid
and practical diagnostic method and, when combined with a Gram stain, is highly
predictive of UTI and allows immediate initiation of treatment (Hoberman et al. 1993).
Microscopic analysis of a centrifuged urine specimen looking for white blood cells or
bacteria is also an indirect evidence of UTI. A bacterial count under high power
objective of >100 bacteria per field corresponds to >103 cfii/mL. However, neither
bacteruria nor pyuria are sensitive or specific enough (Table 6).
It has been suggested that, in febrile children, significant sterile pyuria should not
be dismissed as a nonspecific response to fever but should be considered as UTI in the
absence of an alternative explanation, and should be investigated accordingly, as up to a
third of such patients can have an underlying urological abnormality (Buys et al. 1994,
Giddens et al. 1998). The diagnostic utility of pyuria alone for identifying true UTI has
been quoted as 96% sensitive, and 95% specific, the 4% false negatives being attributed
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to early UTI (Hoberman et al. 1996). Furthermore, it has been shown that urine culture
guided by urinalysis was the most cost-effective strategy in the management of febrile
children (Kramer et al. 1994). However, pyuria can occur in the absence of UTI and can
occasionally be absent in patients with confirmed urinary tract infection (Kumar et al.
1996, Crain et al. 1990). Turner and Coulthard found moderate pyuria (10-100x 106/l) in
43% and obvious pyuria (100-700xl06/l) in 9% of febrile children without UTI. They
demonstrated that pyuria was the result of an increase of urinary leucocyte excretion and
not a direct reflection of a raised blood neutrophil count (Turner & Coulthard\ 1995).
Therefore, urinalysis can only suggest the diagnosis of UTI. No element of the urinalysis
or combination of elements is as sensitive and specific as urine culture, which is the
standard test for the diagnosis of UTI. A properly obtained urine specimen that has not
been left at room temperature for more than 30 minutes should be submitted for culture.
Urine usually is cultured by inoculating a small volume into culture media, or using the
dipslide technique that permits inoculation of urine on agar media in the general practice
setting. The latter technique has a reported sensitivity in the range of 87% to 100%, and
specificity 92% to 98% (Bergman et al. 1999). Criteria used for the diagnosis of UTI in
adults include symptoms plus pyuria on urinalysis plus a single clean-catch urine
specimen that grows greater than 105cfu/mL of a single organism. This definition cannot
be applied in children who often do not have the classic symptoms of UTI and pyuria
may not be present in up to 50% of children who have proven UTI and often is present
in those who do not have UTI.
I. 3. d. Pneunomia
Pneumonia accounts for 13% of all infectious illnesses in the first 2 years of life
{Denny & Clyde, 1986). In the US, the annual attack rates of pneumonia are 4 cases/100
preschool children, 2/100 children in the 5-9 age group, and 1 case/100 in older children
{Sherman J, 2004). WHO estimates that 3 million children die worldwide from
pneumonia each year. Although most of these fatalities occur in developing countries,
pneumonia remains a significant cause of morbidity in industrialized countries. Occult
pneumonia, i.e. without clinical signs indicative of chest infection, is a common
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occurrence in febrile young children (Leventhal et al.1982, Bachur et al. 1999). The
conjugate pneumococcal vaccine is estimated to reduce clinical pneumonia by 10%,
radiographic pneumonia by 32% and pneumonia with definite consolidation by 73% and
may reduce the need for chest radiography in febrile children with no clinical signs of
pneumonia (Black et al. 2000).
The clinical diagnosis of pneumonia is suggested by a constellation of symptoms
such as fever, cough, and tachypnoea. More specific pointers are sought in the physical
findings of respiratory distress (grunting, flaring and retractions) and consolidation
(dullness on percussion, rales, bronchial breathing, aegophony and whispering
pectoriloquy). As these clinical signs are often derived from examining hospitalized or
very ill patients, they may not be as useful in ambulatory patients who are less likely to
show all, or any, of the signs. These signs, besides being difficult to illicit in young
children, lack sensitivity and specificity in detecting pneumonia. Signs suggestive of
pneumonic consolidation, such as crepitations, are frequently detected in patients with
bronchiolitis. Tachypnoea is considered the best clinical sign distinguishing pneumonia
from uncomplicated upper respiratory tract infection (Harari et al. 1991). Signs of
decreased breath sounds and rales are detectable in 46% and 55%, respectively, of
children with pneumonia (Tan et al, 1998). However, many children who have
pneumonia, including those with bacteraemic pneumococcal pneumonia, can have no
respiratory symptoms or signs and present with non-specific symptoms.
Pneumonia appears as an opacity (or opacities) on the chest x-ray film, meaning
that a large number of pathologic processes may mimic pneumonia radiographically.
Furthermore, the radiographic definition of pneumonia and interpretation of chest
radiographs vary widely among radiologists. This variation might not be important in
routine clinical practice but is a cause of great confusion and inaccuracy in clinical
research. In a study of the effect of chest radiograph on the pre-x-ray diagnosis and
management, Alario et al classified a CXR as normal or abnormal (hyperaeration,
peribronchial thickening, patchy or peribronchial infiltrates, subsegmental or segmental
infiltrates, atelectasis, lobar consolidation, pleural effusion, or other specific
abnormalities) (Alario et al. 1987). Studying the utility of chest radiograph in the
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evaluation of the febrile infant, Bramson et al grouped radiographs into four categories:
Normal CXR; type 0 (normal), typel (hyperinflation). Abnormal CXR; type 2
(hyperinflation plus peribronchial thickening), Type 3 (hyperinflation, peribronchial
thickening and pulmonary infiltrates) (Bramson et al. 1993). Patterson et al considered
focal parenchymal opacification, but not peribronchial thickening, as evidence of lower
respiratory tract infection (Patterson et al. 1990). Zukin et al, classified chest
radiographs as normal, pneumonia, major abnormalities (atelectasis, effusion), or any
abnormality (Zukin et al. 1986). Leventhal et al considered the presence of an infiltrate
positive evidence of pneumonia (Leventhal et al. 1982), while Kramer et al, defined
pneumonia on the bases of the presence of one or more focal areas of consolidation or
infiltrates (Kramer et al. 1992). On the other hand, Bachur et al defined pneumonia as
consolidation reported in definite terms {Bachur et al. 1999). This wide variation in
radiographic characterization and definition of pneumonia makes comparison between
studies a difficult task.
Even within defined categories, there can be considerable inter- and intra-
observer variability in the radiographic diagnosis of pneumonia, a disagreement that
does not improve with increasing experience {Young et al. 1994, Cochrane et all952).
Part of this variation could be due to unblinded radiologists being biased by the treating
physician's clinical suggestions (Kramer et al. 1992). Generally, chest radiographs with
dense lobar or segmental opacities are interpreted as pneumonia whereas patchy
opacities are not considered pneumonia {Young et al. 1994). Although radiographic
appearance is not an aetiologic diagnosis, it has been generally agreed that a lobular or
segmental consolidation suggested a bacterial process, while diffuse or ill-defined
densities and infiltrates suggested a viral process {Tew et al. 1977, McCarthy et al.l981).
Therefore, decisions about therapy are often based on the radiographic appearance, and
in routine clinical practice a focal opacification will usually prompt clinicians to start
antibiotic therapy in the appropriate clinical setting {Patterson et al. 1990). In research
studies, a clinical diagnosis of pneumonia has to be supported by roentgengraphic
findings compatible with pneumonia- the chest roentgenogram is the gold standard.
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The chest radiograph is one of the diagnostic tests most frequently obtained in
the evaluation of young febrile children. Views differ as to the necessity of obtaining a
chest x-ray in this process. Alario et al demonstrated that the chest radiograph resulted in
a change of the pre-x-ray diagnosis in 21% and pre-x-ray management plans in 16% of
the patients (.Alario et al. 1987). Bachur et al found 38 (26%) cases of pneumonia in 146
patients without clinical evidence of chest infection and called for routine chest
radiography in highly febrile children with leukocytosis and no alternative major source
of infection (Bachur et al. 1999). In a series of 330 consecutive children younger than 2
years with high fever, McCarthy et al reported 52 cases of pneumonia, 27 of which were
not clinically suspected (.McCarthy et al. 1990). On the other hand, of 41 patients
without pulmonary findings studied by Leventhal, none had an abnormal CXR. The
authors claim that if the criterion of at least one pulmonary sign had been used to order a
CXR, no case of pneumonia would have been missed, and the number of
roentgenograms would have been reduced by 30% (.Leventhal et al. 1982). Other
workers who found much lower rates of occult pneumonia, also called for the
abandoning of the use of chest radiograph as part of routine septic work up in febrile
infants and young children, to be done only in those who show clinical signs of
pneumonia (Bramson et al. 1993, Zukin et al. 1986, Patterson et al. 1990). Occult
pneumonias do occur, but which children need chest radiography remains unclear. Chest
radiography should probably be performed in the evaluation of febrile young children
with no identifiable source, even in the absence of respiratory symptoms. Such children
could be early in the course of infection, and other children probably offer suboptimal
clinical examinations. The true prevalence of bacterial pneumonia is unknown because
only a subset of children receive a chest radiograph, it is difficult to differentiate viral
from bacterial pneumonia and blood cultures are only positive in 3-5% of febrile
children with pneumonia.
Defining the aetiology of pediatric pneumonia is complex for several reasons.
First, a wide variety of microorganisms can cause pneumonia. Second, epidemiologic,
clinical, and routine laboratory features associated with different organisms can be
similar. Third, specimen for specific bacterial etiology is not easy to obtain. Pneumonia
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is an infection of the terminal air exchange units of the lungs. Procedures such as
bronchoscopy or broncho-alveolar lavage are rarely carried out in routine clinical
practice. It follows that the anatomic differentiation between lower and upper respiratory
tract infection is arbitrary and any organism implication is even more speculative. The
frequently used terms of lower respiratory tract or chest infection are imprecise and do
not help in anatomic or microbiologic characterization of the infection. The
microbiology of pneumonia is protean, encompassing viruses, mycoplasma, chlamydia,
bacteria, fungi, protozoa and metazoa. Extensive testing with cultures, serology and PCR
identify a possible microbiologic cause of pneumonia in only a small proportion of
patients (Claesson et al. 1989 Wubbel L et al. 1999). The commonly encountered types
of pneumonia in routine clinical practice are those caused by viruses, mycoplasma and
bacteria. Most pneumonias in young children, including those with radiographic
evidence of segmental consolidation, are caused by viruses (Stashwick et al. 1981,
Bettenay et al. 1988). Epidemics of viral respiratory infections occur throughout the
year, RSV and influenza predominate in winter while parainflunezae occurs in summer
and autumn (Martin et al. 1978). Whereas serologic methods are used to confirm a
diagnosis of pneumonia caused by viruses, mycoplasma pneumoniae and chlamydia
psittaci, the diagnosis of bacterial pneumonia is usually based on cultures from the blood
or the respiratory tract, or on detection of capsular antigens in respiratory secretions or
urine. Respiratory pathogens may colonize the upper respiratory tract, which creates
problems in interpretation of respiratory secretion cultures. Bacterial antigen detection
tests on urine in children who have pnuemonia may have both false-positive (eg, otitis
media, recent Hib vaccination) and false-negative results. Juven et al studied community
acquired pneumonia in hospitalized children using multiple diagnostic techniques. A
causative agent was identifiable in 85% of the patients; 62% viral, 53% bacterial and
30% with concomitant viral and bacterial infections. Streptococcus pneumoniae was
implicated in 37% of the cases with a single (0.8%) positive blood culture (Juven et al.
2000). Although most pneumonias in infants and children are nonbacterial and do not
need antimicrobial therapy, physicians treat more than 80% with antibiotics because of
the difficulty in defining etiology, parental and community pressures to use antibiotics,
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and the desire not to withhold antibiotics when a potentially serious bacterial infection
could be present (Young et al. 1994). Bacteraemia is rare in community-acquired
pneumonia in developed countries, occurring in only 1-3% of paediatric outpatient
pneumonia cases. However, patients with risk factors, such as immunodeficiency,
neonates or hospitalized children or those from the developing countries have higher
rates of bacteraemic pneumonia (Banya et al. 1996). Bactaeremic pneumococcal
pneumonia is characterized by high fever, leucocytosis, and ill appearance, and the
majority of patients will have lobar or segmental consolidation (Toikka et al. 1999).
 
Table 1: Diagnoses in 305 febrile infants <60 days of age*
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Number % of total
Viral illness 256 83.8
Bacterial illness
Meningitis/Bacteraemiaf 11 3.6
Urinary tract infection 7 2.3
Enteric pathogen 8 2.6
Soft-tissue infection 6 2.0
Total bacterial 32 10.5
Other 17§ 5.5
*Adapted from Caspe et al. 1983.
fOf these 11 patients, two had meningitis and bacteraemia and nine had bacteraemia
only.
§Four (1.3%) had pneumonia.
Table 2: Serious illnesses during 996 episodes of acute infectious illness in
febrile children <36 months of age*
Diagnosis Number %
Bacterial meningitis 9 0.9
Aseptic meningitis 12 1.2
Pneumonia 30 3.0
Bactaeremia 10 l.Of
Focal soft-tissue infection 10 1.0
Urinary tract infection 8 0.8§
Bacterial diarrhea 1 0.1
Abnormal electrolytes,
abnormal blood gas 9 0.9
Total 89 8.9
* McCarthy, 1988.
|Some studies have noted a mean occurrence of bactaeremia of approximately 4% if the
fever is >39°C (102.2°F).




Table 3: Incidence of invasive infection following bacteraemia*:
Organism Severe invasive disease (%) Meningitis (%)
Streptococcus pneumoniae 5.7 3.4
Haemophilus influenzae 22.1 13.9
Neisseria meningiditis 43.5 34.8
*: Steele RW, 2007
Table 4: Organisms isolated from blood in outpatients who have occult
bacteraemia*
1 9 3
Organism Number Number" Number
S pneumoniae 130 23 164
H influenzae type b 29 2 9
Neisseria meningitidis 5 0 2
Salmonella sp 0 2 7
Others 0 0 10
*: McCarthy 1995.
1: Alario AJ et al, 1998
2: Jaffe DM et al, 1991
3: Fleisher GR et al, 1994
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Table 5: Incidence of bacteraemia in febrile children by age.*






*: Steele RW, 2007






Leucocyte esterase 83 (67-94) 78 (64-92)
Nitrite 53 (15-82) 98 (90-100)
Leucocyte esterase or Nitrite positive 93(90-100) 72 (58-91)
Microscopy: WBCs 73 (32-100) 81(45-98)
Microscopy: bacteria 81(16-99) 83 (11-100)
Leucocyte esterase, or nitrite, or microscopy positive 99.8 (99-100) 70 (60-92)




Management of Febrile Children
II. l. A Continuing Controversy
Despite the myriad of reports and attempts to define criteria that predict serious
illness in febrile children, the management of these patients remains a major practice
inconsistency within emergency medicine (Green et al. 1999). In the early seventies,
Mcgowan et al described unsuspected bacteraemia in 4% of apparently well children
brought to an urban walk-in clinic who had a temperature of 38.5°C or higher and no
focus of infection (McGowan et al. 1973). It was then shown that, untreated,
approximately 10% of patients with bacteraemia could be expected to acquire serious
infectious morbidity, including meningitis (Long et al. 1994). Three decades on,
paediatricians still differ widely in the evaluation of young non-toxic-appearing febrile
children and the controversy continues (Baraff~ 2000).
When confronted by a febrile young child, who does not look seriously ill and in
whom no focus of infection is evident, the clinician must make a series of decisions:
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• Whether to hospitalize the child or to observe as an outpatient and what follow-up to
arrange if the child is not admitted.
• Whether to perform diagnostic tests to identify an occult bacterial infection.
• Whether to prescribe empiric antibiotic treatment if no focus of infection is
identified, and what route, oral or parenteral, to use.
As consensus on these issues remains elusive {Kramer et al. 1997), the increasing
complexity of medical care and the desire to control costs and improve quality have led
to a growing use of clinical practice guidelines. One widely recommended approach,
based on meta-analysis of original articles and the opinions of an expert panel, uses risk-
stratification algorithms. The recommendations of this approach are summarized as
follows:
• All toxic-appearing infants and children and all infants under 28 days of age should
be hospitalized for full septic screen and parenteral antibiotic therapy.
• Febrile infants 28 to 90 days of age defined as low risk by specific clinical and
laboratory criteria may be managed as outpatients if close follow-up is assured.
• Older children with fever less than 39.0°C without source need no laboratory tests or
antibiotics.
• Children age 3 to 36 months with fever of 39.0°C or more and whose white cell count
is 15,000/mirf or more should have a blood culture and be treated with antibiotics
pending culture results.
• Urine cultures should be obtained from all boys 6 months of age or less and all girls 2
years of age or less who are treated with antibiotics.
• Low risk criteria in febrile non-toxic looking infants less than 12 weeks old were
defined as:
1. Previously healthy.
2. Having no focal bacterial infection identifiable on physical examination.
3. Having negative laboratory screening:
i. White blood cell count of 5,000 to 15,000/mm3.
ii. Less than 1,500 bands/ mm3.
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iii. Normal urinalysis.
iv. When diarrhoea present, less than 10 WBCs/hpf in stool.
• A sepsis evaluation, when indicated, included:
1. A culture of CSF, blood and urine.
2. A complete blood cell and differential count.
3. Examination of CSF for cells, glucose and protein.
4. A urinalysis obtained by catheter or suprapubic aspiration.
This guideline (Baraff, 1993) was published in the official journal of the American
Academy of Pediatrics in 1993, but it was not officially endorsed by the academy or any
other professional organization. However, because it was developed by authors who
were widely recognized in the field, it was expected to have an important impact on both
clinical practice and health care policy. The guideline was meant to help physicians
navigate the complexity of medical issues and reduce their uncertainty and perception of
liability.
However, years after its publication, there was poor compliance among clinicians
across the specialties concerned with the management of febrile children (Zerr et al.
1999) and many paediatricians have not found it very helpful (Christakis et al. 1998)
and it did not seem to have changed the behaviour of many physicians {Young et al.
1995, Wittier et al. 1998). Reasons for non-compliance included lack of awareness of
the guideline, particularly among family physicians, a perceived negative relationship
with the patient's family when obtaining laboratory tests, feeling that their served
population was different from those in an academic setting, and distrust for clinical
applicability of scientific reports {Zerr et al. 1999). Many physicians rejected such a
resource-intensive approach in favour of the simplicity of clinical judgment alone and
argued that it was based on studies fraught with design and analysis flaws and outdated
data {Manger et al. 1993, Kramer et al. 1997). Many studies, especially those favouring
outpatient antibiotic treatment, were observational which are inherently biased:
• Because they were not randomly assigned, the patients in each group were not
necessarily similar.
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• Some of the untreated children may have an unrecognized focus at the initial
visit e.g. missed pneumonia when no chest x-ray is performed, or red tympanic
membranes dismissed as due to crying or viral catarrh.
• Most of the treated children already had identified foci of infection, so the
"subsequently" identified infections were fewer in this group.
The experimental studies also had drawbacks:
• Many studies analyzed only bacteraemic patients, which on average constituted
only 3% of the patients, and ignored the outcomes in the overwhelming majority
of febrile children, with other serious infections.
• Blood cultures are not 100% sensitive and bacteraemia can be intermittent or
occur late in the course of a febrile illness, so many serious infections may not
have been included in the analysis.
• Some studies included no placebo controls, therefore non-blinding could have
influenced the diagnoses and outcome at follow-up.
• Categorization into definite or probable bacterial infections produced intrinsic
bias.
The evidence from randomized trials does not demonstrate a benefit of either orally
or intramuscularly administered antibiotics in reducing the risk of meningitis or of other
serious bacterial infection (.Kramer et al. 1997, Bauchner et al. 1997). Moreover, these
studies have been performed at single institutions and, therefore, their usefulness may
differ among different medical centres. There were also major differences among studies
that determined risk criteria (see above). These differences, along with the small number
of children with serious illness, resulting in wide confidence intervals, added to the
difficulty in universal applicability of the low risk criteria (.McCarthy et al. 1994). As
there is no valid mechanism of adjusting for these biases in the absence of compelling
evidence, the guideline was considered to reflect the authors' own beliefs and biases
(Schriger et al. 1997). More importantly, the changing epidemiology of infectious
disease, such as the decline in Hib disease and the anticipated reduction in invasive
pneumococcal disease, has the largest impact on the validity of the guideline.
Nevertheless, the guideline is regarded as an evidence-based structured methodical
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strategy that could minimize adverse sequelae from occult infections, save lives and
perhaps lower liability risk. It could also partially compensate for the insensitivity of
clinical examination (Green et al. 1999). The controversy surrounding the guideline may
simply reflect different beliefs that rise from different models of the problem, such as
hospital vs primary care practice (Schriger et al. 1997). The main areas of controversy
will now be discussed in some detail.
ii. I. a. Hospitalisation vs. outpatient treatment
Because febrile young children are at risk for potentially life-threatening
infections and because findings from the outpatient evaluation may be misleading
(Procop et al. 1997), a large proportion of these children are admitted to hospital.
Infectious diseases are the most common reasons for hospitalization among young
children (Soulen et al. 1994, McConnochie et al. 1995). This high admission rate
represents a major use of resources which might be allocated more appropriately to
effective out-patient management of these would-be inpatients. Inappropriate
hospitalization is defined as time during which an inpatient fails to receive clinically
appropriate services. Several studies have shown that a substantial proportion of child
hospitalization is medically unnecessary (.Kemper 1988, Soulen et al. 1994). A large
proportion of children admitted would unnecessarily run the potential risks of
hospitalization (De Angelis et al. 1983). Obviously, there are factors other than the
severity of the medical illness that may affect the decision to hospitalize a child. These
factors include the degree of parental anxiety, parental education, distance from a health
care facility, whether the family has a telephone or a car, and the physician's intuition
about a child or the situation. Lowered thresholds for admission may reflect concerns
about the adequacy of home care, or the level of experience of the attending physician.
Demographic factors have their effect on hospitalization rates. For example, the
increasing numbers of single parent families and the continued high rates of teenage
pregnancy leave little support for children in the community (Goodman et al. 1994).
These factors can be equally as important as medical pathology {McConnochoie et al.
1997). Nevertheless, these factors do not by themselves explain all of inappropriate
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hospital use, nor do they solely account for the vast variation in admission rates among
institutions serving populations of similar social and ethnic make up (.Perrin et al. 1989).
As an example, the study by Soulen et al showed that only 6% of admissions were
identified as social by the admitting physicians (Soulen et al. 1994). There is less
variation in hospitalization rates among hospitals for conditions in which the diagnosis is
certain and admission obligatory, for example bacterial meningitis and appendicitis,
reflecting similar prevalence (Goodman et al. 1994). Meanwhile, hospitalization
practices differ markedly in the face of similar disease severity for illnesses like gastro¬
enteritis, viral illnesses and fever of unknown aetiology, aseptic meningitis and
abdominal pain (Dershewitz et al. 1983, Perrin et al. 1989). Furthermore, there is ample
evidence that much hospitalization is discretionary, and these admissions account for the
majority of the difference in admission rates among hospitals within and between health
districts (McConnochoie et al. 1995). Factors other than funding mechanisms contribute
to inappropriate hospitalization, although the organization of health services and the
availability of hospital beds may also influence rates of hospitalization (Wennberg et al.
1984, Gloor et al. 1993). The growth of ambulatory care has contributed to the lowering
of hospitalization rates (Gloor et al. 1993). Good quality follow-up assures both parents
and physicians of the safe management of children with avoidable hospitalization
conditions (Flores et al. 2003).
Hospitalization is the most expensive component of medical care and accounts
for a large proportion of expenditure for child health care (Kemper et al. 1988). It has
been shown that admission rate, not length of stay, is the primary determinant of this
cost and of decisions determining the use of hospital beds (Wennebrg et al. 1984). Cost-
containment efforts directed at limiting the length of hospitalization may therefore not
reduce inappropriate hospital use. So, in this respect, admission policies are more
important than length-of-stay decisions. Reducing delays in care due to lack of available
inpatient beds is an important goal for health authorities. The financial burden on the
family is also often overlooked when hospitalization is considered. Costs incurred by the
family may include missed workdays, travel expenses, baby-sitting for siblings of the
patient, hotel accommodation, and meals. Hospitalization exposes children to the risk of
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nosocomial infection (.Dashefsky et al. 1983) and of iatrogenic events, such as adverse
drug reactions and unnecessary invasive procedures (»Startwell et al. 1974, Couch et
ail981, Steel et al. 1981). As many as 20% of young febrile infants were found to have
suffered a complication as a result of hospitalization. An appreciable proportion of these
complications occurred in patients who probably did not require hospitalization. In
addition to the therapeutic complications, these infants were also subjected to a large
number of diagnostic misadventures (DeAngelis et al. 1983). Hospital days are
threatening to young patients and disruptive of families. Hospital admission in early
childhood can lead to acute emotional distress, which may persist for some time after the
child returns home (.Douglas et al. 1975). There is also evidence that prolonged or
repeated hospital admission in early childhood can increase the risk of behaviour
disturbance or delinquency in adolescence (<Quinton et al. 1976). Obviously, recovering
at home in a familiar environment is a preferable approach, if possible. Thus, every
admission that is avoided reduces potential morbidity, mortality, and cost created by
nosocomial infections and iatrogenic complications.
One major reason for calling for outpatient management of febrile young
children is the relatively low incidence of serious bacterial infection in these patients
(.Roberts et al. 1983, De Angelis et al. 1983, Krober et al. 1985, Long et al. 1994,
Edwards et al. 1996). Hence, given the iatrogenic complications and cost of unnecessary
hospitalization, most of these children can be safely discharged to home observation
provided close-follow up is ensured. De Angelis reported that a third of febrile infants
younger than two months of age were managed as outpatients and none of these infants
suffered morbidity as a result of not being admitted. The majority of these patients did
not even have a complete septic work up (.DeAngelis et al. 1983). Other studies have
shown, however, that unacceptably high rates of infectious morbidity, and mortality,
occurred in febrile children not hospitalized on the basis of the outpatient assessment
(.Bratton, 1977). Dashefsky reported that half of episodes of meningococcaemia
occurred in febrile patients who were not suspected of having serious invasive disease.
A large proportion of these patients suffered significant morbidity, and a few of them
died (.Dashefsky et al. 1983). Similar outcomes were also reported in patients discharged
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with an obvious clinical diagnosis such as isolated otitis media {Schutzman et al. 1991).
This demonstrates an urgent need in improving the accuracy of our assessment of young
febrile children, to reduce the cost and complications of unnecessary hospitalizations on
one hand, while avoiding the consequences of missing serious disease on the other.
Given the inadequacy of clinical assessment alone, there is certainly a need to develop
some objective tools to aid in this delicate process.
II. l. b. Laboratory testing
Screening laboratory tests are used to assist in determining the extent of the
diagnostic evaluation and to help decide whether empiric antibiotic therapy should be
initiated in patients in whom there is no evident focus of bacterial infection. In a
hospital-based outpatient setting, where physicians caring for children have varied levels
of experience and where follow up may not be consistent, these tests can be useful
adjuncts in the evaluation and management of febrile children (Bennish et al. 1984).
However, studies examining indicators, such as WBC, ESR and CRP, have shown that
these parameters are not helpful in the acute care setting of the emergency department
{Browne et al. 1997). It follows that the greatest area of controversy is the necessity of
performing laboratory studies on the febrile child who appears well and has no
abnormalities on history and physical examination to suggest serious illness {McCarthy
et al. 1997). In this regard, many argue that the guideline, discussed above, reflects a
climate of unnecessarily increased and invasive diagnostic testing:
• The diagnostic tests called for are difficult to obtain for many primary care
practitioners. In addition, the volume of blood required for these tests and the delay in
obtaining results make them impractical.
• The costs incurred in performing these tests are formidable. For instance, routinely
performed, individually inexpensive tests are estimated to account for 25% of costs in
hospital and ambulatory settings. Of routine laboratory procedures, WBC and
electrolytes ranked as high as 2nd and 9th in overall costs {Gombos et al. 1998).
• The risk of serious outcomes is too low as to justify the time, expense, and
invasiveness of the routine risk-stratification approach. Close follow-up or return
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emergency department visits will identify those children who progress to serious
bacterial illness.
• Routine performance of these tests may not be justifiable in terms of risk vs benefit
and the parents" values for these risks and benefits (.Kramer et al. 1997). It can be
argued that parents might not necessarily be willing to tolerate the risk of serious,
however rare, sequelae (Bauchner et al. 1997). However, it has been demonstrated
that parents may prefer less testing and treatment and may be more willing to take a
greater risk of rare adverse outcomes (Kramer et al. 1994, Green et al. 1999). The
risks incurred in performing these tests include the pain and discomfort of the
procedure, the waiting time before the procedure is performed and results are
available, the need for repeat culture due to contamination or transient bacteraemia,
and unnecessary hospitalization and invasive treatment due to false positive urine
analysis or to contaminated blood cultures (Thuler et al. 1997). Although risk and
benefit are not directly comparable i.e. every child tested faces pain while prevention
of serious morbidity is extremely rare, physicians and parents may have different
values for both the risks and the benefits of testing. Parents emphasize the short-term
risks of testing and the possibility of diagnostic error, whereas physicians give greater
weight to rarely-occurring serious sequelae (.Kramer et al. 1994). Therefore the
decisions of even the most capable physicians might not be optimal for the children
and their families.
• Physicians may obtain diagnostic tests because they believe that testing may protect
them from litigation. However, there is no evidence to support this belief and an
aggressive approach is not necessarily in the best interests of the patient or the
community (Stamos et al. 1997).
• The use of tests is largely influenced by practice background and the experience of
the physician; ancillary tests are used more frequently by less experienced clinicians
(.Zolkowski-Wynne. 1986, Procop et al. 1997).
A cornerstone of the evaluative algorithm the guideline recommends is blood culture.
The value of this diagnostic test has been questioned on several grounds:
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• The majority of febrile children who remain febrile do not have persistent
bacteraemia even if they did not receive antibiotic treatment at the first visit
(Jajfe et al. 1987, Rothrock et al. 1997).
• Many children who develop serious infections, such as meningitis, would have
done so by the time the blood culture result is available (Kramer et al 1997).
• Serious sequelae were mostly due to Haemophilus influenzae bacteraemia
(Barraf. 1993, Shapiro et al. 1993), which has become rare in the era of routine
immunization with Hib conjugate vaccine (Lee et al. 1998).
• The prevalence of bacteraemia is at least as high in children with otitis media or
pneumonia as in those without a bacterial focus of infection, so testing of
unknown infections while not testing of known focal infections is hardly
justifiable (Schutzman et al. 1991).
• Use of blood culture does not lead to lower rates of subsequent outpatient visits,
laboratory tests or treatment (Kramer et al. 1989). Furthermore, liberal ordering
of blood cultures may necessitate unnecessary re-evaluations and hospitalizations
for many false positive results (Hammerberg et al. 1992). The sensitivity of
blood culture is also not perfect and can be largely affected by the volume and
number of blood samples drawn (Durbin et al. 1978, Kaditis et al. 1996), by the
culture technique (Kramer MS, 1997), and by prior antibiotic use (Pichichero
ME, 1979). Decision analysis of diagnostic management strategies have shown
that a "no blood culture" strategy has the highest risk-benefit utility (Kramer et
al. 1989).
Similarly, it can be argued that catheterization or suprapubic aspiration for urine are
unnecessary invasive procedures which could be avoided in the majority of these
children (Dagan et al. 1991). The specificity and sensitivity of urine analysis is
reasonably high (Kramer et al. 1994), and can be further improved by enhanced
urinalysis (WBC count in a haemocytometer and Gram stain of un-spun urine)
(Hoberman et al. 1996). However, pyuria might occur in febrile children without a
urinary tract infection (Turner et al. 1995), and it can be absent in the presence of
bacteraemic pyelonephritis (Kumar et al. 1996). Children with positive urine culture
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with a normal urinalysis might be at little risk of pyelonephritis (.Kramer et al. 1997).
Hence, a negative urine analysis on a clean bag specimen may prove sufficient to
obviate the need for urine obtained by a more invasive technique. Although a urine
culture from a bag specimen is associated with a high risk of contamination or
inconclusive results (Crain et al. 1990), a negative result is strong evidence against a
UTI. It has been shown that urine culture has a low yield in early onset neonatal sepsis
(Visser et al. 1979), therefore the risk of suprapubic bladder tap in this group of patients
may not be justifiable.
Following the guideline (Figure 1 & 2), it was estimated that up to 72% of febrile
children will have WBC done for risk-stratification purposes alone (Green et al. 1999).
Because viral infections are far more prevalent than bacterial infections, the WBC,
which is a key determinant in the guideline, has very low predictive powers (8-15%) for
occult bacterial infection. Even among the true positives, i.e. those with a high WBC
count who do have an occult bacterial infection, most will have an infection that is likely
to clear spontaneously (bacteraemia) or to respond to treatment without serious sequelae
even if diagnosis is delayed (pneumonia, UTI, cellulitis). Because of their rarity, the
positive predictive value for more serious infections (meningitis, osteomyelitis, septic
arthritis) is at least several orders of magnitude lower (Kramer et al. 1997). Some argue
that young children with serious infection can often be accurately identified by the initial
clinical evaluation, and that the simplicity of clinical judgment alone might be favoured
over laboratory-intensive slide-rule algorithms (Manger et al. 1993, Long et al. 1994,
Green et al. 1999). It emerges from the above discussion that the role of most tests
currently used to identify serious illness in febrile children, and endorsed by the
guideline, is questionable.
II. l. c. Antibiotic treatment
Whether to administer antibiotic treatment is one of the major controversial issues in
the management of febrile children without a focus of infection. It can be argued that
antibiotic treatment empirically administered to these patients is justifiable:
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• Non-toxic children with untreated pneumococcal bacteraemia still develop serious
sequelae including meningitis (Bratton et al. 1977, Carrol et al. 1983).
• Early sterilization of CSF that follows the high serum and CSF levels obtained by a
single dose of i.m.ceftriaxone can balance the risks of adverse effects of this therapy
(.Bauchner et al. 1997).
• Expectant antibiotic therapy eradicates bacteraemia, prevents the development of
focal complications and reduces fever and improves the clinical condition of the
patient. Hence, it is a cost-effective strategy in the management of febrile children at
the emergency department (Carrol et al. 1983, Baskin et al. 1992, Bass et al. 1993,
Fleisher et al. 1994, Browne et al. 1997). The antibiotic efficacy in preventing
complications has been estimated to be 75% for meningitis, 95% for persistent
bacteraemia, 70% for pneumonia, and 25% for soft tissue infections (Lee et al.
2001).
• With a low negative predictive value of the risk criteria that identify serious bacterial
infection (.Manger et al. 1993), a strong case can be made for the use of outpatient
antibiotics.
• The lack of previous contact of the physician with the child and his/her family, with
consequent uncertainty about the adequacy of parental surveillance and compliance
with follow-up may necessitate aggressive treatment in the accident and emergency
department.
On the other hand, many claim that antibiotic treatment is unwarranted for the majority
of febrile children for the following reasons:
• The estimated risk of bacterial meningitis following bacteraemia is approximately
10% and is predominantly pathogen related, being lowest with S. pneumoniae,
intermediate with H. Influenzae and highest with N. meningiditis (Long et all994)
(Table 3). The Hib vaccine has virtually removed the worry of occult bacteraemia
due to this organism. Streptococcus pneumoniae, which now causes more than 95%
of occult bacteraemia, is an unusual cause of meningitis in childhood, and affected
patients rarely had a history of febrile "well" period when intervention might have
taken place (Long et al. 1994).
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• The efficacy of expectant single dose or short-course antibiotics in prevention of
meningitis, and other serious infective sequalae, is not proven (Rohrock et al. 1998).
• When antibiotics are administered empirically, it is no longer possible to judge the
child's clinical state, need for more therapy or evolution of a partially masked focal
infection. Interpretation of the results of CSF analysis can be particularly difficult.
All urinary tract infections would be mistreated, masked, or missed.
• Compliance among children given oral antibiotics in an outpatient setting is poor
(Sunakawa et al. 1995).
• In addition to the substantial financial and human costs, antibiotics have predictable
as well as idiopathic side effects.
• The routine use of antibiotics selects for more resistant organisms and is an
important risk factor for infection with such organisms, including salmonella and
penicillin-resistant pneumococci (Edwards et al. 1996).
• The practice of treating fever with antibiotics encourages fever phobia and the
substitution of automated management for thoughtful assessment, individualized
management and close follow-up.
It is thought that the influence of studies of febrile children seen in emergency
departments that reported on occult bacteraemia was a contributing factor in the liberal
use of antibiotics and the emergence of resistant organisms (Long et al. 1994).
Consumer satisfaction is also a factor as families may choose practitioners who readily
prescribe antibiotics. With time constraints on practitioners, it takes less time to
prescribe than to explain the differences between bacterial and viral infections.
Nevertheless, performing no tests and giving no antibiotics for the febrile young child is
perfectly defensible, and preferable (Long SS, 1994) and emphasis should be on
individual clinical assessment and close follow up. Telephone follow-up or return visits,
repeated observation over time at the initial visit or admission for a short period are
likely to be more helpful than diagnostic testing and blind treatment. Nonetheless, the
decision to observe should be made on a positive basis; if a suitable combination of
characteristics in the illness, infant, care giver, and physician does not permit a confident
decision to observe, then treatment is the appropriate choice (Roberts et al. 1983). It
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would appear that rejection of expectant therapy for children without focal disease is as
extreme as the recommendation for all febrile children to be treated expectantly
{McCarthy et a!. 1994, McCarthy et al. 1997, Bauchner et al. 1997).
Several changes in the epidemiology and management of occult bacteraemia and its
complications have prompted the reevaluation of these guidelines {Figure 1&2). These
include; i) the near elimination of Hib as a paediatric pathogen by immunization, ii) the
rising incidence of penicillin-resistant pneumococci, iii) additional studies on the
incidence of bacteraemia and utility of diagnostic tests, iv) increased concerns over
testing and empiric treatment, v) continued variability in the use of the guidelines, vi)
ongoing controversy among experts regarding the optimal approach to the febrile child,
and vii) the introduction of the conjugate pneumococcal vaccine. Nevertheless, the
controversy surrounding the management of febrile young children still continues {Stoll
et al. 2004).
It is evident that the management of the young child with fever remains a formidable
challenge and comprehensive evaluation of such a common problem can be costly,
invasive, and not without risk. From the several strategies that have been proposed for
the management of febrile young children, none has been universally adopted. The
controversy in management has been fuelled by studies involving varying populations
with respect to age, definition of fever, and varying clinical and laboratory criteria
defining high or low risk for SBI. Different definitions of fever without source and SBI
have further complicated the selection of children for various management strategies.
Large studies have demonstrated the futility of relying on the appearance of the young
child in determining the source of infection, and there is no single laboratory test that
has been shown to reliably identify young children at high or low risk of having serious
bacterial illness. Establishing early and accurate markers of infection could help
rationalize antibiotic practices. Diagnostic tests may be characterized by their cost,
sensitivity, and specificity. Initially, age and other clinical features define prevalence or
a prior probability of SBI. The test result then divides patients into a higher or lower
probability of the illness. This probability depends not only on the sensitivity and
specificity of the test, but also on the prior probability of SBI among the children being
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tested. Furthermore, management strategies will vary depending on the epidemiology of
illnesses in the population. For instance, if the rate of bacteraemia in a population is
>1.5%, then performing a diagnostic work-up at the initial visit may be considered cost-
effective. At a lower rate of bacteraemia of 0.5%, clinical judgment, for instance using
YOS, can be a cost-effective option and strategies that use empiric testing and treatment
could be avoided (Lee et al. 2001). Because of the variation in prevalence of SBI
between different settings, generalization of study findings may not be appropriate.
However, knowing the local prevalence (pre-test probability) of disease enables a
clinician to estimate the post-test probability using likelihood ratio of a test (which is
independent of prevalence) generated by well designed studies. It is therefore essential













1. Urine leukocyte esterase (LE) and nitrite or
urinalysis and urine culture:
All males <6 months and uncircumcised males 1-
12 months
All females <12 months
If urine screening test positive: Outpatient
antibiotics (3rd generation cephalosporin)
2. Urine LE and nitrite or urinalysis and hold urine
culture:
Circumcised males 6-12 months and all females
12-24 months
If urine screening test positive: Send urine culture
and outpatient antibiotics (3rd generation
cephalosporin)
3. For infants and children who have not received
the conjugate S pneumoniae vaccine:
Temperature >39.5C: Obtain WBC count (or
ANC) and hold blood culture
If WBC >15,000 (or ANC >10,000):
Send blood culture
Ceftriaxone 50 mg/kg up to 1 g
4. Chest radiograph: If Sao2 <95%, respiratory
distress, tachypnea, rales, or temperature >39.5C
and WBC count >20,000 (see above)
5. Acetaminophin: 15 mg/kg/dose q4h or ibuprofen
10 mg/kg/dose q6h for fever
6. Return if fever persists >48 hours or condition
deteriorates
1. No diagnostic tests or
antibiotics
2. Acetaminophen 15 mg/kg/dose
q4h or ibuprofen 10
mg/kg/dose q6h for fever
3. Return if fever persists >48
hours or if condition
deteriorates
Follow-up of children treated as outpatients with positive culture results:
Blood culture positive (pathogen): Admit if febrile or ill-appearing
Outpatient antibiotics if afebrile and well
Urine culture positive (pathogen): Admit if febrile or ill-appearing
Outpatient antibiotics if afebrile and well
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Figure 2<t': Algorithm for the management of a previously healthy infant (birth to
90 days) with FWS with a temperature of 38.0°C (100.4°F) or greater.
Non-toxic-appearing,
28-90 days and
*Chest radiograph if signs ofpneumonia: respiratory distress, abnormal breath sounds, tachypnoea, pulse oximetry
<95%.
Follow-up of low-risk infants treated as outpatients with positive culture results:
Blood culture positive (pathogen): Admit for sepsis evaluation and pareneteral antibiotic therapy pending results.
Urine culture positive (pathogen): Persistent fever: Admit for sepsis evaluation and parenteral antibiotic therapy
pending results.
Outpatient antibiotics if afebrile and well.
Low-risk criteria for febrile infants:
Clinical criteria:
Previously healthy, term infant with uncomplicated nursery stay
Nontoxic clinical appearance
No focal bacterial infection on examination (except otitis media)
Laboratory criteria:
WBC count 5-15,000/mm3, <1,500 bands/mm3, or bands/neutrophil ratio <0.2
Negative Gram stain of un-spun urine (preferred), or negative urine leukocyte esterase and nitrite, or <5
WBCs/hpf
When diarrhoea present: <5 WBCs/hpf in stool
CSF: <8 WBCs/mm3 and negative Gram stain (option 1 only)





The Evaluation of the Febrile Child
Clinical Evaluation
One simple approach in the assessment of a febrile child is to pay careful
attention to history and examination, meanwhile observing the child's responses to the
environment. A systematic approach (Figure 3) can then be used in the clinical and
laboratory evaluation of such a child.
in. l. Observation Scales
History and physical examination are essential steps in the evaluation of the febrile
child. However, findings from the initial evaluation can be of limited value or even
misleading, for the following reasons:
1. Many children present with fever as the sole manifestation. In a private paediatric
practice, a clinically identifiable source of infection, mostly otitis media, could be
found in only half (52%) of toxic appearing highly febrile infants (Schwartz et al.
1982).
2. A febrile illness in a young child may be attributed, mistakenly, to a mild
abnormality such as redness of the tympanic membrane due to crying (Schutzman
et al. 1991). Furthermore, acute otitis media and upper respiratory tract infection
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are frequently associated with underlying serious bacterial infection including
meningitis and bacteraemia. (Teele et al. 1975, McCarthy et al. 1976, Schutzman
et al. 1991)
3. Many children with serious illness, such as meningitis, do not always look
seriously ill i.e. toxic. In one study, an attending-level physician judged that 67%
of infants with SBI appeared to be well, including 63% and 82% of bacteraemia
and UTI respectively (Bonadio et al. 1994). A review of 10 years experience in a
large hospital revealed that nearly one half of episodes of meningococcaemia
occurred in children who were not suspected of having serious, invasive disease
(Dashefsky et al. 1983). Furthermore, attributes many physicians take as signs of
well being, such as the presence of a social smile, have not been found useful in
ruling out serious bacterial infection such as bacteraemia or meningitis (Bass et
al. 1996, Rogers et al. 1995).
4. Classic symptoms and signs of disease, which are usually derived from more ill
inpatients, are the exception rather than the rule. For instance, fever and earache,
two symptoms described in paediatric textbooks as classical manifestations of
otitis media, were absent in 31% and 40%, respectively, of 302 children younger
than 4 years with proven otitis media (Heikkinen et al. 1995).
It would, therefore, be useful to derive a set of sensitive and specific, preferably
objective, clinical criteria for predicting serious bacterial infections in febrile children at
the time of initial evaluation in order to focus invasive and costly efforts at diagnosis,
treatment and aggressive follow up appropriately and economically. Because a young
febrile child with a serious illness often does not manifest classical physical examination
findings suggestive of that illness, physicians usually rely on their instinctive judgment
in assessing the seriousness of a child's illness. Because overall judgments, such as ill,
questionably ill, or well, are considered oversimplifications and too vague, attempts
were made to quantify this instinctive judgment from observational data gathered in an
objective manner. One of the most widely used scales is the Acute Infant Observation
Scale developed at the Yale-New Haven Hospital in New Haven Connecticut.
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hi. l. a. Yale Observation Scale
McCarthy et al developed and applied a 6-point clinical assessment system for
febrile children. The system, based on a series of studies on children <36 months with a
fever >38.3°C, has come to be known as the Acute Infant Observation Scale, or the Yale
Observation Scale (YOS). History and observation variables on which physicians based
their instinctive clinical judgment of overall degree of illness of a febrile child, i.e.
toxicity, were identified. These variables were scored on a 4-point ordinal scale, from 1
for normal to 7 for severe impairment. Pairs of house officers and attending
paediatricians assessed and scored the patients. The sensitivity, specificity, and
predictive values of the scoring system in detecting serious illnesses were, 57%, 76%,
and 20% respectively {McCarthy et al. 1980). Observation rather than history was found
to be more important in a paediatrician's judgment.The inter-observer agreement in
scoring was "only fair". The limited usefulness of the scale in identifying serious
illnesses was, in part, related to:
• A single one-off evaluation, for which either serial clinical evaluation or
supplementation by screening laboratory tests were recommended.
• Poor inter-observer agreement, possibility due to:
1. Ill-defined terminology of the variables especially those with complex
behavioural components such as playfulness.
2. Varied levels of training and experience.
3. Scoring on a seven-point scale instead of dichotomous scoring.
McCarthy and his colleagues further perused the observation variables that physicians
used to assess the overall severity of illness in a febrile child. Variables relating to eye
function, response to stimuli, and motor activity correlated best with overall assessment
and the occurrence of serious illness. The sensitivity, specificity and predictive value of
the scale, based on these well-defined variables, were 70%, 79% and 29% respectively.
There was more inter-observer agreement (88%) than in the previous study, possibly
related to a gain in familiarity with the use of the scoring system (McCarthy et al. 1981).
In their third report, the authors defined and validated the Yale Observation Scale.
Observation items associated with serious illness in the previous studies were selected to
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construct a three-point scale (Appendix 1). A model based on these items had 88%
specificity, 77% sensitivity, and a positive predictive value of 92.3% for serious
illnesses. The sensitivity of the model combined with history and physical examination
was 92%. The inter-observer agreement (97%) was greater than before {McCarthy et al.
1982). This improvement was due to the use of more defined scale points in place of
vague terms, and to a higher prevalence of serious illness in the later population (15.8%
vs. 6.1-9.1%). The model was cross-validated by applying it to different subgroups of
the same population and comparing its performance to that in the whole study
population. This study showed that the chance of serious illness in an ill-appearing child
(YOS >10) was 40%, and 2-3% in a well appearing (YOS<10) febrile child.
The YOS was used as a means of determining the likelihood of serious illness
before physical examination and/or investigations (a priori probability) in a probability
reasoning to aid clinical decision making in the management of febrile children. A cut¬
off point of 10 on the scale classified the patients as ill or well appearing. History and
physical examination were scored as to whether they did or did not suggest a serious
illness. Ill-appearing patients had greater occurrence of physical examination findings
suggesting a serious illness (64%) than well appearing children (15%). The probability
(PPV) of serious illness in ill-appearing children rose from 40% to 79% and from 3% to
25% in well-appearing ones, by the addition of physical examination. History findings
did not have a significant contribution {McCarthy et al. 1985). The same authors studied
the efficacy of YOS, combined with history and physical examination, in identifying
serious illness in febrile children. The sensitivity of history and physical examination for
serious illness was 78%. This was increased to 92% by the addition of the observation
scale. The false negative rate for the items combined, was 14% {McCarthy et al. 1987).
The Yale Observation Scale has been developed as a means of adding accuracy
to the more traditional methods of history and physical examination, in detecting serious
illness in young febrile children. However, the scale failed validation when applied to
different populations and, therefore, has not enjoyed wide acceptance as an aid in
clinical decision making. When applied to a group of infants 4-8 weeks old, the scale
had a sensitivity, specificity, and predictive value of 46%, 78, and 45%, respectively, in
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predicting serious illness. 57% of infants with culture proven illness appeared well, and
12% of well-appearing infants had either a culture-proven bacterial illness or pneumonia
(Baker et al. 1990). In a large number (6611) of a selected group of young febrile
children who were non-toxic looking and had no identifiable focus of infection, the
sensitivity, specificity, and positive and negative predictive values for a YOS score >10
in detecting occult bacteraemia were 5.2%, 96.7%, 4.5%, and 97.1% respectively. The
difference in YOS score between bacteraemic and non-bacteraemic children was not
clinically useful as the overlap in appearance between the two groups was too great
(Teach et al. 1995). In the series reported by Baker et al, 66.2% of children with serious
illness scored 10 or less, placing them in low-risk category on the basis of appearance
alone (Baker et al. 1993). More recently, a study of young febrile children revealed that
69% of bacteraemic patients had the lowest possible score of 6 in YOS (Kuppermann et
al. 1998). The differences in the findings between these studies are in part due to:
1. Differences in the prevalence of serious illness.
2. Inclusion, in some studies, of patients with overt focal infection, or toxic
appearance.
3. Systematic observer bias resulting from assessment by several physicians, in
different institutions, with different levels of experience.
4. Failure to allow for the use of antipyretics before assessment.
5. Small sample size of some studies.
in. l. b. Other Scoring Systems
A different scoring system, based on functional status and clinical judgment, was
used by another group of workers to predict bacteraemia in young febrile children. The
functional status was obtained from the parent's record of the child's eating, drinking,
sleeping, and play activity. It was scored on a 0-2 scale resulting in a composite score of
8 that indicated optimal function (Appendix 2). After physical examination, the
physician predicted the existence of bacteraemia using an arbitrary scoring system: The
physician's assessment was the most predictive factor, with a predictive value 14%,
specificity 83%, and sensitivity 47%. Both functional status and WBC were poorly
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predictive. Combination of findings did not improve the utilized values. It was
concluded that history and physical examination should determine the need for further
tests in febrile young children (Waskerwitz et al. 1981). Schwartz et al used yet another
different scoring system utilizing both historical and observational variables to gauge the
degree of toxicity (Appendix 3). Children with a score of 2+ or higher were considered
toxic. 12% of toxic-appearing febrile children had occult bacteraemia, compared to none
of the non-toxic appearing children. All the six bacteraemic children were identified as
toxic. The sample size of this study was too small to make conclusions more than
recommend obtaining a WBC and a blood culture in a toxic-appearing child (Schwartz et
al. 1982). A severity index using a 0-1-2 point score for the variables (respiratory effort,
skin colour, activity, temperature and ability to play) that were predictive of serious
illness was derived and applied to a group of febrile children. The index had a predictive
accuracy for non-severe illness of 98.7% with a false positive prediction rate of 15.8%.
The index when used as a triage tool could be helpful in selecting febrile children who
should receive blood cultures {Nelson et al. 1980). These later scales have not been
validated by further studies.
in. 2. SBI risk (Rochester) Criteria
A major goal in the evaluative process of febrile children is to maximize the
sensitivity and negative predictive value of the outpatient evaluation while minimizing
the cost and risk of testing, hospitalization and antibiotics. Therefore, studies have
stressed the importance of selected criteria in evaluating febrile children {McCarthy et
al. 1976). Many risk factors have been examined, including age, temperature, existence
of a chronic illness, the presence of focal signs of infection and preliminary laboratory
tests e.g. WBC, erythrocyte sedimentation rate, CRP and a variety of methods of clinical
evaluation {Jaffe et al. 1991). Based on these data, the physician can make informed
decisions about the need for more definitive laboratory tests, therapy, or advisability of
hospital admission. One widely accepted approach is the risk stratification method
whereby patients are categorized into those with high or low probability of having a
serious illness.
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In 1982, Dagan et al introduced the Rochester Criteria that identified young
children unlikely to have a serious bacterial infection {Dagan et al. 1985). These criteria
were based on the experience of the authors and earlier studies {Figure 4). Using these
criteria, 62% of the patients seen at the emergency department would be at low risk of
having a serious illness. Less than 1% of these patients will have a SBI compared to
25% of the high risk group. The incidence of bacteraemia would be negligible compared
to the 10% incidence in the high risk group. The negative predictive value of the low
risk criteria for SBI was estimated to be 99.3%, far beyond that of the traditional risk
factors, such as age, sex, and temperature, clinical symptoms and signs, or laboratory
findings. These criteria were successfully applied to select young infants for outpatient
treatment {Dagan et al. 1988, McCarthy et al. 1990, Baker, et al. 1993). However the
Rochester criteria were not always successful when applied to different populations. The
negative predictive values were found too low for clinical use, which meant that several
infants with SBI would be assigned to the low risk group {Anbar et al. 1986, Avner et al.
1993). Others reported enhanced predictive power when other laboratory tests, such as
ESR and CRP, were added to the criteria {Chiu et al. 1994). The discrepancies in the
findings of these studies can be attributed to differences in:
• The study design, either retrospective or prospective.
• Inclusion criteria:
1. Perinatal events.
2. Previous health and recent antibiotic treatment.
3. Hospitalized infants and infants managed as outpatient.
4. Eligibility in terms of parental ability to provide home care.
5. Appearance of the infant, whether ill or well. Application to a population
including ill appearing infants (with a higher prevalence of SBI) would result in a
lower negative predictive value {Jaskiewicz et al. 1994).
• Definition of serious bacterial infection:
1. Microbiological definition of meningitis and other infections.
2. Inclusion of superficial skin infection and otitis media.
• Definition of low risk criteria:
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1. Spectrum of the septic screen done, e.g. CSF examination.
2. Inclusion, and definition, of stool WBC count.
3. Radiological infiltrates.
• Differences in patient referral pattern.
• Small sample sizes.
• Different geographic sites, e.g. the absence of group B streptococcal infection in the
group reported by Dagan et al from Israel.
• Non-uniformity in subjective assessment.
• Differing aspects of health care delivery, exemplified by a lower rate of
hospitalization in Rochester compared with other hospitals in the same county.
As discussed earlier, a variety of methods of clinical evaluation of febrile children
have been developed but it remains that unremarkable or minimally abnormal clinical
findings do not rule out serious bacterial disease (Procop et al. 1997). Therefore, various
combinations of clinical and laboratory parameters, particularly haematological
variables, have been used as rapid ancillary tests in the diagnosis of serious bacterial
disease. Bonadio et al found a higher incidence of SBI with higher temperatures and
higher WBC count. Although the physical appearance was insensitive in detecting
bacteraemia and UTI, all cases of meningitis were predictable on clinical assessment
alone (.Bonadio et al. 1994). In their study of febrile children younger than three years of
age, Kupperman et al reported that the absolute neutrophil count, temperature and age
younger than 2 years were predictive of occult pneumococcal bacteraemia (.Kupperman
et al. 1998). Other workers found that CRP, duration of fever, clinical impression score,
history of diarrhoea, and the presence of focal signs were independent predictors of SBI
(.Berger et al. 1996). Banya et al reported that a constellation of clinical findings that
included a high temperature, dehydration, grunting, and physical signs of consolidation
were good predictors for a positive blood culture. The authors concluded that use of
these criteria in selecting children for obtaining blood culture would have reduced the
number of blood cultures taken by 55.6% {Banya et al. 1996). In a more recent study,
Bachur et al reported a 26% incidence rate of occult pneumonia in children <5 years
with a temp>39C and WBC>209/L. The authors recommended routine CXR in this
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group of children even in the absence of symptoms or signs of pneumonia (Bachur et al.
1999). Leventhal et al used a constellation of physical signs to categorize patients with
fever, or respiratory symptoms, into high and low risk groups for pneumonia. These
criteria were more reliable than the classical signs of pneumonia i.e. fever, cough, and
rales, in detecting pneumonia (Leventhal et al. 1982). A predictive model consisting of
age, height of temperature, urinalysis and WBC had a negative predictive value of
98.3% and 99.6% for SBI and bacteraemia and/or meningitis (.Bachur et al. 2001). Some
other studies found that the development of bacterial meningitis was strongly associated
only with the species of bacteria but not with any other clinical or laboratory
characteristics identifiable at the initial visit (Shapiro et al. 1986).
 
Figure 3: Clinical evaluation of the young febrile child*.
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1. Assessment of the urgency of the situation: In certain circumstances, management
decisions and actions need immediate institution before establishment of definitive
diagnosis. Signs of severe life-threatening infections should be sought early in the
evaluation of the febrile child. For instance, the complaint or observation that a
child's crying increases with parental attempts to comfort or fondle (paradoxical
irritability) is an important sign of meningitis in infancy (.Manger et al. 1993). Also
altered sensorium and focal neurological signs are indicators of CNS infections.
Drooling and a sniffing position are signs of upper airway obstruction. Dyspnoea,
cyanosis and pallor, tachycardia and hypotension are signs of cardiopulmonary
compromise as seen in septicaemia. The characteristic haemorrhagic rash of
meningococcaemia should be actively searched for.
2. Observational assessment: In less urgent cases, a period of careful observation,
with the child comfortably placed on the parent's lap, helps the physician gauge the
overall toxicity of the child. Observation should include the child's alertness, his /
her responsiveness to persons and objects, respiratory status and colour, feeding,
and age-appropriate motor function.
3. Looking for a possible focus of infection: Sites of common childhood infections
e.g. ears, throat, joints etc. should be thoroughly examined. Gentle palpation of the
anterior fontanelle and abdomen and auscultation of the chest should be performed.
4. Assignment to a low or high risk for a serious infection: Because of the
acknowledged difficulty in the outpatient evaluation of young febrile children, a
commonly adopted approach is to classify febrile children into toxic and non-toxic
looking. Toxic-appearing children are automatically admitted for sepsis work up
and observation and/or parenteral antibiotic therapy. Non-toxic looking patients are
stratified into high or low risk for serious infection. Factors that help in
categorization include; age, height of temperature, and the total and differential
white blood cell count (see text).
*Adapted from Henretig, 1998.
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Figure 4: The Rochester criteria identifying children at low risk for SBI.
• Patient appears generally well
• Patient has been previously healthy:
1. Born at term
2. Did not receive perinatal antimicrobial therapy
3. Was not hospitalized longer than the mother
4. Was not treated for unexplained hyperbilirubinaemia
5. Had not received and was not receiving antimicrobial agents
6. Had not been previously hospitalized
7. Had no chronic or underlying illness
• No evidence of skin, soft tissue, bone, joint, or ear infection
• Laboratory values:
1. Peripheral blood WBC count (5.0 to 15.0xl09 cells/L)
2. <10 WBC /hpf on microscopic examination of a spun urine sediment





The Evaluation of the Febrile Child
Laboratory Evaluation
iv. l. Ancillary tests
Tests commonly performed as part of the evaluative process of febrile children
include chest X-Ray and urine and CSF analysis, especially since urinary tract infection
and pneumonia can be surprisingly "silent" in young children (Krober et al. 1985).
However, there can be difficulties in their interpretation, and the sensitivity and
specificity of each test are far from perfect {McCarthy et al. 1977). Chest radiograph
interpretation, in particular, is hardly an exact science as it is a clinical judgment that
may result in disagreement among radiologists. The inter-observer variability of
radiologists is considerable and can be biased by the clinical information and the
preliminary interpretation of the treating physician {Leventhal et al. 1982, Green et al.
1999). The commonly reported pulmonary infiltrates are not helpful in deciding upon a
causative organism, whether viral or bacterial. They are also neither specific nor
sensitive for positive blood culture. It has been demonstrated that children with otitis
media are more often bacteraemic than those with pneumonia {McCarthy et al. 1976).
Examination of CSF is routinely performed in febrile young infants and in older children
who manifest signs of meningeial inflammation. Because microbiological examination
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of CSF is not always instantly available, initial diagnosis of meningitis usually rests on
the cell count of CSF. Aseptic meningitis with isolation of virus from CSF often occurs
in the absence of CSF pleocytosis which, if present, can vary widely in numbers and can
initially be predominantly polymorphic (Krober et al. 1985). On the other hand, some
bacteraemic children can have aseptic lymphocytosis in the CSF {McCarthy et al. 1976).
CSF culture is more sensitive than the cell count as a test for bacterial meningitis in
patients who have not been taking antimicrobials {Shapiro et al. 1986). Furthermore, a
significant association between the performance of lumber puncture at initial
presentation and the subsequent development of meningitis has been demonstrated
{Woods et al. 1990). The pros and cons of urinalysis in febrile children have been
extensively reviewed in the medical literature {Krober et al. 1985, Bonadio et al. 1994,
Jaskiewicz et al. 1994, Chiu et al. 1994) and will be discussed further in subsequent
sections. Apart from these organ and organism-specific tests, there are other tests in
clinical use, which indicate the presence of tissue injury and inflammation and may help
in the diagnostic or prognostic evaluation of febrile illness. These tests largely represent
various components of the acute phase reaction.
rv. 2. WBC and Differential Count
The peripheral white blood cell (WBC) and differential WBC counts have been
used for over a hundred years to help discriminate acute infectious and non-infectious
disease {Todd et al. 1974). These simple and relatively inexpensive laboratory tests have
become a routine part of the evaluation of unexplained fever and they are widely used as
part of health supervision in paediatric patients {Moyer et al. 1990). The neutrophil is the
leucocyte most intimately involved in the host defence against bacterial infection.
During many systemic infections the bone marrow overcompensates to replenish the
marginating neutrophil pool, which has migrated to tissues, and results in neutrophilia.
This neutrophilia is often accompanied by increased numbers of immature neutrophils
which is called a left shift. This shift is quantified by determining the absolute band
count, band/segmented neutrophil ratio, band/total neutrophil ratio, and immature/total
neutrophil ratio. If the infection is extremely severe or the host is already compromised,
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the bone marrow fails to compensate for the loss in central and marginal neutrophil pool
and neutropenia results. The characteristic WBC pattern that often accompanies bacterial
infection consists of neutrophilia and eosinopenia with or without a left shift. As the
infection resolves, the number of neutrophils decreases and the number of monocytes
increases. This is followed by relative or absolute lymphocytosis and return of
eosinophils (Weitzman et al. 1975).
The WBC count is an inexpensive, easily available test. However, its usefulness
in diagnosis of serious bacterial illness is limited for many reasons:
1. Several physiologic and non-pathologic factors can strongly influence the
interpretation of the WBC. (Table 7).
2. Leucocytosis, with or without left-shifted myelopoiesis, is a non-specific response to
almost any disease. For instance, WBC counts in excess of 50,000/ mm3 have been
demonstrated in vasculitides and connective tissue disorders and profound
leucocytosis has also been described in some viral infections (Morens et al. 1979).
3. WBC fails to respond as expected in some instances of bacterial disease (Procop et
al. 1997).
4. There is no uniformity in criteria used for the proper interpretation of abnormal
values, due partly to the difficulty in making a definitive aetiologic diagnosis in
many cases of apparently infectious illness (Stein et al. 1972).
5. It has been demonstrated that 50-75% of the variance in leucocyte differential counts
is not attributable to disease, but to variability in sampling, in counting, and in
observers (.Moyer et al. 1990).
6. The differential count must be performed manually in many laboratories, and even
when automated, 30-40% of the counts must be repeated manually because of
suspected abnormalities. This undermines the cost-effectiveness of this test because
the potential for cost-savings by reduction in laboratory use is greatest for labour-
intensive tests (Moyer et al. 1990).
7. The published normal ranges for WBC may not be clinically relevant. Benuck et al
demonstrated a whole range of sensitivities (29%-94%) of published neutrophil
criteria in identifying a set of 34 culture proven neonatal sepsis (Benuck et al. 1983).
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8. The WBC, and its differential, is a multi-part test, which results in up to 30% of any
group of patients to have at least one value outside the 95% range.
9. WBC counts from different vascular sources may make the interpretation of these
numbers difficult. It has been demonstrated that venous and arterial blood counts
were 82% and 77%, respectively, of capillary blood value {Liu et al. 1985).
10. Normal ranges are relatively broad, and different values have been cited for different
days of life {Akenzua et al. 1974).
11. An abnormal WBC and differential count does not usually have inherent diagnostic
meaning that is independent of clinical findings at the time of evaluation at the
emergency department {Crain et al. 1982).
12. Several factors relating to the infectious process may modify the accompanying
WBC picture:
i. The infecting micro-organism: pyogenic bacteria often result in a more
pronounced neutrophilia than other bacteria. Typhoid fever, pertussis, and
tuberculosis are typically not associated with neutrophilia. Scarlet fever and
brucellosis are associated with eosinophilia. WBC may not be elevated in gram
negative infections {Lee et al. 1998, Kuppermann et al. 1998, Dashefsky et al.
1983).
ii. Localisation of infection tends to result in greater WBC count than septicaemia.
iii. Severity of infection: with many exceptions, the more severe the infection, the
higher the neutrophil count.
iv. The age of the patient: neutrophil counts are less reliable indicators of infection
in the first few days of life {Kunnamo et al. 1987).
The correlation between both serious bacterial disease and culture positivity and
an abnormal haematological profile is well established {Table 8). Some authors have
even extrapolated the etiologic agent, its virulence, and the severity of disease from the
type of haematological abnormality and therapeutic decisions are frequently made on the
basis of WBC count. However, while many of these studies show acceptable positive
predictive values for both leucocytosis and differential WBC count, others have
emphasized the drawbacks to the use of haematological variables to predict serious
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bacterial disease. It is difficult to rely on criteria developed from these studies for many
reasons. The subjects in these studies were a heterogeneous group, with different disease
prevalence and clinical severity. The definition of serious bacterial disease was not
uniform across the studies. The interpretation of WBC morphology and degenerative
changes and the cut-off values of neutrophil and band cell counts and ratios were also
different {Stem et al. 1972, Todd et al. 1974, Morens et al. 1979, Chiu et al, 1984, Jaffe
et al. 1991, Bonadio et al. 1994, Berger et al. 1996, Procop et al. 1997, Lee et al. 1998,
Gombos et al. 1998).
A prototype of studies evaluating the role of WBC in detecting occult bacterial
infection was that done by Kramer et al who studied a large cohort of febrile young
children seen in a paediatric emergency room. The gain in the probabilities of
meningitis, UTI and pneumonia attained by a high WBC (>15,000/mm3), was negligible.
It was argued that the incidence of meningitis in a child without the symptoms and signs
of this disease was so low that even doubling its probability by a high WBC was
unlikely to alter clinical management. The predominantly viral origin of most
pneumonias, the lack of morbidity associated with its gross under-detection and the
relative ease of obtaining a CXR undermine the value of a WBC in the detection of
pneumonia. The increased probability of UTI resulting from a high WBC is also
obviated by the less invasive, equally sensitive, and much more specific urinalysis. It
was argued that persistence of fever and the development of new signs or symptoms
have far greater differential diagnostic value than WBC {Kramer et al. 1993). Other
leucocyte-associated tests used for detection of bacterial infection are nitroblue
tetrazolium test and acridine orange leucocyte cytospin tests (Kite et al. 1988). It would
seem that most of these parameters would add little to the post-test probability in
situations of diagnostic uncertainty. Furthermore, in patients with a high pre-test
likelihood of serious illness, a haematologic profile would be of little use because an
abnormal result would be expected and a normal result would be ignored.
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IV. 3. The Acute Phase Response
Patients with inflammation, such as infection, develop a number of systemic changes
collectively called the acute phase response, even though these changes accompany both
acute and chronic inflammatory disorders. Acute phase changes may be divided into
changes in the concentrations of many plasma proteins, and a large number of
behavioural, physiological, biochemical, haematological, and nutritional changes. This
response is mediated by cytokines, such as interleukin 6 (IL-6), interleukin-1 (IL-1) and
tumour necrosis factor (TNF), which are synthesized by macrophages and lymphocytes,
that accumulate at the site of tissue damage. Neuroendocrine changes reflecting action of
inflammation-associated cytokines include the production of ACTH and AVP (which
account for hyponatraemia during some inflammatory disorders) by IL-6. Behavioural
changes that often accompany inflammation, including anorexia, somnolence, and
lethargy, are similarly induced by cytokines. Nutritional effects include anaemia and
cachexia induced by cytokines in chronic disease. The presence of any of the
components of the acute phase response provides unequivocal evidence of tissue injury.
However, a wide range of stimuli can produce cellular or tissue injury, or stimulate
macrophages, resulting in the systemic response. Examples of these stimuli are:
1. Chemical or physical trauma
2. Chemical, toxic, or allergic inflammation
3. Infection; bacterial, viral, fungal or parasitic
4. Ischaemic necrosis
5. Malignant neoplasia.
Measurement of the acute phase response may thus be used for either detecting
organic disease, assessing the extent or activity of that disease, monitoring response to
treatment, predicting outcome, or detecting intercurrent infection. In paediatrics, the
main value of tests for detecting and monitoring the acute phase response is as an early
indicator of bacterial infection in circumstances where a microbiological diagnosis is
impossible or delayed {Stuart et al. 1988).
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iv. 3. a. Fever
Fever is the representative of the neuroendocrine changes that characterize the
acute phase response. The hypothalamic thermo-regulatory centre maintains normal core
body temperature at a set point of 37°C (98.6°F) with a narrow range of 1-1.5°C. Fever is
an elevation of body temperature mediated by an increase of the hypothalamic heat
regulatory set-point. Body temperature follows a circadian rhythm; early morning
temperature is low, with the highest level occurring between 16.00 and 18.00 hrs. This
circadian rhythm is apparent from early infancy and is most prominent in mid childhood.
It follows that defining fever in children is a complex issue but most would agree that
any rectal temperature of 38°C or higher constitutes a fever (Manger et al, 1993, Barraf.
1993). The increased heat production associated with fever increases oxygen
consumption, carbon dioxide production, and cardiac output. Thus it may exacerbate
cardiac insufficiency in patients with heart disease or chronic anaemia, pulmonary
insufficiency in those with chronic lung disease, and metabolic instability in children
with diabetes mellitus or inborn errors of metabolism. Furthermore, children between 6
months and 5 years are at increased risk of febrile seizures and those with idiopathic
epilepsy may have increased frequency of seizures as part of a non-specific febrile
illness. Fever by itself, except under unusual circumstances, is not beneficial to the host
response to infection (Barraf. 1993).
Fever occurs when various infectious and non-infectious processes react with the
host defense mechanisms. Non-infectious causes of fever include:
1. Vaccines.
2. Tissue injury (burns, infarction, i.m. injections).
3. Malignancy.
4. Drugs (drug fever, cocaine, amphoteracin B).
5. Immunologic-rheumatologic disorders (SLE, rheumatoid arthritis).
6. Inflammatory diseases (IBD).
7. Granulomatous diseases (sarcoidosis).
8. Endocrine disorders (thyrotoxicosis, phaeochromocytoma).
9. Metabolic disorders (gout, uraemia, Fabry's disease).
92
10. Unknown or poorly understood entities (familial Mediterranean fever).
11. Factious (self-induced): Either by intentional manipulation of the thermometer or
injection of pyrogenic material. The diurnal variation of temperature is usually
preserved in patients with febrile illnesses. When this circadian rhythm is maintained
and is associated with tachycardia, chills (rigors), and sweating, a true rather than
factitious fever should be suspected.
Regardless of the aetiology, the final pathway of most common causes of fever is the
production of endogenous pyrogens, which then directly alter the hypothalamic
temperature set-point resulting in heat generation and heat conservation. Cytokines,
especially IL-1, IL-6 and TNF, released in response to immune and non-immune stimuli,
are the main endogenous pyrogens. The sequence of cytokine generation in response to
exogenous pyrogens, with subsequent hypothalamic prostaglandin E2 production, may
take 60-90 min (Manger et al. 1993). However, cytokines are not the sole inducers of
fever; the observation that subdiaphragmatic vagotomy blocks fever after intraperitoneal
(but not intramuscular) injection of lipopolysacharide implicates neural transmission in
the febrile response (Franklin et al. 1999).
Fever is the most common sign of illness in infants and young children, and highly
febrile (103.0°F rectal) children represent about 20% of all sick patient visits (Wright et
al. 1981). In most children, fever is either due to an identifiable microbiologic agent or
subsides after a short time and it may be categorized as follows:
1. Fever of short duration with localizing signs for which the diagnosis can be
established by clinical history and physical examination, with or without laboratory
tests.
2. Fever without localizing signs, for which the history and physical examination do
not suggest a diagnosis but laboratory tests may establish an aetiology.
3. Fever of unknown origin (.Arvin et al. 1996).
In most infectious processes the fever pattern is of little diagnostic importance,
although the fever associated with malaria, Hodgkin's disease and cyclical neutropenia
may indicate the underlying condition. In some instances, such as diarrhoea (Victoria et
al. 1990) and bronchiolitis (El Radhi et al. 1999) the presence of fever could be an
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indicator of the severity of illness not necessarily associated with bacterial infections.
The most important role of high fever in children is its role as a sign of serious infectious
illness. Mild elevations of temp (37.7-38.3°C) are common in the first few (6) months of
life, accounting for approximately 20% of infant visits. Higher degrees of fever
(temperature >38.3 °C) are uncommon in this age group but are seen more frequently
with each succeeding month (Pantell et al. 1980). There seems to be an emergency
regulatory mechanism in fever that sharply limits the temperature at levels of about
41.1°C (106°F), hence the rarity of hyperpyrexia in infections. In one study, only
0.048% of emergency room patients had such a temperature (Dolan et al. 1976).
However, fevers in this range and higher indicate not only bacteraemia, but also possible
CNS infection, or pathologic hyperthermia (McCarthy PL, 1997). A positive correlation
between the height of fever and the rate of serious bacterial infection has been
established (Teele et al. 1975, McCarthy et al. 1977, Leventhal et al. 1982, Banadio et
al. 1990, Schutzman et al. 1991, Bonadio et al. 1994). The incidence of bacteraemia
increases in a stepwise fashion with increasing temperature (Table 9). The lack of
response to antipyretics, such as acetaminophen, has also been found to indicate an
increased risk of serious bacterial infection (Mazur et al. 1989). This has been
challenged by other workers who found that neither a fall in temperature, nor changes in
clinical appearance after fever reduction could predict the absence of serious bacterial
infection (Baker et al. 1987, Tiller et al. 1988, Baker et al. 1989).
iv. 3. b. The acute phase plasma proteins
An acute phase protein (Table 10) has been defined as one whose plasma
concentration increases or decreases by at least 25% during inflammatory disorders
(Pepys et al. 1983). The magnitude of the increases varies from about 50% in the case of
ceruloplasmin and complement components to as much as 1000 fold in the case of CRP
and serum amyloid A (Gabay et al. 1999). Inflammation causes substantial changes in
the plasma concentrations of acute-phase proteins while moderate changes occur after
strenuous exercise, heatstroke, and childbirth, and small changes occur after
psychological stress and in several psychiatric illnesses (Gabay et al. 1999). The
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changes in the concentration of these proteins are largely due to changes in their
production by hepatocytes. Several cytokines are capable of inducing acute phase
production in hepatocytes. IL-6 seems to be the most important because of the number
of acute phase proteins whose synthesis it influences as well as the magnitude of the
changes it produces (Geiger et al. 1988). Studies have shown that the synthesis of CRP
by human hepatocytes is dependent on IL-6, but not on IL-1 or TNF, and that CRP is a
direct indicator of IL-6 levels in humans in vivo (Bataille et al. 1992).
These plasma protein responses presumably have beneficial overall functions
concerned with restricting injury and promoting resolution and repair. For instance,
caeruloplasmin scavenges superoxide produced by activated neutrophils and fibronectin
non-specifically promotes phagocytosis. The antioxidants haptoglobin and hemopexin
protect against reactive oxygen species. Both ai.protease inhibitor and ai- anti-
chymotrypsin antagonize the activity of proteolytic enzymes and inhibit the generation
of superoxide anions.
The variety of tests available to monitor the acute phase response have led to
controversy over which tests should be used. Individual acute phase proteins vary not
only in the rate at which their blood concentration rises after the onset of inflammation,
but also in the half-life and rate of catabolism in different forms of inflammation. CRP,
SAAP and ai- anti-chymotrypsin rise within 6-10 hours of injury, show large
incremental increases of 10-1000 fold over their normal values, have short half-lives,
and behave consistently in different forms of inflammation. On the other hand,
orosomucoid, aj-anti-trypsin, haptoglobin, and fibrinogen rise after 24-48 hours, rarely
increase more than two fold, have long half-lives and, with the exception of
orosomucoid, show variable catabolism in some diseases. Haptoglobin and ai-anti-
trypsin have common genetic variants which result in their deficiency. C3, C4 and
caeruloplasmin generally show poor and inconsistent acute phase responses. Different
organisms may initiate different patterns of response in acute phase proteins. For
instance, E. coli gives the most reliable increase in CRP, whereas the response in early
onset group B streptococcal infection is less predictable (Philip et al. 1984).
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iv. 3. b. i. C-reactive protein (CRP)
Of the useful acute phase proteins, CRP is the most easily measured and
commercial assay kits are widely available. CRP was discovered in 1930 and derives its
name from its calcium-dependent reactivity with pneumococcal C-polysaccharide. CRP
belongs to the pentaxin family, so named because of their pentagonal appearance in the
electron microscope. This group of proteins also includes serum amyloid A protein
which shares a common structural configuration and considerable homology with the
CRP molecule. Human CRP has a molecular weight of 110 kDa and consists of 5
subunits each with 187 amino acids, with considerable a- helix. This differs from
immunoglobulins, which do not contain a- helix. CRP specific human DNA has been
isolated and its gene has been mapped to chromosome 1 {Philip et al. 1984).
CRP is synthesised by hepatocytes {Aleksander et al. 1984) and there is no
evidence for its production by any other cell type, although surface CRP has been found
on certain lymphoid and phagocytic cells {Nudelman et al. 1983). Cytokines, especially
IL-6 and IL-1 are the main inducers of hepatic synthesis of CRP, and prostaglandins
may also be involved. In serum, CRP is associated with VLDL and LDL fractions.
Following production in the liver, CRP localizes at the site of tissue injury or
inflammation. For instance, CRP has been detected in CSF of patients with meningitis
and in the joint fluid of patients with rheumatoid arthritis {Nudelman et al. 1983). Local
deposition has also been noted in chronic vasculitis. The in-vivo half-life of CRP is 19
hours, the shortest among most human plasma proteins, and its fractional catabolic rate
is independent of the plasma CRP concentration. The synthesis rate of CRP is thus the
only significant determinant of its plasma level, confirming the validity of serum CRP
measurements as an objective index of disease activity in disorders associated with an
acute-phase response. In contrast, the concentration of other acute phase proteins, such
as the clotting factors, complement proteins, proteinase inhibitors, and transport
proteins, is dramatically affected by the activation and/or complex formation involved in
their physiological functions {Vigushin et al. 1993). After the onset of inflammation,
CRP synthesis increases within 4 to 6 hours, doubling every 8 hours thereafter, and
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peaks at 36 to 50 hours. Levels remain elevated with ongoing inflammation, but with
resolution they decline rapidly with a half-life of 4 to 7 hours (Jaye et al. 1997). The
mechanisms of its clearance are not known, although 90% of injected radioactive CRJP
has been recovered in the urine (Vigushin et al. 1993). It was shown that its peak levels
correlate with the severity of tissue damage and that this level depends on the duration of
increased CRP production rather than upon the initial rate of rise. Anti-inflammatory
drugs lead to a decrease in CRP production.
The ligand that CRP binds best is phosphorylcholine, which is a constituent of C-
polysaccharide. CRP, bound to target ligands, can activate the classical complement
system and facilitates phagocytosis by opsonising target substances and it also enhances
NK cell activity (Pepys et al. 1981). CRP and complement components are the only
acute phase proteins directly involved in the elimination of microorganisms. Although
CRP has proinflammatory properties, its net effect is anti-inflammatory. CRP can
prevent the adhesion of neutrophils to endothelial cells by decreasing the surface
expression of L-selectin. It can also inhibit the generation of superoxide by neutrophils
and stimulate the synthesis of IL-1R antagonist by mononuclear cells (Gabay et al.
1999). It efficiently blocks phosphocholine-containing inflammatory mediators, such as
platelet activating factor, and may block phospholipase activity which provides
substrates for the cyclo- and lipooxygenase pathways (Vigushin et al. 1993). There is
some evidence that the prognosis of neonatal infection is better if CRP level is initially
elevated (Nudelman et al. 1983). Hence, CRP has been suggested as a potential tool for
therapy and prophylaxis (.Philip et al. 1984). Binding of CRP with heparin, histones and
myelin basic protein suggests that it has a direct role in clearing necrotic host tissue
{Jaye et al. 1997).
Methods of measuring CRP were originally based on the ability of serum to
precipitate the C-fraction polysaccharide (Quellung reaction/ Then followed the
capillary precipitin and latex fixation agglutination. These semi-quantitative tests are
easy to perform, economical and rapid. However, they are less sensitive, with a limit of
detection greater than 10 mg/1. The capillary test is difficult to read if the serum has a
high lipid content or is haemolysed. In the latex test, undiluted serum with high CRP can
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result in a false negative result (prozone effect) and high titres of rheumatoid factor also
can give false positive results. After biochemical characterization of CRP in 1978 and
development of specific monoclonal antibodies, a wide array of sensitive quantitative
methods evolved. As much of the value of measuring CRP lies in serial monitoring of
the onset or resolution of inflammation, sensitive quantitative assays are much more
useful. Techniques that give the required rapid results include Laser-beam nephelometry
(1.5 hour assay time), or rate immuno-nephelometry, and turbidometry (0.25-0.5 hour):
These sensitive (-0.04 mg/1) assays depend on the Tyndall's phenomenon of light
scattering property of particles in suspension. Lipaemic serum may interfere with CRP
determination. Nephelometry requires only 50 pi of serum, which is obtainable by finger
prick. Even more sensitive and specific assays are the immune assays which include
Enzyme immuno-assay (0.25 hour), Radial immunodiffusion (60-72 hours) and electro-
immunodiffusion (60-90 hours) (Komoroski et al. 1987). These detect as little as 0.3
ug/dl and correlate well with rate immuno-nephelometry (Gill et al. 1981). A most
sensitive test is a solid phase ligand-binding, radiometric monoclonal antibody
immunoassay, which is capable of reliably detecting concentrations in the normal range
not usually detectable by conventional methods (Wasunna et al 1990). A fluorescent
antibody technique detects CRP localized in tissues. Automated chemistry analyzers are
beginning to offer CRP in their test menus. CRP is normally present in trace amounts in
the blood of healthy individuals (Nudelman et al. 1983). Using sensitive assays, CRP
was identified in the serum of normal, healthy individuals in paediatric and adult
populations, at <10 mg/1 (Jaye et al. 1997). CRP shows quantitative differences in
different individuals, which may be genetically determined (Pepys et al. 1983). Different
cutoff values were used in research. Quoted upper limits of CRP varied from 8.0 mg/1 in
newborns (Felix et al. 1966), to 29 mg/1 in adults ( Wasunna et al. 1990). Each laboratory
should establish its own normal ranges for CRP, based on specific patient populations
and the method used.
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CRP response in disease
CRP is the classical and dramatic acute phase reactant with levels rising from a
median normal of <1 mg/1 to as much as 300 mg/1 or more within 24-48 hours of an
acute stimulus.
• Conditions associated with major elevations of serum CRP include:
1. Infections
2. Allergic complications of infection: Rheumatic fever, erythema nodosum leprosum
3. Inflammatory disease: Rheumatoid arthritis, systemic vasculitis, psoriatic arthritis,
Crohn's disease
4. Ischaemic necrosis: Myocardial infarction
5. Trauma: Surgery, burns, fractures
• Conditions associated with minor elevations of serum CRP include:






Clinical applications of CRP
• Screening for organic disease
• Monitoring the extent and activity of disease: Infection, inflammation, and necrosis
• Detection of inter-current infection.
The non-specific nature of the acute phase response coupled with the relatively crude
and poorly standardized semi-quantitative assays have caused clinical CRP tests to fall
out of favour. Earlier methods of CRP assay were either insensitive (e.g. latex
agglutination slide test), required long assay time (e.g. radial immunodiffusion), or were
technically difficult (e.g. electro-immunodiffusion). With the advent of precise immuno¬
chemical assays there has been renewed interest in the value of CRP measurements in
clinical practice. CRP is a precise reproducible test, and it is a sensitive objective index
of disease activity. Although a high CRP is not necessarily due to the same process for
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which the patient is being investigated, an elevated serum CRP concentration is
unequivocal evidence of an active tissue-damaging process, and thus provides a simple
screening test for organic disease. Since CRP is a non-specific response, a CRP value on
its own can never be diagnostic. However, in conjunction with other clinical data, it can
make a valuable contribution to important clinical decisions.
Compared to ESR, CRP has many advantages:
1. CRP levels respond much more rapidly with a much wider incremental range (100
pig/1 to >300 mg/1 in 2-3 days) while ESR changes within a much smaller range over
a period of days or weeks.
2. ESR does not show the same sensitive response to infection nor the same
discriminant difference between diseases like rheumatoid arthritis and SLE.
3. ESR is often not performed correctly so that results may not be reproducible.
4. There is a significant diurnal variation in ESR associated with food intake (Pepys et
al. 1983).
5. In afebrile children with different forms of malignancies, CRP levels are within the
same range of that observed in healthy children (Santolaya et al. 1994). Hence, any
rise indicates an intercurrent infection.
6. CRP can be run quickly and requires a small aliquot of serum, obtainable by
fingerprick.
Opinions vary on which serum CRP levels should be used as cut-off index in
categorizing the severity, and aetiology, of inflammatory responses. Typical serum
concentrations suggested are; mild inflammation and severe viral infection, 10-40 mg/1;
active inflammation and bacterial infection, 40-200 mg/1; and severe bacterial infections
and burns, 200-400 mg/1. However, there is no absolute serum concentration of CRP that
is diagnostic of bacterial infection, although 40 mg/1 has been claimed to give higher
specificity, with acceptable sensitivity, than 20 mg/1. Sensitivity values vary between
studies according to the level of CRP considered, the definition of infection used, and
the time at which blood was taken in the course of the disease. Specificity also depends
on whether patients with obvious non-infective pathology were excluded and on whether
serial measurements were made. CRP peaks within 48 hours and with remission of
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disease it falls at the same rate. When clinical history is less than 24 hours, CRP is the
acute phase protein of choice for its rapid response (6-10 hours) and large incremental
increase. The elevated circulating levels of CRP are expected to fall by up to 50% per
day when the acute phase stimulus resolves, thus it is useful in monitoring the resolution
of inflammation (Vigushin et al. 1993).
CRP is used as a diagnostic aid in a variety of clinical conditions:
1. In conditions where it is not usually significantly raised such as leukaemia, systemic
lupus erythematosus atosis and scleroderma, CRP can be a sensitive sign of inter¬
current infection.
2. Serial CRP determination may be of help in the post-operative follow up of children
requiring shunts for hydrocephalus. It has been shown that an absence of a fall in
CRP levels, 7-10 days post-operatively, provides an early warning sign of
complications, such as infection or thrombophlebitis (Fischer et al. 1976).
3. Serum CRP levels can aid in the differential diagnosis of arthritis in children
(Kunnamo et al. 1987) and its levels in joint fluid may be useful in distinguishing
inflammatory from degenerative or traumatic arthritis {Nudelman et al. 1983). CRP
was also found useful in the identification of concurrent septic arthritis in children
with acute haematogenous osteomyelitis (Unkila-Killo et al. 1994).
4. CRP is helpful in differentiating Crohn's disease from ulcerative colitis.
5. CRP was found to be the most consistently abnormal acute-phase reactant in the
presence of rheumatic fever activity, particularly carditis. It has been used as a guide
in ambulating clinically inactive patients with rheumatic fever since the ESR can be
elevated 1-8 weeks after CRP has returned to normal (Nudelman et al. 1983).
6. Slightly elevated concentrations of CRP, within the range (2-10mg/l) in normal
subjects, have been found to predict subsequent coronary events (Gabay et al. 1999).
7. It has been claimed that CRP can be helpful in differentiating pyelonephritis from
cystitis (Wientzen et al. 1979). These findings have not been confirmed (Hellerstein
et al. 1982) and this distinction may not be of clinical use.
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8. CRP was found to be a reliable and early predictor of infectious morbidity, and thus
aiding in the selective management of patients with premature rupture of membranes
(Evans MI, 1980).
9. Measurement of CRP is of particular value as an aide in differentiation of invasive
bacterial infection from viral infection. In general, CRP elevations in invasive
bacterial disease tend to be in the range of 150 to 350 mg/1. Invasive bacterial
infection without marked CRP elevation is unlikely, but may be encountered if an
early sample is taken. In contrast, CRP values in most acute viral infections tend to
be much lower, <20-40 mg/1. The greater CRP response in bacterial compared to
viral infections may be related to the extracellular existence of bacteria, resulting in
more tissue damage, and as a non-specific response to the components of bacterial
cell wall. However, this distinction is not absolute, as values of >100 mg/1 can occur
in certain viral infections, such as adenovirus (Clarke et al. 1983). Although CRP
cannot be used to classify the precise microbial aetiology of an infection, it may be
of some diagnostic value in conjunction with other tests and physical findings in
certain clinical settings:
i. In the neonate, CRP has been found to be a useful discriminative test for
bacterial infection (Corral et al. 1981, Schouten-Van Meeteren. 1992). However,
because there may be a lag between the onset of infection and the demonstration
of a rise in serum levels of CRP, some investigators have dismissed this test as
unhelpful in neonatal infection (Mathers et al. 1987). Some workers found that
the majority of infected babies had a delayed rise in CRP concentration, 12-24
hours after an abnormal immature/total neutrophil ratio was first detected
(Pulliam et al. 2001). Furthermore, other neonatal problems not resulting from
infection, such as asphyxia, foetal distress, PROM, maternal fever and meconium
aspiration, can also be associated with elevated levels of CRP (Ainbender et al.
1982). ). It is also difficult to apply normal ranges in newborn babies because of
the varying rates of maturity of CRP synthesis after birth (Kebler et al. 1994).
Another difficulty is that some infants seem incapable of responding with an
acute phase response (Philip et al. 1984). Because these infants usually died, it
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was thought that CRP may have a prognostic value in neonatal infection, with a
low CRP implying a poor prognosis (.Pulliam et al. 2001). Nonetheless, CRP has
been found useful in decreasing antibiotic use in neonatal intensive care units
(.Philip et al. 1981), and in guiding the duration of antibiotic treatment in
newborns with suspected infection (Stephan et al. 1982). Serial measurements
can optimise sensitivity and enhance the negative predictive value in deciding to
stop or withhold antibiotic therapy {Massroor et al. 1993, Pourcyrous et al.
1993). Sensitivity of CRP elevation in early detection of neonatal sepsis varied
from 47 to 100%, with specificity from 6 to 97% {Jaye et al. 1997). Such wide
ranges are the result of using different patient selection, sample timing and
method, test methodology, cut-off values and infection definition.
CRP was found predictive of lobar infiltration and discriminated viral from
bacterial pneumonia (McCarthy et al. 1978). However, high serum CRP
concentrations are frequently recorded in viral respiratory infections, especially
those due to adenovirus (Ruuskanen et al. 1985) and little value of CRP is found
in differentiating pneumococcal or other bacterial pneumonia from viral
pneumonia (Korppi. 2004).
CRP was found useful in the rapid differentiation of acute epiglottitis from
spasmodic croup and acute laryngotracheitis (Peltola et al. 1983). CRP could
differentiate children with streptococcal pharyngitis from those who were
carriers {Nudelman et al 1983).
High levels of serum CRP differentiated bacterial from viral acute otitis media
(Komoroski et al. 1987, Tejani et al. 1995), and predicted recurrence of otitis
(.Del Beccaro et al. 1992).
CRP levels completely separated septic meningitis from aseptic (viral)
meningitis and helped follow the course of the disease {Peltola et al. 1982,
Clarke et al. 1983). CRP levels in CSF were also useful in the initial work up of
children with suspected meningitis {Corral et al. 1981). In other studies
however, CSF levels of CRP failed to add to the information routinely obtained
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(i.e. Gram stain, cell count, glucose and protein) in predicting the presence of
bacterial infection (Alistair et al. 1983).
vi. In febrile neutropenic children, CRP clearly discriminated bacterial from non¬
bacterial infections (Santolaya, 1994).
vii. Quantitative CRP concentration is a valuable laboratory test in the evaluation of
febrile young children who are at risk for occult bacteraemia and SBI, with a
better predictive value than the WBC or ANC (Pulliam et al. 2001). Other
workers claim that CRP was costly and offered no advantage over WBC and
ANC in screening febrile children for occult bacterial infection (Isaacman et al.
2002).
iv. 3. b. ii. Erythrocyte Sedimentation Rate (ESR)
This indirect test of acute phase response measures the distance in millimetres
that erythrocytes fall during one hour. It depends on the aggregation of red blood cells
and formation of rouleaux, which is determined by: i) red cell characteristics, ii) plasma
viscosity, and iii) the bridging forces of macromolecules, such as plasma proteins, which
lower the negative charge on the red blood cells. Different plasma proteins, mainly
fibrinogen and immunoglobulins, contribute to this phenomenon. The bridging force of a
plasma protein is proportional to its molecular weight; the heavier a protein, the more
red cells aggregate. Thus, fibrinogen is the strongest aggregator, gamma globulins with
half the aggregating strength, and albumin the weakest. The relative contributions of
different plasma proteins to ESR are; fibrinogen 55%, a-2-macroglobulin 27%, the
immunoglobulins 11%, and albumin 7% (Stuart. 1988). Direct measurements of
fibrinogen are unsatisfactory because of considerable overlap of value between diseased
and healthy persons (Powell et al. 1995).
Many methods are used to measure ESR, the Westergren method being the
earliest and the gold standard. A standard 200 mm glass tube is used and the normal
values are taken as less than 16 mm for men and less than 25 mm for women. The
second most commonly used method is the Wintrobe method, in which a 100 mm tube is
used. The normal rates are <6.5 and <16 mm for men and women, respectively. This
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method is more sensitive than the Westergren method in the mildly elevated range of the
sedimentation rate. However, it is relatively insensitive in the high ranges and may
therefore give misleadingly low results. Both methods can be affected by mechanical,
environmental, and technical factors; i) tube dimensions (a large bore tube or a tall
column will lead to an increase in ESR); ii) temperature, maximum rouleaux occurs at
37°C; iii) a tilted surface can increase the rate; iv) preformed rouleaux in a blood sample
that is not well mixed will increase the rate, v) a clotted blood sample will consume
fibrinogen and lower the rate, vi) low rate in long kept blood sample (>2 hours), and vii)
vibration, e.g. from a centrifuge, will inhibit settling and lower the rate. ESR is also
strongly influenced by anaemia (increases ESR) and polycythaemia (false low rate) and
this cannot be corrected.
Almost any disease can lead to an elevation of the rate, so that its value is
considered more as a sickness index than as a diagnostic tool. Diseases commonly
associated with a highly elevated ESR include malignancy, collagen vascular disease,
and infection. Any infection may raise the ESR, but bacterial infections do so more
commonly than viral infections. Some infectious diseases, such as pelvic inflammatory
disease, meningitis, and infective endocarditis, are characteristically associated with a
highly elevated ESR. On the other hand, there are many disease states which are
associated with a low ESR: i) abnormal cell shapes (e.g. hereditary spherocyctosis) and
haemoglobinopathy, such as sickle cell disease, ii) abnormality of plasma protein such
as hypofibrinogenaemia (e.g.neonatal, herediatry, DIC), hyperproteinaemia (e.g.
Waldenstrom macroglobulinaemia), iii) Drugs such as anti-inflammatory agents,
corticosteroids and asparaginase, and iv) congestive heart failure.
Because it is a manual procedure, ESR quality control is unsatisfactory.
Measuring ESR takes at least one hour and should be performed within two hours after
blood collection, and it requires relatively large blood volume so is not suitable for
paediatric use. Plasma viscocity is analogous to ESR as it reflects the concentration of
the same proteins as ESR. Plasma viscosity can be measured within minutes and on
stored samples. Unlike ESR, its result is independent of anaemia, red cell characteristics
(low ESR in sickle cell anaemia), or gender and is largely independent of age (Stuart.
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1988). Plasma viscosity can be done from a finger/heel prick and is therefore more
suited for paediatric use but automated viscometers are not widely available. An increase
in plasma fibrinogen concentration takes 24-48 hours and the concentration
subsequently decreases with a half-life of 4-6 days. Thus measuring ESR, and plasma
viscosity, is not valuable for monitoring rapid changes in the onset or resolution of the
acute phase response. They do however also respond to increases in immunoglobulins
and immune complexes and other proteins and thus cast a broader net for the detection
of disease than does any other acute phase protein alone. They are less affected by acute
events, such as intercurrent viral infections, that cause a transient increase in sensitive
acute phase proteins such as CRP.
ESR is probably the most widely used index of acute phase response and has
served as a simple laboratory test for decision making since it was introduced in the
1920s {Stuart J, 1988). It is cheap, easy to perform, and does not require a power supply,
equipment or much technical skill. It is especially attractive for small laboratories,
primary health clinics, and countries with limited resources. Nonetheless, compared to
CRP, ESR has several disadvantages as a measure of the acute phase response. ESR is
an indirect measurement of plasma acute-phase proteins and can be greatly influenced
by the size, shape and number of erythrocytes, as well as other plasma proteins such as
immunoglobulins. As the patient's condition worsens or improves, ESR changes
relatively slowly, whereas plasma CRP concentrations change rapidly. The range of
abnormal values for CRP is broader than that of ESR changes, with accompanying
clinical implications. Furthermore, ESR increases steadily with age, while plasma CRP
concentrations do not. Before the advent of sensitive quantitative CRP tests, ESR
performed best in predicting bacterial infection in febrile paediatric patients and was
thus recommended in the evaluation of these patients (McCarthy et al. 1978). Compared
to the more traditionally used screening tests (e.g. WBC indices), ESR was favoured as
an indicator of bacteraemia in febrile children (Bennish et al. 1984). Some studies have
demonstrated that an elevated ESR can also be consistent with non-invasive bacterial
infections, such as acute otitis media {Del Beccaro et al. 1992).
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iv. 3. b. iii. Other acute phase proteins
Examples of acute phase proteins evaluated as diagnostic tools for detecting
bacterial infections include:
Elastase-di- proteinase inhibitor complex: Elastase, a proteinase secreted by
polymorphic neutrophils, is neutralised by complexing with di- proteinase inhibitor (cii-
anti-trypsin). Elastase-di- proteinase inhibitor complex was demonstrated to be a
sensitive marker of sepsis in the newborn. However this test lacked specificity, as both
obstetric and neonatal complications were associated with high levels (Kebler et al.
1994). Reference ranges of E-ai-PI have been developed for the neonatal period
(Rodwell et al. 1992). Elastase plasma levels in whole blood from patients with sepsis,
incubated with lipopolysacharide, were increased by up to 188% above normal, while
the release of TNF, IL-1 and IL-8 was markedly decreased. This suggests that other
mediators or mechanisms may be involved in the up-regulation of detrimental protease
release during sepsis (Ertel et al. 1994).
Complement products: The complement cascade is activated directly by bacteria
and antigen-antibody complexes, and the degree of complement activation could,
therefore, provide early and specific evidence of bacterial infection. C3d, the end
product of the C3 complement component activation via both the classical and
alternative pathways, was found to be as reliable as CRP in the diagnosis of neonatal
bacterial infection, with a sensitivity and specificity of 70% and 97.7% respectively
{Guillois et al. 1994). The value of Ba, (activated factor B from the altenative pathway),
C4d, and C3d in the early detection of neonatal infection has been studied. The highest
sensitivity (47.1%) and specificity (92%) were those of Ba. Complement C9 was also
reported to be more sensitive than CRP (Peakman et al. 1992).
Orosomucoid (ai-acid glycoprotein): Some workers have found normal serum
levels of orosomucoid in healthy full-term and pre-term infants and no elevation in
infants with non-infectious disease. There was a marked increase from the early stages
in infants with bacterial infection, levels returning to the normal range with clinical
improvement (Gotoh et al. 1973, Sann et al. 1984).
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Fibronectin: This is a large opsonic glycoprotein, which promotes reticuloendothelial
system clearance of bacteria, and its levels are reduced in sepsis. An acute reduction in
the concentration of plasma fibronectin has been found to be a valuable marker of sepsis
in neonates and young children (Gerdes et al. 1983, Koenig et al. 1988).
Haptoglobulin: Contradictory results on the usefulness of haptoglobulin in detecting
bacterial infection have been reported (Speer et al. 1983).
These acute phase proteins have certain disadvantages that hamper their routine
clinical use as indicators of infection; overlapping values for normal and diseased
persons, prolonged doubling time and/or half-life, problems with standardization of
assays, and elevations in response to trivial inflammation, such as the common cold.
Some proteins, such as haptoglobin and alpha-1-antitrypsin can be actively catabolised
in some disease states and may be deficient in some inheritable conditions.
iv. 4. Other Markers
Other markers used to detect bacterial infections include:
Leucocyte alkaline phosphatase activity: Low levels of this enzyme have been
reported in infected newborn infants and this was suggested as a helpful aid in the
diagnosis of neonatal bacterial infections (Donato et al. 1974).
Leucocyte lactate dehydrogenase: Elevated levels of leucocyte LDH were found
in infants with bacterial meningitis and it was suggested that this test could also be
helpful in detecting serious bacterial infection (Powers et al. 1974).
MxA protein: It has been demonstrated that elevated levels of MxA protein (an
interferon inducible gene product) in blood lymphocytes could discriminate between
viral and bacterial infections in febrile children (Halminen et al. 1997).
Polymerase chain reaction (PCR): DNA sequences that are highly conserved
among most pathogenic bacteria were amplified by PCR and found useful in the early
diagnosis of systemic bacterial infection (McCabe et al. 1995).
Pro-calcitonin: The specific function of this protein is unknown, but it is thought to
sustain inflammatory reactions after its production in hepatocytes is stimulated by
cytokines, especially IL-6 (Hsiao et al. 2005). It is known to rise slightly in viral
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infection and enormously in bacterial infection. High serum pro-calcitonin levels were
found in the plasma of septic patients (Assicot et al. 1993). This protein was found a
useful marker for the early diagnosis of neonatal infection (Gendrel et al. 1996) and was
recently shown to be superior to leucocyte count and CRP in predicting severe bacterial
infection in children {Hatherill et al. 1999, Galetto-Lacour et al 2003).
Neopterin: This is a pteridine bi-product of activated monocytes/macrophages released
into blood upon immune activation. Raised systemic levels of this substance correlated
with bacterial sepsis and plasma levels differentiated between bacterial and viral
infection in preterm infants (Jurges et al. 1996).
iv. 5. Cytokines
Plasma concentrations of cytokines and their receptors have been studied in
patients with inflammatory conditions. Measurement of cytokines in plasma is difficult,
partly because of their short half-lives and the presence of blocking factors. The high
cost, limited availability, and the absence of standardization of their measurement argue
against its use in clinical practice. This is discussed in further detail in the following
chapters of the thesis. Table 11 summarizes some of the newly introduced diagnostic
tools for predicting bacterial infection.
iv. 6. Neural Networks
This classification technique has been used for many purposes. In the medical
field, its main uses were in radiology and in constructing management algorithms for
cardiac emergencies. Its role in the detection of serious bacterial infection is not fully
evaluated.
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Occurs within minutes, no left shift, e.g. asthma
Corticosteroids Occurs within 4 hours, left shift with eosinopenia
Diabetic ketoacidosis Can be as high as 25,000/mm3, with left shift
Tissue injury
Burns, crush injury, fracture, neoplasm; neutrophilia with left
shift
Acute haemorrhage More with internal bleeding
Acute haemolysis
Limits use of WBC in diagnosing infection, e.g. in sickle cell
anaemia
Myeloid reaction
WBC >50,000/mm3, in severe infections, miliary TB, bacterial
meningitis, staphylococcal pneumonia, and in JRA
 
Ill
Table 8: Relation between the incidence of bacteraemia and the white blood cell
count.*.





*: Steele RW, 2007
Table 9: Correlation between the incidence of bacteraemia and the degree of
fever.*
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Table 10: The acute phase plasma proteins
Protein class Increased Decreased
Proteinase inhibitors
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Cytokines were originally thought to be produced only by lymphocytes and to
communicate with other cells of the immune system, hence the original name
lymphokines. However, it is now known that neither the production of cytokines nor
their effects are restricted to lymphoid cells, therefore the term cytokines was
introduced. Cytokines were originally named according to their biologic effects, e.g.
tumour necrosis factor, B-cell stimulating factor, etc. However, these descriptive names
were misleading because most cytokines possess more than one biologic property. It was
therefore agreed that a new cytokine would be named according to its biologic property,
but once its amino acid sequence was established, it would be called interleukin and
assigned a specific number. For example, human B-cell stimulating factor 1 was called
interleukin-4 after its complementary DNA was cloned. Nevertheless, some cytokines
retain their original names, e.g. interferons, the colony-stimulating factors, and the
thymus derived hormones. The term interleukin is somewhat misleading, because
interleukins are synthesised by and act on leukocytic and non-leukocytic cells (Whicher
& Evans, 1990).
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v. 2. Chemical structure
Cytokines are polypeptides that participate in a variety of cellular responses,
including the regulation of the immune system. In contrast to immunoglobulins, their
chemical composition is not determined by the nature of the stimulating antigen. Most
cytokines are glycated, giving rise to considerable molecular heterogeneity. The sugar
moieties may be important for receptor binding or modulation. Cytokine receptors
contain trans-membrane domains that interact with GTP-binding proteins, which
regulate different enzymes in the signal transduction pathways, e.g. phosphoinositase C,
adenylate cyclase, and tyrosinase kinase. The signals that link these changes to gene
transcription are largely unknown. Many cytokines interact with each other at the
cellular level. The effects of a cytokine on a cell depend on the milieu of other cytokines
and hormones; therefore, measurements of single cytokines may reveal only part of the
story. Advances in protein biochemistry and recombinant DNA technology during the
1980s have transformed our understanding of cytokines. Studies using their recombinant
products have greatly extended our understanding of their many metabolic, endocrine,
haematological, haemodynamic and immunological effects (Whicher & Evans et al.
1990).
v. 3. Effector & target cells
Cytokines are produced throughout the body. Many cytokines can act on the
same cells producing them (autocrine function). In localized areas, such as joint spaces
or lymphoid tissue, they can act on other types of cells in the immediate vicinity exerting
a paracrine effect. Cytokines that are produced in large amounts and gain access to the
circulation act in a hormonal (endocrine) fashion and can have profound systemic
effects. Cytokines have several properties relevant to the immune response as opposed to
the inflammatory response. Cytokines that primarily effect an immune response are
locally active (paracrine) and tend to be of T cell origin, e.g. IL-2, IFN-y, and IL-4. The
more systemically active (endocrine) cytokines are involved more in inflammation and
are produced mainly by macrophages (Whicher & Evans 1990).
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V. 3. aT-ceils
In contrast to the relatively antigen-non-specific inflammatory response, the
immune response is a highly specific reaction effected by lymphocytes, which recognize
specific antigens. The initial event in the immune response is the uptake and processing
of the antigen by phagocytic cells (monocytes and macrophages). Processed antigens are
presented in association with class I or II MHC antigens on the phagocytic cell surface.
T cells with T cell receptors that recognize the antigen-MHC complex can respond by
synthesizing and secreting various growth and differentiation factors; the cytokines.
These cytokines themselves are antigen-non-specific and, in contrast to antibodies, the
structure of the stimulating antigen does not determine their chemical composition.
However, they are responsible for the rapid expansion and differentiation of the antigen-
specific lymphocyte population.
The antigen receptor on the surface of the T cell that interacts with the antigen-
DR (or MHC) complex consists of a complex of five peptides. Of these, three are
invariant from cell to cell while the other two are unique to each T- cell clone. The latter
two peptides account for the antigen specificity of the clone. The invariant three-peptide
complex is called CD3. When an antigen is presented in the appropriate configuration to
the complementary antigen receptor, the T-cell becomes activated. As a consequence of
this activation, the T-cell synthesizes a variety of proteins, of which some are secreted
and others become integral components of the cell membrane. The former include IFN-y
and interleukins-1, 2, 3, 4, and 6, whereas IL-2 R is an example of a membrane-
associated protein generated during antigenic challenge. The cytokines thus produced
are independent of the antigen and function to amplify the response to antigen in a non¬
specific fashion. Gamma-interferon released from activated T-cells enhances DR
expression on the macrophage thereby increasing the T-cell response to the antigen.
Interleukin-1 augments the synthesis of interleukins-1, 2, 3, 4 and 6, gamma-interferon,
and interleukin-2 receptors. Interleukin-2 binds to specific receptors on activated T-cells,
giving rise to the expansion of the activated clone. Interleukins 4 and 6 provide the
critical signals for the growth and maturation of antigen-primed B cells. Two distinct T
helper cell types have been described: activated ThI cells which secrete IL-2 and IFN-y,
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and Th2 cells which produce IL-4 and IL-5. Both types of cells produce IL-3 and GM-
CSF. IL-lp is an accessory signal that is required for the proliferation of T-cells in
response to IL-2 and IL-4. However, not all T-cells respond to IL-1. Reportedly, Th2,
but not ThI, respond to IL-1. Nai've T cells stimulated by lectin require an accessory
signal that cannot be replaced by IL-1. This accessory signal is thought to be IL-6,
because resting T cells express high affinity receptors for this cytokine (Whicher &
Evans 1990).
v. 3. b. B-cells
The principal steps leading to the production of antibodies are i) specific
activation of the virgin or memory B-cell, ii) proliferation (clonal expansion), and ii)
differentiation into antibody-producing plasma cells. Cytokines act in concert to regulate
proliferation and differentiation of B-lymphocytes. A small resting cell is converted to a
large B-cell on binding of its surface immunoglobulin to a specific antigen. Interleukin-4
stimulates the proliferation of this large cell. Interleukin-6 drives this proliferating cell to
become a specialized immunoglobulin-secreting plasma cell. As mentioned earlier,
interleukin-1 stimulates the synthesis of IL-6 by the activated T-cell. Cytokines that
participated at different stages of B-cell stimulation also play a part in determining what
type of antibody is secreted by the plasma cell. IL-4 and IL-5, produced by TH2 cells,
influence the switch towards IgE and IgA. On the other hand, ThI cytokines, IFNy and
IL-2, induce production of IgG. The macrophage-derived IL-6 acts on activated B cells
stimulating the general synthesis of immunoglobulin. It therefore seems likely that the
nature of antibody response is determined by the cytokine profile associated with the
particular immune response (Whicher & Evans 1990).
v. 3. c. The macrophage
The pro-inflammatory cytokines include IL-1, IL-6, IL-8, TNF-a, and interferon
gamma (IFN-y). Most nucleated cells appear able to produce these cytokines, especially
IL-1, but macrophages produce the largest amounts and are thus key producers of
inflammation. These cytokines have a wide range of target cells that possess the
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corresponding receptors. However, some cytokines, e.g. IL-1, can induce prostaglandin
synthesis without discernible receptor interaction. The inflammatory responses mediated
by macrophage-produced cytokines include:
1. Increase in vascular permeability by release of PGE2 from connective tissue
2. Procoagulant production by endothelial cells
3. Production ofproteases from fibroblasts and mesenchymal cells
4. Induction of respiratory burst and production of oxygen radicals and hydrolytic
enzymes by neutrophils and monocytes.
5. Chemotactic attraction of monocytes and neutrophils to the site of inflammation.
This latter effect is induced by IL-8, while IL-1, TNF and interferon- y mainly
mediate the other processes (Whicher & Evans 1990).
v. 3. d. Polymorphs
The neutrophil is the primary cell of the acute inflammatory response. The diverse
anti-microbiological mechanisms of the neutrophil can be broadly divided into non-
oxidative (release of cidal enzymes and other proteins by degranulation) and oxidative
(release of reactive oxygen intermediates). Cytokines play a pivotal role in each of the
steps of neutrophil function:
1. Stimulation of myelopoeisis
2. The release of PMNs from marrow reserves
3. Adhesion to endothelium, which is vital in the transportation of neutrophils to sites
of inflammation.
4. Chemo-attraction to sites of inflammation and micro-organisms. This is mediated by
chemokines which are released in response to the action of many cell products, such
as leukotriene B4, PAF, C5a, and the bacterial peptide formyl-Met-Leu-Phe.
5. Induction of integrin expression on the surface of neutrophils. Adhesion via the
integrin CDllb/CD18b plays a critical role in priming the neutrophil for both
microbicidal mechanisms and in providing an environment that protects the killing
mechanisms from the inhibitory effects of tissue fluids and plasma.
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6. Stimulation of the micro-organism-killing activities of polymorphs. (Saez-Liorens &
McCracken. 1993).
v. 3. e. The endothelium
Under normal circumstances, peripheral blood polymorphs are distributed
between the circulating pool (in the central, axial stream of the vessel) and the
marginating pool (along the endothelial surface of the blood vessels). The half-life of
these cells in the circulation averages 6 to 7 hours. In patients with sepsis, an initial
transient neutropenia develops and is followed several hours later by an increase in the
peripheral blood PMN count. This initial neutropenia results from the activation by
cytokines of leucocyte-endothelium adhesion receptors that promote margination of
polymorphs.
Initially, the neutrophils start to roll along the wall of the post-capillary venule, at
a rate much slower (30 pm/s) than the progress of erythrocytes flowing past (1000 pm
/s). The progress of some cells becomes arrested and they become flattened and
elongated. These cells begin to move by a slow crawling action and to emerge through
the intact endothelial wall. Distinct proteins expressed on the surfaces of the cells
involved mediate these steps. These proteins are referred to as adhesion molecules and
bind specifically to receptor structures on the surface to which adherence is occurring,
which is usually another cell or elements of the extra-cellular matrix. Endothelium-
leucocyte interaction represents a critical event in the generation and amplification of the
inflammatory cascade and results from cytokine-induced activation of both cells to up-
regulate synthesis and surface expression of adhesion molecules. Adhesion is controlled
through the amount, distribution and adhesiveness of these molecules brought about by
signals from within the cells expressing them, these latter being mediated by cytokines.
Examples of such molecules expressed on polymorphs include the integrin (CD 11 /
CD18) and the selectin group of receptors (Whicher & Evans 1990).
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v. 3. f. Selectins
The selectins are a family of three adhesion molecules which are vital in the
initial rolling stage of leukocyte-endothelium adhesion and are expressed on both cell
types. Leukocytes roll on stimulated endothelium before migrating to sites of
inflammation or vascular injury. This initial and essential step is mediated by the
selectins and their ligands. There are three types of selectins. L-selectin is abundantly
expressed on unstimulated neutrophils and mediates the homing of lymphocytes to
lymph nodes. E-selectin is expressed only by endothelial cells relatively slowly in
response to stimulation by cytokines such as TNF and IL-1 and aids in migration of
leukocytes. P-selectin is stored in a-granules of platelets and Weibel-Palade bodies of
endothelial cells and is expressed on these cells after stimulation by rapidly acting agents
such as thrombin or histamine. All three selectins mediate the rolling type adhesion of
leucocytes. These proteins are mobilized to the surface of the cells by transport of
intracellular stores contained in granules. All three proteins share a similar structure with
a terminal lectin moiety, a protein structure that specifically binds to carbohydrate
structures, facing outwards from the cell surface. The fucose-containing neutralizingO de
Lewisx (Lex) antigen, a blood group antigen with an added sialic acid residue (sLex), is
one of the carbohydrate ligands for these selectins.
The binding of the selectins to their ligands makes the leukocytes decelerate by
rolling on endothelial cells. Rolling greatly increases the affinity of the leucocyte p2
integrin adhesion receptors for ligands (the adhesion molecules) on activated
endothelium. The same types of receptors also mediate the extravasation of leukocytes.
Leukocytes migrate, using their pi integrins, toward a chemotactic stimulant produced
by bacterial invasion. Vascular injury immediately induces endothelial cells to release
the contents of their storage granules (Weibel-Palade bodies), including P-selectin and
von Willebrand factor (vWF). VWF is quickly deposited on the exposed extracellular
matrix, where it enhances adhesion of platelets (Ib-a) to the damaged site.
Degranulation of platelets and activation of the platelet integrin anbP3 (Iiib/IIIa) induce
further accumulation of platelets and recruit neutrophils and monocytes to aid in repair
(.Lorant et al. 1995, Frenette et al. 1996).
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v. 3. g. Integrins
The integrins are a family of cell-surface receptors involved in almost every
aspect of cell signaling and mobility. All members are D eutral, consisting of two
dissimilar protein chains designated a and [3, non-covalently linked together. The
members of the subfamily of integrins that share the (32 (CD 18) chain are found only on
leukocytes, e.g. CDlla/CD18 (LFA-1), CD llb/CD18 (Mac 1), and CDllc/CD18, all of
which are expressed on neutrophils. The integrins mediate the firm adhesion and
subsequent crawling of the flattened bipolar neutrophils. These proteins are also
mobilized from granular stores. While LFA-1 varies little between cells or in response to
stimuli, Macl expression increases rapidly in response to a wide variety of stimuli,
including C5a and IL-8. ICAM-1, expressed on endothelium, is the ligand for these
integrins (Frenette et al. 1996).
v. 4. Cytokine modulation
Cytokines are powerful molecules with the potential for auto-stimulation; therefore
equally powerful regulatory processes must also exist. Negative control exists at many
levels: gene transcription / translation, binding of the protein, either specifically or non-
specifically, thus increasing catabolism, and finally competition for receptor occupation.
Additional control is provided with the opposing action of other cytokines that are
released simultaneously:
1. A group of related cytokines are released in acute inflammation that appear to
provide a negative feedback to cushion the effects of the inflammatory process.
Inflammatory stimuli activate the production of counter-inflammatory cytokines that
can modify the host inflammatory response. For instance, IL-10 and IL-4 have
multiple down-regulating effects on specific immune responses, including down-
regulation of TNF release, and induction of IL-lra and IL-1 receptor type 2.
2. IL-6 induces the release of acute phase proteins, such as CRP, fibrinogen, some
complement components and many anti-proteases, from the liver.
3. Many cytokines have soluble binding proteins. Theses are either shed from the
membrane or separately translated as a truncated protein. Soluble receptors have
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been described for IL-1, IL-2, IL-4, IL-6, TNF-a, and IFN-y. Certain receptors, e.g.
p55 IL-2R, have very little affinity for their cytokines, so their functional role is not
clear. Soluble receptors retain the ability to bind their respective cytokines. Free and
bound cytokine exists in equilibrium, and this balance may determine the bioactivity
of a given cytokine concentration. With regards to sepsis, sTNF-R has been most
extensively studied. Plasma sTNF-R concentrations are present in normal humans
and are released in excessive amount into the circulation in response to endotoxin.
Endotoxin injection results in a 4-5-fold increase in sTNF-R concentration by 3
hours, with peak plasma concentrations 10 times that of TNF. In human sepsis,
sTNF-R is increased and correlates with severity of illness and mortality, but its
pathophysiologic role is incompletely understood. TNF-sTNFR complex may serve
as a slow release reservoir of TNF, which could perpetuate the inflammatory
response.
4. Cytokines also bind to non-specific binding proteins e.g. IL-6 binding to a.2-
macroglobulin. These may act as carriers regulating cytokine breakdown, or as
regulatory proteins inhibiting their biological functions.
5. Autoantibodies for cytokines have been described not only in disease, but also
naturally, e.g. anti-IL-la and anti-TNF-a.
6. A natural inhibitor for IL-1 has been described. A 22 kDa protein, with 26%
homology for IL1, binds to IL-1 receptors on target cells and blocks the actions of
IL-1. This IL-1 receptor antagonist binds only to type 1 receptors. It does not
immunologically cross-react with IL-1. This protein has been purified from the urine
of febrile patients. It has been observed that as monocytes mature into macrophages,
the production of IL-1 decreases and that of IL-lra increases. Paradoxically, sTNF-R
and IL-ra are released into the circulation in 10-100-fold excess compared with TNF
and IL-1. In patients with sepsis syndrome, prognosis may be determined by the






vi. l. Tumour necrosis factor-a (TNF)
TNF was first described, in the serum of mice challenged with endotoxin, as a
factor that caused the necrosis of some tumours in vivo. It was later cloned as a 17 kDa
protein, and retained the name TNF-a. TNF-P, a lymphocytotoxin derived from T-cells,
has 28% homology, and shares the same receptor, with TNF-a. Genes coding for both
molecules are on chromosome 6, near the region coding for MHC. There are two
independent cell surface receptors for TNF-a, with MW of 65 and 75 kDa. All somatic
tissue, except erythrocytes, possess TNF-a receptors, but with great variation in density.
This is reflected on the ubiquitous effects of TNF-a {Emery et al. 1991).
TNF-a is synthesised by cells of the monocyte-macrophage lineage, notably
astrocytes, microglial cells, and kupffer cells-, and by lymphocytes. Synthesis is induced
by bacterial products such as endotoxin, toxic shock protein-1, mycobacterial proteins,
fungal antigens, viruses, and C5a. This underlies the importance of this cytokine in
infection and inflammation. Following synthesis, it becomes widely distributed in the
tissues and then rapidly degraded. Pre-treatment of macrophages with dexamethasone
effectively inhibits its synthesis upon exposure to endotoxin. Pre-treatment with anti-
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TNF serum also protects against the lethal effects of injected endotoxin (Bellomo et al.
1992).
TNF is a primary mediator of inflammation with pleiotrophic effects on target cells
(.Morrison et al. 1987). TNF is distinct from other cytokines by being strikingly
cytotoxic. TNF was initially known as cachectin because of its ability to induce lipolysis
and glycogenolysis, and to induce anorexia, weight loss, and anaemia if given in
sublethal doses to animals. Effects of TNF established by in vitro studies include
neutrophil adherence to endothelium, induction of the coagulation cascade, production
of free radicals and stimulation of osteoclast bone resorpotion. TNF also enhances the
production of other cytokines, such as IL-1, IL-6, IL-8 and PGE2. Clinical effects
attributed to TNF include; fever, lactic acidosis, hyperglycaemia, diuresis, capillary
leakiness, and haemodynamic features of shock. Infusion of recombinant TNF results in
systemic inflammatory response syndrome (SIRS) with fever, haemodynamic
abnormalities, leucopenia, elevated liver enzymes and coagulopathy. TNF is capable of
causing end organ dysfunction, which occurs in severe sepsis. After i.v. administration
of endotoxin in humans, TNF concentrations increase rapidly to peak at 4 hours,
coinciding with the peak of fever, rigors, myalgia, headaches and nausea. In contrast to
IL-1, TNF seems to have no direct effect on lymphocyte activation, but both induce the
same spectrum of acute phase changes (Whicher & Evans et al. 1990). The two
cytokines act synergistically in a variety of biologic responses, including tissue damage,
metabolic abnormalities and neuro-enaocrine changes. TNF-a has a major amplifying
effect on most of the diseases characterised by increased IL-1 production, e.g.
malignancy. In meningitis, cerebral malaria and the acute respiratory distress syndrome
(ARDS) the excessive production of TNF-a is of primary pathological importance.
Increased levels of TNF were first demonstrated in plasma of patients with
meningococcaemia in 1987. TNF can be detected in the plasma of many patients with
sepsis, and concentrations generally correlate with severity of illness and outcome
(Peakman et al. 1992). Persistently elevated levels of TNF might be more determinant of
prognosis than peak levels (Thijs LG, 1995). There are wide variations among studies in
the reported proportions (16-100%) of septic patients with elevated TNF levels
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(Dinarello et al. 1987). Raised TNF-a levels also appear to be a feature of certain
healthy people (Emery et al. 1991).
vi. 2. lnterleukin-1
There are two structurally related forms of this cytokine; IL-la and IL-1 p. Both
activate the same IL-1 receptor, exerting the same biological effects, with little
homology (26%) in their structure. In contrast to IL-ip, IL-la is rarely found in body
fluids in soluble form. IL-1 P is the predominant form produced by endotoxin-stimulated
monocytes. Interleukin-1 exerts effects through its two receptors by inducing signal
transduction, which may involve G proteins and serine kinase or cAMP and protein
kinase. Monoclonal antibodies directed against type 1 (80kDa), but not type 2 (60kDa)
receptors, block signal transduction. IL-1 can act by inducing prostaglandin synthesis
without discernible receptor interaction (Whicher & Evans et al. 1990, Morrison et al.
1987).
IL-1 is produced by nearly all cell types, including T & B lymphocytes, natural
killer cells, skin keratinocytes, astrocytes, microglia, epithelial cells, mesangial cells and
vascular tissue. However, macrophages produce the largest amounts. Antigens, toxin,
injury, and inflammatory processes induce the production of IL-1. Endotoxin is one of
the most potent, at picogram levels, inducers of IL-1. Antigens may induce IL-1 directly
by cell/cell contact or indirectly by release of other cytokines from activated T cells, e.g.
IL-2, IFN-y and MCSF. Factors known to down-regulate IL-1 production include
steroids, IL-4, IFN-P, and IL-1, PGE2, fever and malnutrition {Emery et al. 1991).
The physiological role of IL-1 is not known, but its levels in the CSF are raised
during sleep. IL-1 induces slow-wave sleep and the synthesis and release of hepatic
acute-phase proteins, ACTH, Cortisol, and insulin. IL-1 has effects on a wide variety of
tissues: i) T-cell activation and production of cytokines such as IL-6, IL-8 and TNF. ii)
Leukocyte adhesion to endothelium, prostaglandin release and production of a
procoagulant state, iii) Induction of proteases and bone resorption, and iv) Induction of
the acute phase response. Infusion of IL-1 causes fever, haemodynamic abnormalities,
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anorexia, malaise, arthralgia, headache, and neutrophilia. IL-1 has been implicated in the
pathogenesis of Crohn's disease, sunburn, burns, psoriasis, endometriosis, silicosis,
immune complex glomerulonephritis, scleroderma, acute arthritides and rheumatoid
arthritis (Bellomo et al. 1992).
IL-1 is not normally present in human plasma (.Blackwell et al. 1996). IL-1
production can be detected in the circulation within a few hours after the onset of
infection or injury. Peak levels are reached around 4 hours after endotoxin (Morrison et
al. 1987). Detectable levels of IL-ip have been reported in 0-100% of patients, and its
correlation with outcome remains unclear (Ozdemir et al. 1994, Blackwell et al. 1996).
Markedly elevated levels of IL-lra were detected in plasma of septic patients, and
persisted for longer periods than IL-1 (Thijs et al. 1995) Measurements of IL-1 in
biological fluids has been confounded by many factors. Preparations were often
contaminated with LPS thus confusing the specificity of any response seen. Production
of IL-1 is induced by other cytokines, and its actions overlap with those of different
cytokines suggesting redundancy of function {Emery et al. 1991). Nevertheless, the high
recovery of IL-ip added to normal plasma or serum from septic patients suggests that
the presence of serum inhibitors of IL-1 could not have impaired the detection of IL-1 in
the study patients (Peakman et al. 1992).
IL-1 receptor antagonist (IL-1 ra)
IL-ra was first identified as a 23 kDa protein from the urine of patients with
monocytic leukaemia. The amino acid sequence of this protein is 26%, and 19%
homologous to IL-ip and IL-1 a respectively. IL-lra blocks the activity of IL-1 by
competing for binding to type 1 and type 2 IL-1 receptors without causing signal
transduction. IL-lra can attenuate endotoxin effects in animal models of sepsis. In
human volunteers, plasma IL-lra concentrations peak 3-4 hours after endotoxin
injection. In humans with sepsis, IL-lra is present in plasma at markedly higher
concentrations than IL-1, but its function in this setting is uncertain {Dinarello et al
1987).
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vi. 3. lnterleukin-6 (IL-6)
Biologically identified in 1981 and molecularly cloned in 1986, IL-6 has been
known by various designations. Originally it was labelled IFN-2 when found as a
secretory product of fibroblasts after induction for IFN {Emery et al. 1991). It was also
known as BSF2/BCDF and HPGF when found to stimulate B-cell differentiation and
hybridisation, respectively (Assicto et al. 1993). It was then called hepatocyte
stimulatory factor for stimulating hepatic synthesis of acute phase proteins {Calandra et
al 1991). IL-6 exists in five or six different forms, with molecular masses between 21.5
and 28 kDa, which are the result of post-translational changes such as glycation and
phosphorylation. These post-translational modifications may play a role in tissue-
specific functions and/or in plasma half-life. A high-molecular-mass form of 42-45 kDa
has also been described in plasma, possibly a complex formed with a carrier protein
{Kishimoto et al 1989). Three regulatory regions on chromosome 7(p21) are involved in
its gene expression.
Chromosomal abnormalities of human chromosome 7 and 5 (the site of murine
IL-6) have been found to be associated with a variety of haematopoeitic disorders,
among them multiple myeloma. Initially, a 1.3 kb mRNA is translated into a 212-amino
acid precursor protein with a MW of 26 kDa {Heinrich et al. 1990). After removal of a
28-amino acid signal peptide, the resulting 184-amino acid protein, containing two
possible N-glycosylation sites, is N- and O-glycosylated and subsequently secreted.
Human IL-6 shows significant homology with G-CSF and has a homology of 65% at the
DNA level and 45% at the protein level, with murine IL-6 {Kishimoto et al. 1989). The
kinetics of IL-6 clearance is biphasic, consisting of a rapid initial elimination
corresponding to a half life of 3 minutes, and a second slower decrease corresponding to
a half life of 55 minutes. IL-6 binds to a2-macroglobulin, retains its biologic activity and
becomes resistant to proteases {Heinrich et al. 1990).
IL-6 is synthesised and released in response to inflammatory stimuli by
monocytes, macrophages, endothelial cells, and fibroblasts. T and B cells produce it
under non-physiological conditions. Tumours are also potent producers of 11-6 {Emery et
al. 1991). Virus-infected microglial cells and astrocytes have produced IL-6, which was
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also detected in synovial fluid during bacterial and viral infection (Kishimoto et al. 1989,
Heinrich et al. 1990). Monocytes/macrophages are preferentially stimulated by bacterial
LPS, whereas fibroblasts and endothelial cells respond better to the endogenous
cytokines IL-1 and TNF, which are abundantly synthesised by monocytes, suggesting
that these cytokines play a key role in the production of IL-6. IL-1 and TNF act via two
second messenger systems: protein kinase C and cAMP. The production of IL-6 by T
cells requires the presence of monocytes, while monocytes produce IL-6 in the absence
of any apparent stimulus in in-vitro cultures. In addition, it was shown that the peak of
IL-6 mRNA in monocytes was achieved in five hours, while that from T cells was at 24-
48 hours. This suggests that IL-6 produced by monocytes and T cells, with different
kinetics, may exert distinct effects at different phases of the immune response. A variety
of cytokines, including IL-1, TNF, PDGF, and IFN-P, as well as serum, poly (I) poly (C)
and cyclohexamide also enhance the expression of IL-6 gene in different cell types.
Viruses induce 11-6 production in fibroblasts or in the CNS. Dexamethasone inhibits IL-
6 production and oestradiol-17[3 impairs its formation in human endometrial stromal
cells. The glucocorticoids increase the stimulatory effect of monokines on the synthesis
of acute phase proteins, but also inhibit the synthesis of monokines themselves. The
effects of abnormal expression of IL-6 gene have been studied in IL-6 transgenic mice
following the mapping of the genomic gene of human IL-6 on chromosome 7. Several
potential transcription control elements, such as glucocorticoid responsive element
(GRE), a serum responsive element (SRE), cAMP responsive element (CRE), and a NF-
kB binding site, were identified within the IL-6 promoter. Three regulatory regions have
been shown to be involved in the regulation of IL-6 gene expression; multi-responsive
element, NF-IL6, and NF-kB. These mediate induction, or inhibition, by different
regulators such as IL-1, TNF, LPS etc. Glucocorticoids negatively regulate the IL-6 gene
expression in various tissues and cells. Studies on the regulation of IL-6 gene expression
and its action through its receptor will provide information on the molecular
mechanisms of a variety of diseases and may provide novel diagnostic and therapeutic
approaches (Whicher & Evans et al. 1990).
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The receptor for IL-6 belongs to the immunoglobulin supergene family. It is a
glycoprotein with a MW of 80 kDa, consisting of 449 amino acids. The cytoplasmic
domain of 82 amino acids lacks a tyrosine kinase, unlike other growth factor receptors,
and it is not essential for signal transduction {Emery et al 1991). The underlying
mechanisms of signal transduction are still unknown. The action of IL-6 appears to be
independent of protein kinase C, ITP and adenylate cyclase activity. A possible signal
transducer (gpl30) with a MW 130 kDa could associate with IL-6 receptor after the
interaction of IL-6 with the 80 kDa receptor. Polymorphism in this 130 kDa gp can
explain the multiple functions of IL-6 on various tissues. On the other hand, the
redundancy in cytokine function may result from several cytokine receptors sharing the
same signal transducer {Heinrich et al. 1990). IL-6 receptor is expressed on both
lymphoid and non-lymphoid cells. Whereas expression of IL-6R by monocytes is down
regulated by binding to 11-6, hepatocytes express it only after prior treatment with IL-6
or IL-1. The liver seems to be the major target for IL-6. In the rat, 80% of injected
radiolabeled IL-6 localizes on the surface of the liver parenchymal cells, suggesting the
existence of IL-6 receptors on the plasma membrane of hepatocytes. The number of
cytokine receptors is usually in the order of 102 to 103 per cell, which is less than that for
hormones or growth factor receptors. In monocytes, the synthesis of IL-6 receptor
mRNA is strongly inhibited by IL-6, IL-1 and LPS. Thus, during inflammation, a switch
from monocytes to hepatocytes and activated B cells as target cells for IL-6 may occur.
Dexamethasone stimulates IL-6 receptor mRNA in human hepatocyte cultures. A
soluble IL-6 binding molecule can be found in the serum of healthy individuals. Unlike
all known soluble cytokine receptors, the soluble receptor (sIL-6R) has no antagonist
role but, on the contrary, enhances the response to IL-6 {Kishimoto et al. 1989,
Lehrnbecher et al. 1995).
IL-6 is a pleiotropic cytokine exerting growth-inducing, growth-inhibitory and
differentiation-inducing effects, depending on the nature of the target cells:
1. The first identified function of IL-6 was the induction of the terminal B-cell
differentiation and immunoglobulin production. IL-6 acts directly on B cells
activated by IL-4 and IL-5 and induces immunoglobulin M, G, and A production.
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Normal resting B cells do not express IL-6 receptors; hence IL-6 does not exert any
growth-promoting activity on these cells. IL-6 augments the primary and mainly the
secondary antibody responses in mice. IL-6 is an important helper in primary
antigen-receptor-dependent T cell activation and subsequent proliferation of
activated T cells. This is synergised by IL-1 and is said to be dependent on IL-2.
These two cytokines induce the production of IL-2 and IL-2 receptor expression on
T-cells. IL-6 enhances the action of IL-2 in the late phase of cytotoxic T cell
generation and plays a role in the expression of class I histocompatibility antigens in
human fibroblasts. IL-6 also primes neutrophil and monocyte oxidative burst
response (Heinrich et al. 1990).
2. IL-6 has been strongly implicated as an autocrine growth factor for several tumours,
such as myeloma and cardiac myxoma, and it stimulates proliferation of lymphatic
leukaemia and lymphoma cells. On the other hand, IL-6 inhibits the growth of
certain myeloid leukaemic cell lines and induces their differentiation into
macrophages. It also exerts a strong inhibition on the growth of human fibroblasts,
breast carcinoma cells and endothelial cells in culture (Calandra et al. 1991).
3. IL-6 synergies with IL-3, M-CSF, GM-CSF to enhance the growth of haemopoietic
progenitor cells. IL-6 shortens the G0 period of stem cells and up-regulates IL-3
receptors on bone marrow stem cells. It was therefore suggested that IL-6 might
have a role in bone marrow transplant (Whicher & Evans et al. 1990).
4. Induction of mesangial cell growth and neural cell differentiation. IL-6 also induces
the secretion of nerve growth factor by astrocytes, hence it may be involved in repair
mechanisms in the course of viral infections (Kishimoto et al. 1989).
5. IL-6 can activate the coagulation system (Blackwell et al. 1996).
6. IL-6 may induce fever, and its synthesis by endometrial cells has been suggested as a
mechanism for the temperature fluctuations during the menstrual cycle (.Blackwell et
al. 1996).
7. IL-6 is probably the major physiological inducer of acute-phase protein synthesis in
the liver, with IL-1 and TNF playing only subsidiary roles (Calandra et al. 1991).
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8. IL-6 may have an important role in the release of corticosteroids during
inflammation. IL-6 triggers the release of ACTH from murine pituitary glands. IL-6
shows a synergistic effect with glucocorticoids on the induction of acute phase
proteins, thus IL-6 induced secretion of ACTH may have a positive feedback loop on
acute phase reaction. On the other hand, glucocorticoids are potent inhibitors of IL-6
production in various cells. Therefore, the interaction of IL-6 with the neuro¬
endocrine system may regulate positively and negatively acute phase reactions and
immune responses (Kishimoto et al. 1989).
9. IL-6 was first described as an additional factor released along with fibroblast IFN-p,
thought to have antiviral activity, so was called IFN-P2. However, it is doubtful if IL-
6 has any antiviral activity.
10. The relative lack of toxicity of IL-6 argues against a major causative role in septic
shock.
The multiple effects of IL-6 contribute to a co-ordinated response of the body to
aggression. IL-6 is induced by other cytokines such as IL-1, PDGF, and GM-CSF. It is
synergistic with others in inducing many of its actions, e.g. induction of fever, acute
phase protein synthesis and thymocyte growth. This underlines the complexity of the
cytokine network (Bellomo et al. 1992).
The role of 11-6 in disease is complex. Its association with disease states and its
causative role of certain disease manifestations are undoubted. However, there is no
consensus on whether it is a harmful or a protective molecule although it is regarded
anabolic in some situations:
1. The first example of a disease associated with abnormal IL-6 production was cardiac
myxoma. Patients with cardiac myxoma are hypergammaglobulinaemic, display
various kinds of autoantibodies and increased acute phase proteins and have high
plasma IL-6 levels. These features disappear with myxoma resection. Furthermore,
myxoma cells contain increased amounts of IL-6 and its mRNA {Kishimoto et al.
1989).
2. Patients with Castleman's disease, benign hyperplastic lymphadenopathy, show
hypergammaglobulinaemia, increased acute phase proteins and platelets, and high
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plasma levels of IL-6. Some patients develop multiple myeloma. The germinal
centre of the hyperplastic lymph nodes in Castleman's disease produces large
amounts of IL-6 with no significant production of other cytokines. Thus abnormal
production of 11-6 may be the primary event in the pathogenesis of this disease
{Kishimoto et al. 1989).
3. Macrophage-derived IL-6 may also be involved in the in vivo growth of Lennerf s T-
cell lymphoma, which is characterised by massive infiltration of macrophage-
derived histiocytes (Kishimoto et al. 1989).
4. Patients with rheumatoid arthritis characteristically show polyclonal plasmacytosis,
autoantibodies, and increased acute phase proteins and platelets. Elevated levels of
11-6 can be detected in synovial fluid and sera of patients with active disease. T-cells,
B-cells, synovites and chondrocytes have been identified as sources of IL-6. Patients
with Felty's syndrome treated with GM-CSF showed simultaneous induction of IL-6
release and flare up of arthritis. It is not known whether the abnormal expression of
these inflammatory cytokines is a primary event in the disease process, or a
secondary phenomenon (Whicher & Evans, 1990).
5. In mesangioproliferative (MPG) GN, IL-6 is found in urine, and its levels in urine
correlated with the progressive stage of MPG (Whicher & Evans, 1990).
6. IL-6 is involved in the polyclonal B-cell activation in HIV infection, which induces
IL-6 production in monocytes. Its levels in the sera of patients with this disease is
increased, and anti-sense of the IL-6 gene blocks the in vivo proliferation of
Kaposi's sarcoma (Whicher & Evans, 1990).
7. Diseases characterised by a marked acute phase response and sensitivity to steroids,
such as giant cell arteritis and rheumatoid arthritis, have increased levels of IL-6
{Emery et al. 1991).
8. IL-6 contributes to the thrombocytopenia seen in diseases with marked acute phase
response, e.g. SLE, and inflammatory bowel disease {Emery et al. 1991).
The biologic activities of IL-6 suggest that, like TNF and IL-1, interleukin-6 may be
an important mediator involved in host defense against infection. In vitro, endotoxin has
been shown to induce gene expression and secretion of IL-6 by
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monocytes/macrophages, human fibroblasts, and human endothelial cells. In healthy
volunteers, an intravenous bolus infusion of endotoxin is followed by a transient
increase of circulating levels of IL-6. IL-6 was also detected in the serum, CSF, and
synovial fluid of patients with bacterial infections. The exact role of IL-6 in sepsis is
uncertain, although it is an integral part of the cytokine cascade. Infusion of IL-6 does
not result in a sepsis-like state {Emery et al. 1991)
After endotoxin infusion, IL-6 peaks in 4 hours, after TNF and IL-1 which synergise
to increase IL-6 production. IL-6 exhibits a very short half-life due to its rapid binding to
skin and hepatic receptors where it is degraded {Castell et al. 1988, Whicher & Evans,
1990). The half-life of IL-6 was calculated to be 70 ± 11 min, compared to 103 ± 27 min
for TNF {Waage et al. 1989). Hence, serum IL-6 levels only reflect a minority of the IL-
6 produced in vivo, i.e. the portion not absorbed by either cell surface receptors or the
kidneys {Bataille et al. 1992). In vitro studies have shown that non-stimulated
monocytes do not produce IL-6 {Schindler et al. 1999). However, IL-6 is detectable in
the plasma, but not other fluids, of normal individuals {Van Oers et al. 1988). In other
tissues, detectable levels of IL-6 were predictive of a variety of morbid states. For
instance, increased amounts were found in the urine of renal transplant recipients and
persisting high levels were predictive of rejection {Van Oers et al. 1988). IL-6 is also
significantly elevated in synovial fluid from patients with rheumatoid arthritis {Houssiau
et al. 1988). An elevated amniotic fluid IL-6 was found to be a sensitive and specific
marker for the identification of intrauterine infection in women with preterm labour
{Greig et al. 1993) and reliably predicted perinatal morbidity and mortality {Yoon et al.
1995, Singh et al. 1996). IL-6 in the cervical secretions was also predictive of preterm
labour {Rizza et al. 1996). IL-6 is most consistently elevated in patients with sepsis,
reported proportions of high levels varying between 64-100% of cases {Schindler et al.
1990). The highest levels were detected in patients with shock and a clear correlation
with mortality was observed. IL-6 levels were highest on admission and showed a rapid
decline, though it was detectable for up to 36 hours {Thijs et al. 1995). There are,
however, wide individual variations in IL-6 levels reported in different studies {Van
Oers et al. 1988), due in part to different methods of assay. IL-6 concentrations correlate
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more closely than other cytokines with severity and outcome of human sepsis, and its
levels predicted bacteraemia (Blackwell et al. 1996).
vi. 4. lnterleukin-8 (IL-8)
IL-8, also called neutrophil attractant/activation protein-1 (NAP-1), is a 72 amino
acid small basic protein with a MW of 10 kDa {Blackwell et al. 1996). It is a heparin-
binding member of the oc-chemokines (C-X-C) family of proteins {Miller et al. 1996).
Originally isolated from supernatants of LPS-stimulated monocytes, IL-8 is now known
to be produced by a variety of cell types, including polymorphonuclear phagocytes
(PMN), endothelial cells, fibroblasts, hepatocytes, and keratinocytes in response to
several inflammatory stimuli, including LPS, TNF and IL-1, but not IL-6. Bacterial
products, such as endotoxin, are potent inducers of IL-8 {DeForge et al. 1991). IL-8
production is also stimulated by several other products of both G+ve and G-ve bacteria
{Miller et al. 1996). IL-8 is one of the main cytokines produced by PMN. Cytokine (IL-
1, IL-6, IL-8 and TNF) concentrations are unrelated to leukocyte counts and markers of
neutrophil (elastase) or monocyte (neoptrin) activation {Remberger et al. 1997). This
suggests that cytokine release associated with evolving septic shock may not depend on
circulating leucocytes. The cytokines IL-10, IL-4, IL-13 and TGF-{3 can repress IL-8
release by activated PMN {Dinarello et al. 1987). Compared with healthy controls, the
release of IL-8 by PMN from septic and non-septic SIRS patients is significantly
reduced whether activated by LPS or heat-inactivated bacteria. This dampening of PMN
reactivity is not thought to be due to endotoxin tolerance, but may be due to other LPS
mediators, such as IL-10 {Marie et al. 1998). Basal cytokine production is not
demonstrable in primary amnion culture, whereas incubation with group B streptococcus
leads to a significant increase in IL-6 and IL-8, but not of IL-1 or TNF {Klaus et al.
1991). In LPS-stimulated human whole blood, TNF and IL-6 mRNA and protein peak at
2-4 hours and 4-6 hours, respectively. IL-8 mRNA and protein plateau between 6 and 12
hours then rise again in a second wave which continues to escalate until the end of 24
hours {DeForge et al. 1991). This suggests that the early mediators may augment
continued expression of IL-8 to recruit and retain neutrophils at the site of inflammation.
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Similarly, in human volunteers, IL-8 could be detected after LPS or TNF administration.
After incubation with Pseudomonas aeruginosa supernatant, bronchial epithelial cells
and monocytes show a marked increase in the level of IL-8 gene expression. Infection of
mucosal cell monolayers by invasive bacteria result in expression and up-regulation of
IL-8, MCP-1, GM-CSF, and TNF. These same cytokines are up-regulated after mucosal
stimulation by TNF or IL-1. Non-invasive bacteria, and Giardia, fail to produce the same
effect. Coagulation also efficiently induces IL-8 production {Johnson et al. 1996).
Following endotoxin injection, IL-8 plasma levels peak in 2-3 hours, and its kinetics
mirror those of IL6 (Chae et al. 1996). IL-8 has a short (± 8 minutes) half life in the
circulation {Terashima et al. 1998).
The primary function of IL-8 is to activate and chemo-attract neutrophils to sites
of inflammation and to help in the process of marginalization and migration of
polymorphs (see below). In addition, basophils and T-lymphocytes are attracted by
nanomolar concentrations of IL-8. IL-8, has the ability to bind to the endothelial cell
surface and the extracellular matrix, and hence has both haptotactic and chemotactic
effect. IL-8 is also a potent activator of polymorphonuclear leucocytes and mediates the
release of granule contents. This latter function is enhanced by TNF-priming of
neutrophils {Rot et al. 1993). Intravenous injection of IL-8 causes no haemodynamic
abnormalities, but causes transient granulocytopenia followed by granulocytosis
{Terashima et al. 1998). IL-8 does not stimulate monocytes {Whciher & Evans, 1990).
IL-8 has been implicated as a critical cytokine in mediating the early phase of
tissue injury and organ dysfunction. Its production is increased in the lung following
hypoxia-hyperoxia and in the setting of neutrophil alveolitis {Blackwell et al. 1996).
Bronchoalveolar lavage (BAL) IL-8 concentrations correlate with BAL neutrophil count
and increased mortality in patients with ARDS {Dinarello et al. 1987). High
concentrations of IL-8 are found in the sputum of CF patients {Bellomo et al. 1992).
Elevated plasma levels of this cytokine have also been found in septic shock, with higher
levels in survivors suggesting a protective role {Blackwell et al. 1996). Elevated IL-8
levels have also been reported in a number of other inflammatory diseases, such as
rheumatoid arthritis and alcoholic hepatitis {Whciher & Evans. 1990). IL-8 has been
142
identified in the amniotic fluid of patients with preterm labour and IU infection
(Cherouny et al. 1993).
vi. 6. Intercellular adhesion molecule-1 (CAM-1)
ICAM-1 belongs to a group of cell-surface proteins called the immunoglobulin
superfamily. These include the T-cell receptors CD3, and the co-receptors CD4 and CD 8
and their respective counter-receptors MHC 2 &1. All these proteins share the
immunoglobulin domain structure, and they play a critical role in the specific immune
response. ICAM-1 is a sialylated glycoprotein with tissue specific differential
glycosylation resulting in a wide molecular weight range of 70-120 kDa. It has five
extracellular domains, a single transmembrane region, and a short cytoplasmic tail
(Sessler et al. 1995). ICAM-1, like E-selectin, is expressed by the endothelial cells only
following exposure to stimuli such as TNF and IL-1. It serves as a counter-receptor for
the leucocyte beta 2-integrins; LFA (CDlla/CD18) and Mac-1 (CD1 lb/CD18). The
latter may also adhere to proteins of the endothelial extracellular matrix such as
fibrinogen. ICAM-1 has a restricted tissue distribution and is constitutively expressed at
low levels on sub-populations of haematopoeitic cells, fibroblasts and various epithelia.
It is however, highly inducible on various cells during inflammation (Haung et al.
1996). Endotoxin, TNFa, IL-1 and interferon-y all induce a large increase in the
expression of ICAM-1, but not ICAM-2, by endothelial cells. E-selectin expression is
also increased, although more transiently than ICAM-1. These changes occur relatively
slowly (in hours) as they involve transcription and translation of mRNA. Thus these
cytokines induce receptors for both the rolling and subsequent firm steps in neutrophil
adhesion (Seth et al. 1991). A proportion of ICAM-1 (sICAM-1) is released into the
circulation upon activation of the endothelium by cytokines. ICAM-2 is a shorter, two
domain protein that is expressed by unstimulated endothelial cells and also binds to
CDlla/CD18. ICAM-3, also called ICAM-R, is expressed by leucocytes but not by
endothelial cells and is involved in lymphocyte homotypic adhesion. It is a five-domain
protein with extensive homology to ICAM-1 (.Baines et al. 1998).
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vi. 6. a. Polymorph adhesion and margination
These are the processes by which polymorphic leucocytes are attracted to and
transported to areas of injury and inflammation. IL-8 has a major regulatory role in the
process of neutrophil extravasation. IL-8 induces cleavage of the extracellular portion of
L-selectin, up-regulation of CD1 lb/CD 18 expression and adhesiveness on the surface of
the neutophil. It also induces the formation of the bipolar shape that characterises
crawling neutrophils. IL-8 then forms fixed (haptotactic) rather than soluble
(chemotactic) gradients, by binding to glycosaminoglycan heparan sulphate of the
endothelial matrix, and neutrophils migrate up this gradient. Other members of this
family appear to have similar effects on other leukocyte types, although there is
considerable overlap and redundancy in the system. The early phase of neutrophil
migration involves rolling of neutrophils on P-selectin and some increase in vascular
permeability induced very rapidly by histamine or thrombin. During the late phase, 1-2
hours later, endotoxin, TNF and IL-1 induce endothelial E-selectin and ICAM-1
expression, and IL-8 release, which results in neutrophil L-selectin activation. This
results in a prolonged period of neutrophil rolling, activation, and migration out of the
blood vessels into the tissues. TNF induces a rapid increase in the adhesiveness of L-
selectin, reduces deformability of neutrophils, and induces degranulation and respiratory
burst, but only in cells adherent to endothelium. Extravasation of neutrophils during
acute inflammation occurs mostly through the endothelium of postcapillary venules, for
reasons which relate to the relatively slow blood flow and associated shear stresses as
well as the specialized function of endothelium at this site. Cytokines, such as TNF, can
directly induce a reversible increase in permeability of endothelium, and addition of
neutrophils can further increase this permeability. Leucocyte adhesion and signaling are
important steps in the development of inflammatory and immune responses. ICAM-1
(CD54) promotes leucocyte adherence, antigen presentation and subsequent immune-
cell proliferation by binding to the leukocyte integrin adhesion receptors CDlla/CD18
and CD lib/CD 18. Invasive bacterial infection results in increased expression oflCAM-
1 in various immune and non-immune cells and this is followed by increased neutrophil
migration and adhesion to these cells (Sessler et al. 1995, Haung et al. 1996).
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vi. 6. b. Adhesion molecules in disease
Two inherited diseases illustrate the importance of adhesion molecules for the
transit of leukocytes. In leukocyte adhesion deficiency type 1 (LAD-1) P2 integrin
subunit (CD 18) is lacking. Patients have severe leucocytosis and recurrent infections,
and leukocytes from these patients have defective adherence, chemotaxis, and
phagocytosis. In LAD II, there are developmental abnormalities, leucocytosis, and
recurrent infections. Neutrophils from these patients do not roll in vivo. There is
impaired synthesis of fucosylated carbohydrates (sLe- X), which include the ligands of
the selectins. Neutrophils from LAD II patients do not bind to E-, or P-selectin, although
they have normal levels of L-selectin and CDllb/CD18 integrin. This shows that
integrins and selectins adhesion molecules have distinct but interdependent roles in
neutrophil adhesion during inflammatory response. Experimentally, ischaemic brain
damage in mice lacking ICAM-1 is less severe than in normal mice. It has also been
noticed that up-regulation of several vascular adhesion receptors occurs in rejected
transplanted organs and in the synovium of patients with rheumatoid arthritis. This
demonstrates the pivotal role of adhesion molecules in the immune and inflammatory
processes and in the pathogenesis of many diseases. Administration of antibodies against
ICAM-1 prolongs the survival of murine cardiac allografts, suggesting a potential for
anti-adhesion therapy.
Corticosteroids have been shown to decrease the expression of E-selectin and
ICAM-1 by stimulated endothelium, and colchicine appears to decrease the adhesiveness
of endothelial cells to neutrophils by changing the distribution of E-selectin molecules
on the surface of the endothelial cells. Adhesion molecules also have a primary role in
platelet homeostasis. anbP3 (Ilb/IIIa) glycoprotein on resting platelets adheres to
fibrinogen and is defective in Glanzmann's thromboasthenia. Platelets adhere to matrix
vWF by their glycoprotein Ib-a receptors. Glycoprotein lb complex of platelet adhesion
receptors is deficient in Bernand-Soulier syndrome. Cancer cells may also use adhesion
molecules and receptors to form metastases (.Phillips et al. 1995, Frenette et al. 1996).
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vi. 7. Interleukin -2
IL-2 is a protein with a molecular weight of 15,000 D (103 amino acids) coded
on chromosome 4. The main cellular source of IL-2 is activated lymphocytes. IL-2 has
various immunologic functions, the most important being the ability to initiate
proliferation of activated T-cells. High-affinity receptors for IL-2 are absent from resting
T-cells but appear within hours of activation. The IL-2 receptor consists of two chains, a
(CD25) and P (TAC). Both chains are required to generate a functional IL-2 receptor.
The binding of IL-2 to these receptors gives rise to the clonal expansion of T-cells
activated by the specific antigen. Withdrawal or elimination of the antigen leads to the
involution of the IL-2 receptor and the cessation of T-cell proliferation even in the
presence of IL-2, thus limiting the extent of the clonal expansion. IL-2 may have a role
in T-cell maturation, suggested by the presence of immature thymocytes bearing IL-2
receptors. IL-2 markedly enhances the cytolytic activity of a population of natural killer
cells capable of killing tumour cells, hence its use in clinical trials in patients with
cancer. IL-2 is also critical in clonal expansion of cytotoxic T-cells. Antibodies to its
receptors show promise as immunosuppressive agents. No measurable increase in its
concentration has been found in sepsis (Bellomo et al. 1992). Soluble interleukin2
receptor levels were found useful in facilitating the diagnosis of sepsis in preterm babies
(Spear et al. 1995).
vi. 8. lnterleukin-4 (IL-4)
IL-4 is a glycoprotein of 19 kDa MW. Its gene is located on chromosome 5. A
high affinity IL-4 receptor has a MW of 140 kDa. IL-4 is principally made by T-helper
cells. IL-4 was originally described as a co-stimulator of B-cell proliferation. It also
functions as an important growth factor for T cells. IL-4 is responsible for IgE
production. It also has some inhibitory effects on some B cell responses and
proliferation induced by IL-2, and can suppress the macrophage-induced TNF, IL-1 and
IFN-y production. It can block the immune response against Leishmania major and
schistosomiasis in experimental animals, leading to progressive disease. IL-2 and IL-4
appear to have complementary but subtly different roles by activating distinct
146
populations of T cells. Preferential stimulation of particular T cell subsets may
contribute to the pathology of disease. One mouse strain with high IL-4 and IgE but low
IFN-y when infected with leishmania, shows poor delayed hypersensitivity responses,
suggesting overactive Th2 cells, and develops a severe generalized form of disease.
Another strain with low IL-4 and IgE has a milder, localised, infection. Injection of ThI
clones into infected mice clears infection, whereas injection of TH2 cells exacerbates
infection (Bellomo et al. 1992).
vi. 9. lnterleukin-5 (IL-5)
IL-5 is a T cell derived glycoprotein of 45k Da (123 amino acids) which induces
B cells to differentiate into immunoglobulin-secreting cells following antigenic
stimulation. IL-5 was originally described as a B-cell-differentiating antigen and was
called T-cell-replacing factor. It induces the growth of bone marrow cells committed to
the eosinophilic lineage, hence the term eosinophil-differentiating factor (EDF).
Cytokines from both types of T cells and from antigen processing cells (APCs) act in
concert to regulate the proliferation and differentiation of B lymphocytes. Th2 cells
produce IL-4 and IL-5, which together influence the switch towards IgE and IgA. TH1
cytokines, IFN-y and IL-2 acting together, induce production of IgG and IgM. (.Bellomo
et al. 1992, Whicher & Evans, 1990).
vi. 10. lnterleukin-7 (IL-7)
IL-7 is a 25 kDa protein which acts as a stromal cell factor capable of inducing
the growth and proliferation of B cell precursors. It also induces the proliferation of
immature thymocytes (.Bellomo et al. 1992).
vi. li. lnterleukin-9
IL-9 is a growth factor for lymphoid and myeloid lineage. There is no
information on the role of these cytokines in human disease (.Bellomo et al. 1992).
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vi. 12. lnterleukin-10 (IL10)
IL-10 was first described as a product of Th2 lymphocytes that inhibits cytokine
production by activated macrophages. IL-10 is active on T cells, mast cells and B cells.
IL-10 inhibits in vitro production of TNF, IL-1, and IL-6 by monocytes and has been
shown to be protective in animal models of sepsis. IL-10 levels peaked during the first
48 hours, and elevated levels of this anti-inflammatory cytokine have been reported in
sepsis {Thijs et al., 1995, Dinarello et al. 1987).
vi. 13. Interferons
Interferons were initially identified for their ability to interfere with viral
replication in infected cells. This family of cytokines may be natural negative growth
regulators for several different types of cells. Interferons are a multi-gene family of
proteins, with MW between 17 to 25 kDa. On the basis of amino acid sequence, three
families of these cytokines are identified; IFN-a (with 15 different functional proteins),
IFN-p and IFN-y. Alpha and beta interferons are structurally related polypeptides
induced by viral infection and have potent antiviral, antiproliferative and immunologic
properties. Their production is induced by bacteria, viruses and double stranded DNA.
IFN-y is induced by mitogens and antigens. Whereas endotoxin directly induces IFN-a
and -p from B cells and macrophages, the induction of IFN-y requires IL-1 and IL-2.
IFN-a is a mononuclear cell product, while IFN-P comes primarily from fibroblasts and
epithelial cells, and IFN-y from T-cells.
Despite only 29% homology, IFN-a and IFN-P use the same receptor. They are
anti-viral, inducing (2\ 5")-oligoadenylate synthetase which causes mRNA breakdown.
In addition, they are anti-proliferative for many transformed cell lines and cancers.
These two cytokines are potent stimulators of natural killer and cytotoxic T cells and up-
regulate MHC class I antigens, enhancing antigen recognition. One of the most dramatic
therapeutic applications of all cytokines has been the complete remission obtained by
IFN-a in hairy cell leukaemia. IFN-a also is effective in chronic myeloid leukaemia, has
some activity in myeloma and lymphomas but the response of solid tumours was
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disappointing (Whicher & Evans, 1990). IFN-a has been extensively used in the
management of various malignancies and recently in the treatment of chronic active
hepatitis of viral aetiology (Bellomo et al. 1992). IFN-y has a wider role in
inflammation, is a much more potent immunomodulator, and interacts more closely with
cytokines (.Morrison et al. 1987). It participates in the cytokine network by inducing
synthesis of IL-1 and TNF, resulting in subsequent production of IL-2 and IFN-y by T-
cells, and thus a positive feedback loop. IFN-y induces TNF receptors on many cells and
enhances the cytolytic effects of TNF. Gamma interferon induces class I & II MHC
molecules and is a potent activator of macrophages. It enhances macrophage oxidative
metabolism (which results in increased bactericidal and tumouricidal activity) and
stimulates their phagocytic activity by inducing the expression of Fc receptors. This
cytokine augments B-cell stimulating cytokines and increases antibody production, but
antagonizes IL-1 effects on connective tissue by inhibiting the synthesis of collagens.
IFN-y has been shown to be protective in leprosy, to aid in vaccination against malaria,
to partially correct the phagocytic defect of chronic granulomatous disease, and to
increase survival and reduce sepsis in mice with simulated surgical wound infection
fBellomo et al. 1992).
vi. 14. Haematopoeitic cytokines
Cytokines affecting haematopoeisis are called colony-stimulating factors because
of their ability to induce the formation of colonies when marrow is suspended in vitro.
Interleukin -3 and granulocyte-monocyte colony-stimulating factor (GM-CSF) are two
well-characterised examples. These substances probably play no part in base-line
haematopoeisis but they are responsible for myeloid hyperplasia and peripheral
leucocytosis. Some cytokines, such as gamma-interferon and TNF, antagonize CSFs and
may contribute to aplastic anaemia (Dinarello et al. 1987).
vi. 14. a. lnterleukin-3 (IL-3)
IL-3, also known as multi-colony stimulating factor, is a glycoprotein produced
by activated T cells. It is encoded on chromosome 5 (5q23-31) and has a MW of 28 kDa
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and 140 amino acids. It is involved in regulating the growth and differentiation of
haematopoeitic progenitor cells. It is synergistic with IL-6 and erythropoeitin. IL-3 has
the widest range of targets, stimulating proliferation of macrophages, neutrophils,
eosinophils, megakaryocytes, early erythroid cells, and mast cells.
vi. 14. b. Colony Stimulating Factors (CSF)
CSF defines a collection of glycoproteins that regulate the proliferation of bone-
marrow-derived precursor cells into functionally active cells and modify the effector
functions of the mature cells. Three CSFs have been described; GM-CSF, G-CSF and
M-CSF. There is no significant homology between these proteins. CSFs are produced by
many cell types including fibroblasts, macrophages, endothelial cells, T- and B-cells,
and some epithelial cells. Endotoxin is a potent inducer of CSFs from these cells. The
precise role of this endotoxin-induced production of CSFs is not clear, but they appear to
play a key role in the development of endotoxin tolerance, and thus may serve as a host
defense mechanism (Morrison et al. 1987). CSFs affect mature cells at lower
concentrations than required to enhance proliferation of precursor cells. CSF act on
macrophages and monocytes to stimulate their phagocytic activity, synthesis of
prostaglandins, secretion of proteases, and expression of cytolytic activity. They induce
granulocyte production of superoxide, and produce other cytokines. Clinically, they
reduce the duration of chemotherapy-associated neutropenia in BMT and may be of use
in overwhelming sepsis (Bellomo et al. 1992). GM-CSF acts on virtually the same cells
as IL-3, except mast cells, and is encoded on the same chromosome 5 (5q23-33). It has a
MW of 35 kDa and 127 amino acids. GM-CSF exerts its primary effects later in the
maturation sequence supporting cells committed to becoming myelocytes and
monocytes. GM-CSF also increases the bactericidal competence of granulocytes and the
numbers of receptors for chemoattractants. G-CSF gene is located on chromosome 17
and encodes a 20-kDa glycoprotein. G-CSF is produced by stromal cells, macrophages,
neutrophils, and endothelial cells. Unlike the other CSFs, which are produced as single
chain polypeptides, G-CSF is a dimer. Each of these CSFs acts on its own receptor, and
different CSF receptors can be expressed on the same cell at the same time, allowing
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different CSFs to act in concert. IL-3 would act on pluripotent cells producing a wide
range of cell types, but GM-CSF and G-CSF would act on cells committed to certain
lineage. All CSFs can induce production of IL-6 in normal myeloid cells, and the latter
in turn induces the production of GM-CSF and expression of receptors for GM-CSF, IL-
3 and G-CSF (Whicher & Evans, 1990).
vi. 14. c. Monocyte chemoattractant protein-1 (MCP-1)
MCP-1 is a 76 amino acid polypeptide capable of activating and attracting
monocytes. It can be produced by lymphocytes, fibroblasts, or monocytes stimulated by
IL-1, TNF, PDGF, or LPS (Bellomo et al. 1992).
vi. 15. Platelet derived growth factor (PDGF)
PDGF has a MW of 30 kDa. Other cells, such as monocytes, fibroblasts, and
endothelial cells, can also produce it. It is a growth factor acting on a broad spectrum of
cells. It is likely to be important in the generation of granulation tissue during wound
repair, in fibroproliferative inflammation, and in atherosclerosis. It has been implicated
in the development of pulmonary fibrosis, in the pathogenesis of scleroderma, and in
synovial cell proliferation in rheumatoid arthritis. PDGF also participates in the release
of pro-inflammatory cytokines (.Bellomo et al. 1992).
v. 16. Transforming growth factor (TGF)
TGF-a and TGF-P are distinct peptides with unique biological activities and
separate receptors. TGF-a is made by keratinocytes and monocytes and is produced by
cancer cells. It is a powerful growth factor. It may function as an autocrine stimulator of
growth in malignancy. TGF-P is released by the alpha granules of aggregating platelets.
It is powerfully chemotactic for monocytes. It induces production of IL-1, TNF, PDGF,
and therefore amplifies the phlogistic response. TGF-P also inhibits B- and T-cell
proliferation at femtomolar concentrations, being one of the most potent biological
lymphocyte suppressers known. Flence it may play an important immunoregulatory role
in inflammatory states {Bellomo et al. 1992).
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Chapter VII
Pathophysiologic Role of Cytokines
No direct causative role of a cytokine has been established in any disease.
However, the excessive or insufficient production of cytokines may contribute to certain
disease states, particularly those of infectious and autoimmune origins. For instance,
decreased production of IL-2 from the leucocytes of patients with AIDS, autoimmune
disease, type-I diabetes mellitus, burns and cancer, has been reported. The production of
gamma interferon is reduced in patients with lepromatous leprosy and connective tissue
disease, such as SLE and rheumatoid arthritis, as well as in newborns. The production of
alpha interferon is reduced in patients with myeloproliferative disorders and chronic
hepatitis B. It remains to be seen whether these defects could be corrected in vivo by the
systemic administration of cytokines or cytokine inducers. Defects have also been
identified in cytokine signaling pathways, such as the defect in IL-2 receptor that is
associated with recurrent or severe atypical mycobacterial or BCG infection.
Overproduction of TNF-a protects against mycobacterial infection, but causes
overwhelming septic shock in meningococcal infection. Absence of the common
cytokine receptor y chain, which is essential for -2, -4, -7, -9 and-5 receptor function,
leads to T-, B+, NK- ve severe combined immunodeficiency (SCID). Absence of Jansus-
associated kinase 3 (JAK-3), a cytokine-receptor-associated signaling molecule, also
leads to a similar form of SCID. In arthritis, synovial cells spontaneously produce high
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levels of IL-1. Intra-articular injection of IL-1 produces a transient arthritis, which
becomes chronic on repeated injections. TNF-a produces less joint inflammation than
IL-1, but the two have additive effects. IL-6 is present in large amounts in the joint fluid
and its levels correlate with systemic measures of disease activity. However, IL-6 does
not stimulate either collagenase or PGE2 from synovial flbrobalsts or chondrocytes. It
was postulated that abnormalities of cytokine production, or the expression of their
receptors, might underlie some forms of malignancy. For instance, it was shown that
human myeloma cells and Kaposi's sarcoma, respectively, respond to IL-6 and
fibroblast growth factor in an autocrine fashion. Both cardiac myxoma and the
hyperplastic lymph nodes of Castleman's disease produce high quantities of IL-6. In the
latter, multiple myeloma may result, and removal of involved lymph nodes results in
complete recovery. On the other hand, patients with a large tumour burden have
deficient IL-1 production. The interferons, IL-2 and TGF-p have growth-inhibitory
properties and have been successfully used in the treatment of some malignancy, such as
hairy cell leukaemia (Gennery et al. 2001).
Cytokines seem to have a prominent role in graft rejection. Both the
immunoregulatory and the inflammatory cytokines appear to participate in this process.
IL-2 is a key component in T cell priming for allograft rejection and high levels of IL2-
R have been found in liver transplant recipients, levels rising 6 days before rejection.
Acute renal allograft rejection is associated with high levels of TNF detectable 3-4 days
before the clinical rejection episode. High levels of IL-6 are detected in plasma and urine
of renal transplant recipients. Without complications, peak levels of this cytokine are
reached 2-3 days after transplantation, falling to normal within 3 weeks. In rejection, IL-
6 levels start to increase 2-3 days before clinical evidence of rejection, urinary levels
being most marked. IL-8 may be of value in determining prognosis in bone marrow
transplant (BMT). Patients who developed veno-occlusive disease showed a short, very
high IL-8 peak 1-4 days after diagnosis of the liver disease. The highest levels of IL-8
was in those who developed acute GvHD, whereas IL-6 was highest in those who
developed bacteraemia (Remberger et al. 1997).
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vii. l. Cytokines and sepsis
Cytokines are decisive factors in determining the pathophysiology of the sepsis
syndrome. Sepsis syndrome seems to result from overwhelming systemic inflammation
which is caused by excessive release of cytokines into the systemic circulation. Four
cytokines, TNF-a, IL-ip, IL-6, and IL-8 have been most strongly associated with the
sepsis syndrome. Cytokines are released in a sequential manner resulting in a cytokine
cascade. TNF and IL-1 appear to mediate most of the physiological disturbances that are
characteristic of sepsis. Proximal cytokines (TNF and IL-1), as well as endotoxin,
stimulate the production of distal cytokines, such as IL-6 and IL-8. The latter seem to
intensify and perpetuate the inflammatory response and might have a role in tissue
repair. IL-6 may, however, down-regulate TNF and IL-1 production, which might be
important in limiting the inflammatory response. IL-8 is a potent activator and
chemoattractant for polymorphs and is thought to mediate neutrophilic tissue
inflammation (Blackwell et al. 1996).
vii. l. a. The acute phase response
The acute phase response is a systemic reaction to tissue injury induced by
inflammation, infection and trauma. It is characterised by fever, leucocytosis and
negative nitrogen balance and an increased synthesis of hepatocye-derived plasma
proteins known as acute phase reactants (e.g. CRP and SAAP) and by the reduced
synthesis of albumin and transferrin. IL-6, IL-1 and TNF have been implicated in the
induction of the acute phase response. There is a synergistic interaction between these
cytokines and glucocorticosteroids. IL-1 and TNF stimulate IL-6 and all three induce
acute phase response reactant genes. IL-6 acts at the level of transcription with
maximum mRNA response at 4 hours. The maximum response is increased by
concomitant dexamethasone. IL-1 and IL-6 stimulate ACTH release with a subsequent
increase in Cortisol levels to inhibit cytokine and hence switch off the response. IL-6 is
the most potent inducer of the acute phase response and it only can induce the full range
of acute phase proteins. Diseases characterized by markedly high IL-6 levels, e.g.
polymyalgia and myeloma, are also characterized by marked acute phase responses with
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very high CRP and ESRs and by being very responsive to steroids. In trauma patients,
IL-6 and IL-8 are elevated early and can identify those who develop multiple organ
failure (MOF). Elevated levels of sICAM-1 take longer to develop (Patrick et al. 1996).
vii. l. b. The systemic inflammatory response syndrome (SIRS)
High levels of cytokines are found in the plasma of patients with a variety of
infectious diseases, such as meningococcemia and cerebral malaria. Cytokines mediate
multiple effects in these conditions, including changes in vasomotor tone, procoagulant
activity, and leucocyte adhesion, and their levels are associated with adverse outcome.
Sepsis syndrome represents a spectrum of pathophysiology that results from an
exaggerated host inflammatory response to a specific inciting event. The clinical
spectrum of sepsis syndrome ranges from mild physiological derangements to severe
multiple organ dysfunction and death. Clinically, four stages of the sepsis syndrome can
be identified:
1. Systemic inflammatory response syndrome (SIRS) is a term used to define a
constellation of clinical signs, which include tachypnoea, fever or hypothermia,
tachycardia and leococytosis, or leucopenia, with a left-shifted differential white
blood cell count. SIRS can result from either infectious or non-infectious conditions.
Non-infectious conditions include trauma, burns, haemorrhagic or hypovolaemic
shock and pancreatitis.
2. Sepsis is considered when there is a systemic response to a possible infection, which
can be bacterial, parasitic, protozoan or viral. Evidence of bacteraemia or a focus of
infection is not required. Septicaemia is sometimes used when an organism is
recovered from blood culture or its toxic products are identified. Although most
cases are related to gram-negative infections, full-blown septicaemia can result from
Gram-positive infections.
3. Severe sepsis is defined as sepsis which is associated with specific or multiple organ
dysfunction.
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4. Septic shock is when there is systemic hypotension associated with tissue
hypoperfusion and anaerobic metabolism.
This classification predicts mortality in a stepwise fashion; a mortality of 7% for
SIRS, 16% for sepsis, 20% for severe sepsis, and 46% for septic shock. The severity of
sepsis is proportional to the intensity of the host response. Usually, an invading micro¬
organism is efficiently cleared by the monocyte-macrophage system after opsonization
by antibody and complement. Thus bacteraemia results only in short-lived illness.
Sometimes, however, depending on the age of the patient, the virulence and number of
bacteria in the blood, the nutritional and immunologic status of the host, and the timing
and nature of therapeutic intervention, a systemic inflammatory response is established
and can progress independently of the original infection. In many patients with sepsis, it
is difficult to document a bacterial cause.
Endotoxin is a major factor contributing to the pathogenesis of bacterial infection
and the host responses such as fever. The responses elicited by endotoxin are neither
specific nor unique. All endotoxin components, lipid-A, protein and the polysaccharide,
participate in endotoxin pathophysiology. The polysaccharide portion of endotoxin
initiates the alternative complement pathway and acts as ligands for the receptors on
monocytes and macrophages. The most unique feature of endotoxin is its ubiquitous
capacity to elicit the entire spectrum of host effector molecules. The diversity of these
molecules confound efforts to define a unifying concept of endotoxin action. Other
microbial products, including those from gram-positive organisms, elicit similar
pathophysiological responses. There is increasing experimental and clinical evidence
that a number of cytokines play a major role in the response to injury and infection and
in the development of organ damage in critically ill patients (Aleksander et al. 1984).
TNF is a key mediator of organ injury during sepsis, its levels are elevated in early
shock and high levels correlate with unfavourable outcomes (see above). Interleukin-1
induces leucocytosis and muscle catabolism, and causes hypotension and tachycardia.
Interleukin-6 is a pyrogen and a lymphocyte activator and is the major stimulator of the
acute phase reaction. Interleukin-8 is a powerful neutrophil activator and is involved in
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the production of ARDS. High levels of IL-8 have been found in patients with septic
shock. As a result of the interplay of microbial products and pro-inflammatory
mediators, many biochemical and immunologic pathways are activated to control
bacterial invasion and to regulate physiologic derangements. Thus, there is activation of
the complement and coagulation cascades, the kallikerin-kinin system, and production of
P-endorphins. If these physiologic responses surpass the host's tolerance, the disease
progresses and can result in multiple organ dysfunction and death (Bellomn et al. 1992).
vii. l. c. Anaphylatoxins
C3a and C5a are low MW cationic polypeptides generated following the
activation of the complement system. They induce vasodilatation, smooth muscle
contraction, and chemotaxis of neutrophils and monocytes (C5a). They are also effective
immunoregulators of the humoural immune responses. Endotoxin can activate the
complement system in the absence of any anti-endotoxin antibodies. Lipid-A activates
the classical pathway while the polysaccharide region activates the alternative pathway.
Both the core polysaccharide (1-glycero-d-mannoheptose) and O-antigen polysaccharide
independently contribute to this activation. As a consequence, individual endotoxins
from different gram-negative organisms vary widely in their capacity to mediate
complement activation.
vii. l. d. Arachidonic acid metabolites
The generation of arachidonic acid by the action of phospholipase A2 on cell-
membrane-localized phospholipids is an early event in the activation of most mediator
cells. Subsequent metabolism of arachidonic acid by either the cycoloxygenase (to
produce prostaglandins) or the lipoxygenase (to produce leukotrienes) pathway is critical
to the development of host inflammatory responses. Endotoxin can induce both
pathways. These products are essential intermediates in the triggering signal for
macrophage activation. PGE2 is required for generation of collagenase and tissue factor
activity. The leukotrienes are required in induction of IL-1 and tumouricidal activity.
Arachidonic acid metabolites also act as regulatory modulators in the end-stage of
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macrophage activation and have direct effector function such as vasodilatation,
vasoconstriction, and chemotaxis.
vii. l. e. Platelet Activating Factor (PAF)
PAF represents a family of cell-derived lipid mediators with acetyl-glycerol-
ether-phosphorylcholine as their basic structure. PAF is produced in many cell types,
including neutrophils, basophils, monocytes, platelets, and endothelial cells. It has
diverse biological activities including platelet aggregation and secretion, neutrophil
degranulation, smooth muscle contraction, increased vascular permeability, hypotension,
and death. It is one of the most potent autocoid mediators yet described. It plays a role in
anaphylactic shock and endotoxin shock. PAF induces neutrophil margination on
endothelial cells. IL-1 is a potent stimulator of PAF production from endothelial cells.
vii. l. f. Tissue Activity Factor (TAF)
Diffuse microvascular thrombosis is a significant clinical finding in acute endotoxaemia
and gram-negative sepsis. Both the intrinsic pathway (by endotoxin mediated activation
of FXII) and the extrinsic pathway (by expression of TAF by endotoxin-stimulated
monocytes) participate in this coagulopathy. Tissue factor is a cell-surface-localised
glycoprotein induced by endotoxin on monocytes and macrophages. This glycoprotein
serves as a receptor for factor VII, which undergoes allosteric conformational change to
an enzymatically active form upon binding to tissue factor. The active protease then
cleaves factors X and IX. Tissue factor remains cell associated. The mRNA inhibitor
cycolhexamide, indomethacin and hydrocortisone have inhibitory effects on the
generation of tissue factor {Morrison et al. 1987).
vh. l. g. Endorphins
Endorphins are endogenous opioids recently implicated as mediators of the
hypotension of septic shock. Endotoxin can induce their synthesis and release from
splenic adherent monocytes. Naloxone has a palliative effect on their hypotensive action
although no demonstrable beneficial effect on survival in gram-negative sepsis. These
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neurohormones have a variety of physiologic effects including analgesic and
behavioural changes; in addition they have both enhancing and suppressive
immunoregulatory effects. The pituitary gland is a major source of the 31kDa precursor
molecule that contains sequences for both ACTH and p-endorphin. Modification of the
latter yields a and y endorphins, which represent the first sixteen and seventeen
aminoacids of p-endorphin respectively. The pentapeptide metencephalin has also been
shown to have immunoregulatory activity (Morrison et al. 1987).
vii. 2. Cytokines & fever
Fever is produced by three mechanisms; the first involves the raising of the set
point in the hypothalamic thermostat {Figure 5). This occurs in infection, collagen
vascular disease, and malignancies. This type of fever is lowered by antipyretics and
physical removal of heat. A second type of fever results from heat production in excess
of heat loss. Examples of this mechanism include salicylate overdose, hyperthyroidism,
and malignant hyperthermia. The third type of fever is caused by defective heat loss, as
seen with ectodermal dysplasia, heat stroke (excessive environmental temperature), and
poisoning with anticholinergic drugs. Antipyretics are ineffective for the second and
third types of fever. Fever occurs as a result of a number of complex biologic
interactions. Exogenous pyrogens, including viruses, bacteria, fungi, antigen-antibody
complexes, and drugs, are engulfed by phagocytic leucocytes. Phagocytic leucocytes,
when activated by leukotrienes, prostaglandins, and calcium, synthesize the endogenous
pyrogen interleukin-1. Monocytes and macrophages are particularly effective producers
of interleukin-1, polymorphic neutrophils and eosinophils less so, and lymphocytes not
at all. Interleukin-1 (also known as lymphocyte-activating factor), in conjunction with
interleukin-2, is responsible for increasing the number of helper T cells and initiating the
production of prostaglandins in the hypothalamus. Flelper T cells play a key role in
fighting infections, and prostaglandins are responsible for producing fever. Interleukin-1
acts on the arachidonic acid pathway, stimulating the production of prostaglandins from
the phospholipids in the vascular endothelial cells of the hypothalamus. Prostaglandins
increase the firing rate of cold-sensitive cells in the preoptic anterior nuclei (PON) and
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decrease the activity of warm-sensitive cells, resulting in shifting of the set point to a
higher temperature setting. The body responds to a perceived colder peripheral skin
temperature by vasoconstriction, which decreases heat loss, and through increased
shivering, which increases heat generation. Antipyretics lower the central set point,
resulting in the periphery feeling hot at the skin surface. The body lowers its temperature
by vasodilation, which increases heat loss, and lying quietly, which minimizes heat
generation. Aspirin, paracetamol, and non-steroidal anti-inflammatory drugs exert their
antipyretic effect through inhibition of the cyclo-oxygenase enzyme, thereby preventing
synthesis of prostaglandins from arachidonic acid. Because they do not suppress
interleukin-1, they do not diminish proliferation of helper T cells and, thus, do not
adversely affect the body's ability to fight infection. Corticosteroids, on the other hand,
decrease interleukin-1 release from monocytes and macrophages quantitatively. This
activity is detrimental to the body's ability to fight infection. Aspirin, paracetamol, and
non-steroidal anti-inflammatory agents all have excellent antipyretic and analgesic
activity. Only aspirin and non-steroidal agents have anti-inflammatory activity.
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Clinical Uses of Cytokines
vm. 1. Cytokines in therapy
Recombinant growth factors such as EPO and G-CSF are widely used for treatment
of anaemia and neutropenia in cancer patients undergoing cytotoxic therapy and in
severe sepsis. In vivo administration of IL-6 in primates increases platelet counts by
100% (Kishimoto et al. 1992). This observation could be of major practice importance
and may lead to the use of various combinations of haematopoeitic cytokines, such as
IL-6, IL-3 and stem cell factor (c-kit ligand) in new therapeutic approaches of
thrombocytopenia. A number of theoretical strategies exist for reducing the actions or
interactions of these cytokines and adhesion molecules. They include inhibiting their
production or expression, e.g. the non-specific inhibition by steroids in meningitis, and
blocking their actions once released. The latter include naturally occurring competitive
antagonists, soluble receptors, antibodies and blocking agents. Examples of anti-
cytokine treatment strategies that have been evaluated include:
1. Polyclonal or monoclonal endotoxin antibodies: Monoclonal antibodies are of
large molecular weight and thus tend to induce an immune response in
themselves. Anti-lipid A (of LPS) is the most extensively studied. A neutrophil
164
granule protein called bactericidal/permeability increasing protein binds and
neutralizes the lipid A component of the LPS.
2. Anti-TNF antibodies or TNF receptor constructs: Two distinctive TNF receptors
and a whole family of TNF-related proteins have now been described. Both TNF
receptors exist in monomeric soluble form in plasma, as well as being expressed
on the cell surface. TNF itself exists as a trimer that probably binds two receptors
simultaneously on the cell surface. Monomeric soluble receptors appear to have
little antagonistic activity. However, engineered dimeric receptors bound to the
Fc portion of immunoglobulin appear to block the effects of TNF highly
effectively.
3. Blocking the actions of IL-1 by IL-lra: There are three members of the IL-1
family of cytokines - IL-la, IL-ip, and IL-1 receptor antagonist. All three bind
to the two recognized IL-1 receptors but the IL-lra has no signaling effect and
thus acts as a competitive antagonist. The type-2 IL-1 receptor also acts as a
negative-feedback regulator as it does not transmit a signal on binding to IL-1.
This type-2 receptor is shed from the cell surface and has been found in high
concentrations in plasma of patients with septic shock and appears to have a
selective high affinity for IL-1 p. A more indirect approach is the inhibition of the
enzyme that cleaves the IL-1 p precursor into its active form.
4. Several disorders, including allograft rejection, are due to an undesired immune
response in which cytokines play a part. Immunosuppressive agents such as
glucocorticoids and cyclosporin are potent inhibitors of both cytokine synthesis
and the response of cells to cytokines. Immunosuppression may also be induced
with the use of cytokines fused to toxins (chimerism) which home activated cells
bearing the cytokine receptors. Antibodies directed towards cytokines or their
receptors are also potentially useful immunosuppressive therapy. Some cytokines
are themselves immunosuppressive, e.g. IL-6 and interferons inhibit cellular
responses and proliferation.
Human trials of anti-cytokine therapy have been disappointing for the following
reasons:
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1. The timing and dose may be critical
2. Blocking cytokines may inhibit host defenses
3. Such therapy might disturb the complex immunoregulatory balance with
extremely unpredictable effects
4. Cytokines have redundant and overlapping functions and inhibition of a single
cytokine is unlikely to provide a solution.
A better approach may be the use of counter-inflammatory molecules such as IL-10
or targeting more proximal points in the cascade e.g. NF-kB. Cytokines are not stored in
intracellular compartments and are newly synthesized and released in response to
inflammatory stimuli. This regulation occurs predominantly at the level of gene
transcription with new expression of cytokine mRNA. Nuclear factor kB (NF-kB) is a
transcription factor that plays a central role in regulating the cytokine cascade by binding
to regulatory portions of the cytokine genes. NF-kB is activated by endotoxin, TNF and
IL-1. Intervention to inhibit NF-kB activation could down-regulate systemic
inflammation to a much greater extent than blocking the production or action of a single
cytokine.
Ways to apply these new therapeutic strategies are being sought in numerous other
disease processes including acute infection. In addition to chronic inflammatory
conditions such as autoimmune arthritis and inflammatory bowel disease, processes as
diverse as proliferation of leukaemic cells, tumour metastasis and destruction of
pancreatic-p cell in diabetes mellitus, all appear to involve cytokines {Finn et al. 1995).
Interferon therapy has been found to be beneficial in chronic myelogenous leukaemia,
hairy-cell leukaemia and other cancers. Alpha interferon has some success in chronic
hepatitis B and some neurologic disorders, and topically for herpetic keratitis, genital
warts and upper respiratory tract infections. Beta interferon has also been used to treat
juvenile laryngeal papilloma. IL-2 has received the most attention in cancer therapy,
melanoma and renal cell carcinoma being the most sensitive {Dinarello et al. 1987).
166
viii. 2. Cytokines in diagnosis
To enter the repertoire of the clinical chemistry laboratory, cytokine assays must
either provide new information of use in diagnosis or management, or surpass existing
assays of disease markers in sensitivity, specificity, or speed of response. Although new
information is being obtained from studies of cellular cytokine production, none of these
has given rise to useful diagnostic tests as yet. It is in the area of improved markers that
cytokine assays are beginning to play a role. Most of the current markers of
inflammation or tissue damage - such as the acute phase proteins, enzymes and tissue
antigens - reflect either the effects of cytokines (e.g. acute phase proteins and fever) or
the cellular damage caused by the inflammatory process (e.g. tissue enzyme release).
Cytokine measurements are of fundamental interest because increases in their
concentrations can be expected to precede the other changes. Indeed, it is this
characteristic that so far suggests most of the potential clinical applications for cytokine
measurement (Whicher & Evans. 1990). Cytokines are usually of low MWt (<80 kDa)
and are extremely potent (acting at picomolar concentrations). They regulate both the
amplitude and duration of the inflammatory response. The response of a cell to a
ctyokine depends on the cytokine's local concentration, the cell type, and the presence of
other cytokines to which it is being concomitantly exposed. Cytokine interactions are
also modulated by changes in receptor density and solubilisation of receptors, which
may then act as inhibitors of cytokine function. The concept of an intricate network of
polypeptides, gained from in vitro research, makes the interpretation of in vivo data very
difficult to interpret. The measurement of cytokine concentrations in body fluids may or
may not reflect anticipated intercellular interactions and cannot take into account the
concomitant effects of other cytokines on effector or target cells. Hence, the inability to
measure the presence of a cytokine in a biological fluid does not necessarily imply a lack
of biological activity at a cellular level. Likewise, a markedly elevated level of a
cytokine might reflect deficiency of inhibitors. Therefore, the interpretation of what we
measure is, at best, controversial (Bellomo et al. 1992).
The inflammatory cytokines (IL-1, TNF, and IL-6) are increased in blood and tissue
fluid during inflammation from causes as diverse as burns, graft rejection, and sepsis. If
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measurements are to have a value in clinical practice, they must lead to a more rapid and
precise diagnosis. IL-6 and TNF may have this potential in graft rejection and
septicaemia. However, large inter-study variations in the proportion (16-100%) of
patients with detectable plasma levels of TNF & IL-1, and correlation with outcome,
exist. Possible explanations for this discrepancy include:
1. Peak levels of these cytokines occur rather rapidly after the challenge, and
therefore the time of measurement after the onset of sepsis may have influenced
the results. In patients admitted to intensive care units, TNF levels, when
detectable, are usually higher at the time of admission than during subsequent
sampling, especially in survivors (Dinarello et al. 1987).
2. The cytokine levels in plasma may not wholly reflect their synthesis by the cells.
For instance, plasma levels of TNF do not correlate with monocyte-associated
TNF in septic patients.
3. Differences in assay technique could also be responsible for the differences
observed; Receptor-bound cytokines may not be detected by bioassays that
measure unbound portions only and also by immunoassays that use monoclonal
antibody against the receptor binding sites of the cytokine. Levels of both TNF
receptors have been found elevated in sepsis. TNF/sTNF-R ratio at the time of
admission has been found to be of predictive value for outcome.
4. Some cytokines, such as TNF, are detectable in plasma of healthy individuals.
This is partly explained by non-specific reaction and, also, if heparin is used as
an anticoagulant, it can stimulate TNF-a release. Raised TNF-a levels also
appear to be a feature of certain healthy people {Emery et al. 1998).
In patients with sepsis, detectable or elevated levels of the pro-inflammatory
cytokines TNF, IL-1, IL-6 and IL-8, as well as the anti-inflammatory cytokine IL-10, are
found in the circulation. TNF-a levels are increased in most patients with sepsis,
whereas IL-1 and IFN-y are increased in fewer than 20% of the cases. Elevated IL-6
levels are found most consistently, but elevated levels of IL-8 are often detected as well.
Whereas increased concentrations of soluble TNF receptors and IL-lra appear in
circulation, sIL-6 receptor levels seem to be reduced in sepsis. The immune cytokine IL-
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2 may have a role in indicating activation of cell-mediated immunity as
immunoglobulins indicate involvement of the humoural immune system. Patients with
IL-1 detectable with increased concentrations of TNF have a poor outcome, but the
association with mortality or severity of disease is most obvious for IL-6 (Whicher &
Evans 1990). IL-6 may be the marker of choice, given the assay sensitivity and the
massive incremental changes observed. Clinical implications of mean levels might be
greater than those of peak levels, so measurements at regular intervals could be more
helpful for many of these cytokines (Thijs et al. 1995).
viii. 3. Cytokines as markers of bacterial infection
Attempts have been made to incorporate cytokines in the armamentarium used to
detect or predict bacterial infection in patients presenting with the sepsis syndrome. Of
the cytokines proved to be of value in this respect are; IL-6, IL-8, and sICAM-1.
IL-6 was most extensively studied as a marker of sepsis. Initial studies showed that the
majority of patients admitted to intensive care units (ITU) with the sepsis syndrome had
elevated levels of IL-6 (Hack et al. 1989, Casey et al. 1993). In a group of septic
surgical patients, IL-6 was the only cytokine consistently elevated and its levels
correlated with clinical severity and outcome (Damas et al. 1992). In children with fever
and malignant disease, IL-6 was more sensitive than CRP in detecting sepsis. However,
it failed to differentiate infected from non-infected patients and could not influence
initial treatment decisions in patients with granulocytopenia (Calandra et al. 1991,
Abrahamsson et al. 1997). Conditions other than sepsis are also associated with high
plasma levels of IL-6. For instance, in patients with severe burns, IL-6 rose to 2-100
times the normal levels within hours of the injury (Nijsten et al. 1987).
IL-6 in umbilical cord blood has consistently been shown to be a sensitive
marker for early infection in newborn infants (Lehrnbecher et al. 1996, Mehr et al.
2000). IL-6 was found more useful than CRP in predicting sepsis in very low birth
weight babies {Kuster et al. 1998), and was more predictive of necrotising enterocolitis
than TNF {Harris et al. 1994). IL-6 combined with TNF gave 100% specificity in
diagnosing early neonatal sepsis (de Bont et al. 1994). Combining IL-6 with CRP
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yielded 98% sensitivity and 91% specificity in detecting early neonatal sepsis (NG et al.
1997). 100% sensitivity was reported for IL-6 in identifying infected newborns who had
a negative CRP test (Buck C, 1994). However, earlier studies found no correlation
between plasma levels of IL-6 and the febrile response in newborns suspected of sepsis
(de Bont et al. 1993). Furthermore, non-septic babies with physiological jaundice were
reported to have had significantly higher plasma IL-6 levels than adult controls
(Ozdemir et al. 1994). Serum IL-6 levels were elevated in all children with bacterial
sepsis, with significantly higher levels in non-survivors, whereas no IL-6 was detectable
in control subjects {Sullivan et al. 1992). High IL-6 levels were also found in serum of
patients with septic shock {Jacobs et al. 1996) and in CSF of children with acute
bacterial meningitis {Helfgott et al. 1989). The median serum concentration of IL-6 was
1000 times higher in patients with meningococcal septic shock than in patients with
bacteraemia, meningitis, or combined septic shock and meningitis, and levels correlated
with mortality {Waage et al. 1989). Children with bacterial acute otitis media (AOM)
had significantly higher IL-6 levels than those with non-bacterial AOM. Pneumococcal
AOM was associated with higher levels than H. Influenzae or Moraxella AOM {Tehro et
al. 1995). Urinary levels of IL-6 were found elevated in febrile children with UTI, and
were reduced after initiation of antibiotic therapy {Jantausch et al. 2000). Serum IL-6
levels effectively predicted bacteraemia in patients presenting with sepsis in the A&E
department {Moscovitz et al. 1994).
IL-8 became measurable by a fully automated random access assay in 1996.
Cytokines generate an inflammatory response both systematically and locally, at the
mucosal level. Like interleukin-6, urinary IL-8 concentrations are elevated in patients
with febrile UTI, and the response appears to be related to the virulence of the invading
bacteria {Jantausch et al. 2000). IL-8 has also been detected in CSF of patients with
meningitis {Marty et al. 1994). IL-8 was present in the pulmonary oedema fluid of all
patients with ARDS. The high concentrations of IL-8 in pulmonary oedema fluid,
coupled with the relatively low concentrations of IL-8 in the plasma, suggested that the
lung was the primary source of IL-8 in the patients with ARDS {Miller et al. 1996). IL-8
has been found a more sensitive (Sensitivity 100% and 95% respectively) marker for
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histologic chorioamnionitis and preterm delivery than amniotic fluid culture and G stain
Cherouny et al.l993). This supports the role of IL-8 in recruitment of neutrophils into
chorionic membranes and placenta during intrauterine infection, and that IL-8 is released
into the amniotic fluid during the early phase of ascending infection before bacteria or
their products are detectable in amniotic fluid. Cord IL-8 concentrations measured in
septic newborns were also significantly elevated compared with non-septic newborn
infants (.Berner et al. 1998). Other workers found elevated cord IL-6 levels in babies
with many non-infectious neonatal complications while IL-8 was elevated only in early
neonatal bacterial infection (Santana et al 1997). In newborn infants evaluated for
sepsis, IL-8 was positive at the first suspicion of bacterial infection (BI) in 100% of
infants with culture proven BI and in 78% of infants with clinical BI. CRP was initially
positive in 33% of culture proven BI and in 27% of infants with clinical BI and was
raised in all, 12-60 hours after the initial evaluation. The combination of both tests
increased the sensitivity from 91 to 100%. IL-8 rose earlier and tended to return to
normal within 24 hours {Franz et al 1999).
In septic patients, high amounts of circulating IL-8 concentrations correlated
with fatal outcome, whereas only low plasma concentrations of IL-8 were present in
patients with non-septic multiorgan failure. This suggests that the signals involved in the
exacerbation of IL-8 production are different, depending on infectious or non-infectious
aetiology (Marty et al 1994). Levels of cytokines (TNF, IL-1, IL-6, and IL-8) were
higher, and persisted for longer, in plasma and broncho-alveolar lavage (BAL) from
patients with ARDS associated with sepsis and more so in the non-survivors (Headley et
al 1997). In pertussis, inflammatory parameters, such as ESR, CRP and ai acid
glycoprotein, were normal, while cytokines, especially IL-6 and TNF, were significantly
elevated (Ostermann et al. 1994). All cytokines (IL-1, TNF, IL-8 and IL-6) were
significantly higher in children with acute febrile illnesses {Torre et al 1993). Increased
levels of ICAM-1 were found in a number of pathologic conditions including
malignancy, SLE, hepatitis, LBV, miliary TB and neonatal sepsis {Sessler et al. 1995).
Newborns with early onset sepsis had high cord blood levels of sICAM-1, which did not
correlate with maternal blood levels of this cytokine, indicating that the neonate's
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response to sepsis is different from the mother (Lehrnbecher et al. 1996). A rise in the
concentration of ICAM-1 has been described in adults with meningococcal sepsis or
meningitis (Baines PB, 1999). Increased levels were also found in septic adults admitted
to ICU and these levels correlated with severity of sepsis and shock and subsequent
organ failure and eventual outcome (Sessler et al. 1995). .
vm. 4. Cytokine Assay
vm. 4. a. Bioassay
All cytokines were initially described as biological factors before being purified
and chemically characterized. Therefore, virtually all cytokines can be measured by
bioassay. The major problem with bioassays is that they are not specific. The thymocyte
proliferation assay for IL-1 can be influenced by other cytokines; IL-6 and TNF can
replace IL-1, and IL-2 and IL-4 can synergise with IL-1. Modifications, such as
neutralization with specific antibody or saturating the assay with IL-2, or IL-4, still do
not solve the problems arising from yet unknown cytokines or other biologically active
molecules like steroids and prostaglandins, which are known to alter cytokine responses.
The measured biological activity in some cytokines has been less than that measured by
immunoassay. Inhibitory factors, cytokine-binding molecules, or biologically inactive
but immunoreactive cytokines can result in this discrepancy. Chloroform has been used
to extract an agent interfering with IL-1 assay. a2-Macroglobulin, an acute phase protein
in some species, binds to IL-1 and IL-6. Furthermore, bioassays are labour intensive,
expensive, and subject to considerable operator influence. They are not suitable for
routine clinical chemistry. However, they are very sensitive, detecting orders of
nanograms per litre. The materials required for assays are easily obtained, compared to
the difficulty in obtaining good antibodies for immunoassay. Thus bioassays may
identify which areas warrant investing in the development of immunoassays. IL-6-
dependent mouse-to-mouse hybridoma cells 7TD1, is a bioassay that is specific to IL-6
with a limit of detection less than 1 pg of recombinant mouse IL-6 (Calandra et al.
1991). Bioassays for IL-6 using hybridoma cell lines detect IL-6 at concentrations of 5-
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100 pg/ml. However, although not responding to other known cytokines, these assays
could be influenced by combinations of cytokines and/or inhibitory substances present in
human body fluids or produced by cultured cells. Moreover, some pharmacologic agents
possibly present in samples from patients might also influence the bioassay. Since these
agents are often protein-bound, as is IL-6 in human plasma, it is difficult to separate
them from IL-6 (Scindler et al. 1990). It has proved difficult to detect the presence of
biologically active IL-1 or TNF in the peripheral circulation during the acute phase
(.Helfgot et al. 1989).
viii. 4. b. Immunoassay
Immunoassays are simpler to use and control. However, they are expensive and
generally have been validated as research tools, often only for cell culture supematants.
They may lack the sensitivity for use with plasma, and some are subject to interference
with rheumatoid factors or heterophilic antibodies. They are frequently imprecise and
often do not demonstrate acceptable recovery profiles from plasma, CSF, or synovial
fluid. It has been suggested that laboratories set up their own assays to ensure the
validity of their results and encourage production of reagents such as cytokine-specific
antibodies. The immunoradiometric assay (IRMA) needs incubation for 16-20 hours.
Reported sensitivity of IRMA for TNF and IL-6 was 5pg/ml, and 4pg/ml for IL-1 p. In
normal subjects, neither IL-1, nor TNF or IL-6 could be detected by IRMA. Radio¬
immunoassay (RIA) correlated well with the hybridoma bioassay for IL-6 (r=0.87)
(.Damas et al. 1992).
viii. 4. c. Standardization
The problem of standardization in cytokine assay is enormous. A single cytokine
may have different biological activities, and numerous preparations (natural and
recombinant) of a cytokine might be available. Such materials may differ in potency in
bio- and immunoassay. Comparing data from different laboratories requires proper
cytokine standards and carefully prescribed assay conditions such as the choice of serum
supplements, type of sample, and sample preparation. Cytokine standards are becoming
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available. Quality control will be important to address the problems of cytokine assays
in clinical chemistry (Wicher & Evans 1990). The evaluation of the precise role of these
lymphokines requires specific assays. Specific immunoassays satisfy this requirement,
but the high sensitivity required poses quite a problem. Bioassays are often used to
detect the small quantities of cytokines present in biological fluids. Purified natural IL-1
preparations were shown to be contaminated with IL-6, and some antisera to IL-1
contained anti-IL-6 activity. Both IL-1 and IL-6 are active in the Thymocyte assay. The
detection limit of this assay for both is 100 pg/ml. The detection limit of the IL-6 assay
on hybridoma cell line, which is highly specific to IL-6, is 0.5pg/ml. IL-1 can be
specifically measured with D10 cells, the detection limit for which is around 1 pg/ml
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The Edinburgh Sick Children's Hospital NHS Trust is one of only two Trusts in
Scotland dedicated solely to the treatment of children, both in the acute and community
setting. The hospital provides a fully combined child health service for the children of
Lothian, South-East Scotland and beyond. Patients referred from the A&E and other
departments are seen in an ambulatory/short-stay unit which has been opened only
recently. In-patients are accommodated in 138 beds distributed among medical and
surgical wards as shown in Table 12. There are 27 consultants in the surgical directorate,
23 paediatric medical consultants and nine consultants in community paediatrics. The
hospital also employs a number of consultants in the support services and a few numbers
of the staff from the University of Edinburgh also hold honorary posts at the hospital.
The hospital operates a computerised information system designed to provide speedy
access to information needed by clinical staff to help with their treatment of patients.
The A&E department is staffed with a consultant in accident and emergency
medicine and two full time staff-grade doctors. A number of senior house-officers work
in a partial-shift system and are supported by both medical and surgical middle grade
staff (specialist registrars). A consultant paediatrician with special interest in ambulatory
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paediatrics supports the A&E staff and also runs an ambulatory clinic on site. A number
of nurses were specially trained and qualified as paediatric A&E nurse practitioners and
they are actively involved in patient management and can provide independent advice
and treatment for simple ailments. The department runs a telephone advice service for
the parents, which is run by nurses under the supervision of the medical staff. The
department is well equipped and operates a 24 hour stand-by service for resuscitation
and advanced life-support. All admissions to the hospital, except those referred from
other district hospitals, go through the A&E department.
About 35000 children are treated in the A&E Department each year. On average,
45000 patients are seen annually in the outpatient clinics, 72% of whom are review
patients and the remainder are new referrals. Each year, around 3800 patients are seen in
the ambulatory clinic attached to the A&E department. The average annual number of
in-patients is 9500, over half of which is from the A&E department. From a total number
of 20446 beds occupied in 1998/99, 13712 (67%) were for medical cases, excluding
cardiac and neurology cases. During the last three years increasing numbers of children
were being treated as day-cases. There was an increase of 16% (to 4476) in 1997/98, and
18% (to 5287) in the year 1998/99 in the number of day cases. This was mirrored by a
1% reduction in admissions in 1998/99. These achievements were largely due to the
development of Ambulatory Paediatrics and changes in clinical practice emphasizing a
short-stay philosophy. There was also an increase in the numbers of children being
treated in their local community. Accompanying these changes were large improvements
in waiting times for both outpatient appointments and day-case and in-patient
treatments. The year 1998/99 witnessed an 18% reduction in the total number of patients
waiting for admission.
Twenty percent of the 35000 patients attending the A&E department at
Edinburgh Sick Children's Trust (ESCT) annually present with medical problems.
Varying with the season, 30%-75% of these have infectious illnesses. In winter, an
average of 35 cases of infectious diseases are seen daily with up to 26 admissions a day.
Fever is a major symptom in the majority of these children. A pilot study was done to
study the determinantnts and appropriateness of hospitalization of febrile children from
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the emergency department. Data were collected from all children presenting with an
infectious illness over nine weeks (10 December 1997 to 22 February 1998). A study
proforma was used to collect clinical and laboratory data and on it the admitting
physician indicated the reason for admission. The definitive study's aims were to to
determine the probability (prevalence) of serious bacterial illness in highly febrile
children and identify the clinical and laboratory determinants of SBI.
ix. 2 Subjects
The target population was all the children aged 0-5 years of age who lived in the
council areas served by the Edinburgh Royal Hospital for Sick Children (Table 13). The
study spanned over a whole calendar year, from 1 September 1998 to 31 August 1999.
The study group consisted of children seen at the emergency department fulfilling the
inclusion criteria (Appendix 4):
1. Age <5 years
2. Temperature >38.5°C
3. Informed written parental consent obtained
Patients referred for admission from district hospitals were not included. Patients
were prospectively enrolled as they presented to the emergency department. The
numbers of all patients attending the previous day were collected from the hand-written
attendance list and were verified by cross-examining with the computer-generated
emergency room register. Patients eligible for the study who were not enrolled were
identified by examining the date of birth and temperature on the ER evaluation form
completed by the nurse. Demographic data and relevant clinical information, including
the time of arrival, source of referral, and recent antibiotic and antipyretic use, were
recorded. The administrative outcome, i.e. admission to hospital or discharge from the
emergency department, was noted and further clinical information was collected by
review of the case notes. This included the initial diagnosis, route and duration of
antibiotic use, admission to ITU, laboratory and radiographic investigation results and
the discharge diagnosis. Blood culture results were cross-examined and verified with a
list of all blood cultures done during the study period obtained from the microbiology
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department. A written study protocol was distributed among the medical and nursing
staff concerned with the management of medical patients at the emergency room. This
was also prominently displayed at different sites of the department. Upon arrival to the
department a triage nurse saw the patient and recorded the axillary temperature using
Sure-Temp electronic thermometer (WelchAllyen™, Henleys Medical Supplies Ltd
Brownfields, Welwyn Garden City, Herts AL7 IAN). This device takes about 15 seconds
to record axillary temperature with an accuracy of ±0.1 °C (0.2°F). The nurse then
alerted the investigator or the attending doctor if the patient met the study criteria. The
nurse attached a clinical assessment form to the clinical notes of the patient and
delivered a study information sheet to the parent. The attending doctor obtained a
written informed consent and completed the assessment form as he/she took the medical
history and examined the patient. The emergency department policy indicated a CBC on
all patients with similar age and temperature criteria. The majority of the patients were
also investigated by a blood culture.
Other tests, such as urine culture and radiography, were done at the discretion of
the attending physician. During the study period, September 1998 to August 1999, urine
was collected by suprapubic aspiration from babies less than 6 months and a clean catch
specimen was collected from older patients. Urine bags were only used for children not
thought to have a high risk of infection. Spun urine was microscopically examined for
pyuria and reported as the number of white blood cells seen per high power field.
Significant results were expressed in absolute numbers. Urine was cultured using
standard quantitative techniques in the hospital microbiology laboratory. Chest
radiography was done at the discretion of the assessing physician and the radiologist's
report was immediately available to guide management in the emergency room. The
radiologists had access to clinical data on the radiography request form but were blinded
to the study group or outcome.
An extra 1-2 ml of blood was collected for cytokine assay immediately on entry to
the study. Sera for comparison were obtained from afebrile children who were not
acutely ill and were attending various clinics at the outpatient department. The
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investigator reviewed the case notes of all patients and collected informed written
consent from the parents. Inclusion criteria were:
1. Age <5 years
2. Parental consent.
Exclusion criteria were:
1. Acute febrile illness
2. Current antibiotic treatment
3. Recent vaccination (in the last 48 hours)
4. Chronic or intermittent infections (e.g. cystic fibrosis)
5. Primary or secondary immunodeficiency
6. Neoplastic disease including haematological malignancies
7. Renal disease e.g. nephrotic syndrome and nephritis
8. Blood disorders e.g. active ITP, sickle cell disease
9. Significant recent trauma or burns (in the last 48 hours)
10. Autoimmune diseases e.g. SLE
11. Chronic inflammatory disease e.g. rheumatoid arthritis, Crohn's disease
12. Prolonged corticosteroid treatment
13. Prolonged non-steroidal anti-inflammatory drug use
The study protocol was approved by the Ethics Committee for the Lothian Health
Authority.
ix. 3. The Clinical assessment form
The assessment was based on the Acute Infant Observation Scale (Yale Infant
Observation Scale) developed by McCarthy et al, with a slight modification to make it
easier to use in a busy emergency department (.Appendix 5). The clinical assessment data
were collated from history, observation and physical examination variables. Each
variable consisted of three specific items and each item was scored on a three-point scale
of impairment; 1 (no or mild impairment), 2 (moderate impairment) and 3 (severe
impairment). An overall subjective impression of the severity of illness, and the
probability of SBI were similarly scored (Appendix 5). On the form, serious bacterial
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illness (SBI) was defined as bacteraemia or septicaemia, urinary tract infection,
pneumonia, osteomyelitis or septic arthritis, meningitis or gastro-enteritis of bacterial
aetiology. Physicians chose the options descriptive of the patient's condition rather than
ticking the scale points. Physicians used their discretion in assigning the scores
according to the age and developmental stage of the child. Historical and observational
parameters could be used interchangeably.
ix. 4. Definition of outcome variables
The outcome result was the presence of serious bacterial infection (SBI) defined
as bacteraemia / septicaemia, urinary tract infection, pneumonia, osteomyeltis, septic
arthritis and soft tissue infection, and bacterial gastro-enteritis. Bacteraemia was defined
on the basis of a single bacterial pathogen grown from blood by standard culture
techniques. Bacterial organisms regarded as non-pathogenic in immuno-competent
patients, such as staphylococcus epidermidis, were considered contaminants. Bacterial
meningitis was considered present in the context of clinical signs and cytological
evidence of meningeal inflammation with a pathogenic organism grown from CSF,
blood or throat swab. Urinary tract infection was defined as a significant (>105 cfu/ml)
growth of a single urinary tract pathogen according to universal criteria. Other evidence
of UTI, such as gram stain of urine for bacteria, nitrites or leucocyte esterase, was not
routinely sought. A conservative definition of pneumonia was used in that only findings
reported as consolidation were considered pneumonia. Other abnormalities described
with less definitive terms, such as patchy infiltrates, peri-bronchial or peri-hilar
infiltrates were not considered pneumonia. Readings other than consolidation, such as
patchy infiltrates or peribronchial thickening, were not considered indicative of
pneumonia. Bacterial gastro-enteritis included Clostridium difficile infections, either the
organism grown on culture or its toxin detected in the stools. Osteomyelitis and
cellulitis were considered bacterial infections on clinical grounds but other evidence of
baterial aetiology was necessary to make a diagnosis of pyogenic arthritis.
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ix. 5. Statistical analysis
Non-parametric data were analysed using the Mann-Whitney U-test for
continuous variables. Normally distributed data were analysed using the two-tailed t-
test. Categorical data were analysed by the % test. The clinical assessment score (The
Acute Illness Observation Scale, modified) was analysed as continuous data. Backward
step-wise logistic regression analysis was used to identify independent parameters
predictive of SBI. Receiver-operator characteristic curves (ROC) were used to compare
the differential performance of variables. Based on the ROC curves, cut-off values and
corresponding optimum sensitivities and specificities for each variable were determined.
The level of statistical significance was 0.05. Statistical analyses were performed using




Table 12: Bed allocation at the Edinburgh Sick Children Hospital
Specialty Number of wards Number of beds
Medical 4 61
Surgical 3 56
Infectious diseases 1 6
High dependency 1 6
Intensive care 1 6
Neonatal unit 1 3
Table 13: Mid-year population estimates: Council areas by age group 0-5 years*.
Age (years) 1 2 3 4 5 Total
City of
Edinburgh
4894 4935 4997 4870 4995 24691
Midlothian 948 936 911 946 1020 4761
TOTAL 5842 5871 5908 5816 6015 29452






1-2 ml of blood was collected in tubes containing EDTA and aprotonin (trasylol)
and labelled by the patient's addresograph. Blood was gently shaken and then
centrifuged at 13000 rpm for three minutes using a microfuge kept in a side room at the
A&E department. Plasma was removed, using disposable pipettes, and divided into three
fresh plain tubes without anticoagulants. The tubes were similarly lablled by a sticker
from the patient's case notes. The tubes containing plasma were placed in a refrigerator
(4°C) in A&E for only a few hours according to the manufacturer's instructions. The
tubes were then transferred to the adjacent University of Edinburgh laboratory and kept
frozen at -20°C until the time of assay. The technician who performed the assays had no
access to any clinical details concerning the patients. Cytokine ELISA kits were
provided by the Immunodiagnostic Systems Limited, Boldon Business Park, Boldon Tyne
& Wear, NE35 9PD, United Kingdom. The assays were done at the Department of
Child Life & Health Laboratories, by Dr J Smith, PhD, University of Edinburgh. The
kits were kindly funded by Mason Company.
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x. i. IL-6 assay
IL-6 kit:
The IL-6 kit is a solid phase sandwich Enzyme-Linked Immune-Sorbent Assay
(ELISA). A monoclonal antibody specific for IL-6 has been coated onto the wells of the
provided microtitre strips. Samples, including standards of known IL-6 concentrations,
control specimens and unknowns are pipetted into these wells. During the first
incubation, the IL-6 antigen and a biotinylated monoclonal antibody specific for IL-6
were simultaneously incubated. After washing, the enzyme (streptavidin-peroxylase)
was added. After incubation and washing to remove all the unbound enzyme, a substrate
solution acted upon by the bound enzyme was added to induce a coloured reaction
product. The intensity of this coloured product was directly proportional to the
concentration of IL-6 present in the samples.
Reagents Preparations:
Standard buffer diluent:
5 ml of standard diluent buffer was diluted in 50 ml of distilled water.
Standards and Controls:
Two standard diluents were provided by the manufacturer, one for culture supernatant
and one for sera or plasma samples. The standard diluent for human serum was used in
this assay. Standards were reconstituted with 1.1 ml of standard buffer diluent to give a
concentration of 200 pg/ml IL-6. Controls were resuspended in 1 ml of standard buffer
diluent to give a concentration of 64±13 pg/ml IL-6.
Dilution ofbiotinvlated anti-IL-6:
The biotinylated anti-IL-6 was diluted with the biotinylated antibody diluent in a clean
glass vial according to the number ofwells to be used:








0.5 ml of HRP diluent were added to a 5 pi vial of Streptavidin-HRP. Further dilutions
were made according to the number of wells required:






Dilution of Washing Buffer:
2 ml of washing buffer was diluted in 400 ml of distilled water.
IL-6 Assay Method:
A. Before use, all reagents were mixed thoroughly without making foam.
B. For each round of assay, the number of microwell strips required to test the
number of samples available was determined and removed from the pouch. The
appropriate number of wells needed for running blanks and standards was also
prepared. Every sample, and every blank and standard and optional control
sample was assayed in duplicate.
C. lOOul of appropriate standard diluent were added to standard wells Bl, B2, CI,
C2, El, E2, Fl, and F2. A standard vial was reconstituted with the appropriate
volume as described above. 200ul of standard were pipetted into wells A1 and
A2. lOOul from A1 and A2 were transferred to Bl and B2 wells, respectively.
The contents were mixed by repeated aspirations and injections. This procedure
was repeated from the wells Bl, B2 to wells CI, C2 and from CI, C2 to Dl, D2
and so on creating two parallel rows of IL-6 standard dilutions ranging from 200
to 6.25pg/ml. lOOul from the content of the last microwells used (Fl, F2) were
discarded.
D. lOOul of appropriate standard diluent were added to the blank wells (G1-G2).
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E. lOOul of samples and lOOul of control were added to the sample wells and to the
control wells (HI, H2), respectively.
F. Biotinylated anti-IL-6 was prepared as above.
G. 50ul of diluted biotinylated anti-IL-6 were added to all wells.
H. The wells were covered with a plate cover and incubated for 1 hour at room
temperature.
I. The cover plate was removed and washed as follows:
1. The liquid was aspirated from each well
2. 0.3ml of washing solution was dispensed to each well
3. The contents of each well were aspirated again.
4. Steps 2 and 3 were repeated twice.
J. HRP solution was freshly prepared as above.
K. lOOul of HRP solution were dispensed into all wells, including the blank wells.
The wells were covered with the cover plate.
L. The microwell strips were incubated at room temperature for 30 minutes.
M. The plate cover was removed and the wells emptied. The microwell strips were
washed according to point (I) above.
N. lOOul of ready-to-use TMB substrate solution were pipetted into all wells,
including the blank wells. The wells were then incubated in the dark, by
wrapping the plate in aluminium foil, for 15 minutes at room temperature.
O. The Optical Density values of the plate were monitored and the substrate
reaction stopped before positive wells were no longer properly readable
(maximum time allowed was 20 minutes).
P. The enzyme-substrate reaction was stopped by pipetting lOOul of 1.8 N sulphuric
acid into each well, including the blank wells, to completely and uniformly
inactivate the enzyme. Results were then read immediately after the addition of
sulphuric acid.
Q. The absorbance of each well was read on a spectrophotometer using 450nm as






A 200 200 65 65 86 86/50 120 120/50 132 132 147 147/50
B 100 100 70 70/50 87 87 122 122 135 135/50 150 150/50
C 50 50 73 73/50 88 88/50 124 124 136 136 151 151/50
D 25 25 74 74 89 89 125 125 138 138/50 152/50 152/50
E 12.5 12.5 75 90/50 126 126 141 141 158 158
F 6.25 6.25 79/50 79/25 91/50 127 127 143/50 143/25 159 159
G Blank Blank 81 81 92 92 130 130 144 144/50 161 161
H Ctrl Ctrl 83/50 93 93 131 131 145 145 163 163
Data Analysis:
A linear standard curve was generated by plotting the average absorbance on the
vertical axis versus the corresponding IL-6 standard concentration on the horizontal axis.
The amount of IL-6 in each sample was determined by extrapolating OD values to IL-6
concentrations using the standard curve.
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Typical I L - 6 standard curve ranging
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I L - 6 (p g/m I)
Limitations of the Procedure:
The standard curve should not be extrapolated beyond the 200 pg/ml standard
curve point. The dose-response is non-linear in this region and good accuracy is difficult
to obtain. Therefore concentrated samples (>200pg/ml) had to be diluted with standard
diluent and the results were multiplied by the dilution factor. The influence of various
drugs, aberrant sera (haemolysed, hyperlipaemic, jaundiced, etc....) and the use of
plasma instead of serum specimens has not been thoroughly investigated. The rate of
degradation of native IL-6 in various matrices has not been investigated. The
immunoassay literature contains frequent references to aberrant signals observed with
some human sera and attributed to heterophilic (or anti-mouse) antibodies. The
possibility of this occurrence cannot be excluded
Performances and Characteristics:
Sensitivity:
The minimum detectable dose of IL-6 is less than 2 pg/ml. This has been
determined by adding 3 standard deviations to the mean optical density when the zero




Sample n Mean (pg/ml) SD CV%
A 8 198.7 1.667 0.83
B 8 28.69 1.118 3.86
Inter-assay
Sample n Mean (pg/ml) SD CV%
A 29 198.9 3.772 1.89
B 29 25.68 1.505 5.84
Linearity ofdilution:
A human serum pool containing lOOpg/ml of measured IL-6 was serially diluted
in standard buffer diluent over the range of assay. Linear regression of samples versus
the expected concentration yielded a correlation of 0.99.
Recovery:
Recovery of IL-6 added to pooled normal serum was 96.2% (85.4% to 100%) for
IL-6 concentration ranging from 200 to 6.25 pg/ml (data provided by the manufacturer).
x. 2. IL-8 Assay
IL-8 kit:
The IL-8 kit is a solid phase sandwich Enzyme-Linked Immune-Sorbent Assay
(ELISA). A monoclonal antibody specific for IL-8 has been coated onto the wells of the
provided microtitre strips. Samples, including standards of known IL-8 concentrations,
control specimens and unknowns are pipetted into these wells.
During the first incubation, the IL-8 antigen and a biotinylated monoclonal antibody
specific for IL-8 were simultaneously incubated. After washing, the enzyme
(streptavidin-peroxylase) was added. After incubation and washing to remove all the
unbound enzyme, a substrate solution which acted on the bound enzyme was added to
induce a coloured reaction product. The intensity of this coloured product was directly




5 ml of standard diluent buffer was diluted in 50 ml of distilled water.
Standards and Controls:
Two standard diluents were provided by the manufacturer, one for culture supernatant
and one for sera or plasma samples. The standard diluent for human serum was used in
this assay. Standards were reconstituted with 1.42 ml of standard buffer diluent to give a
concentration of 2000 pg/ml IL-8. Controls were resuspended in 0.5 ml of standard
buffer diluent.
Dilution ofbiotinylated anti-IL-8:
The biotinylated anti-IL-8 was diluted with the biotinylated antibody diluent in a clean
glass vial according to the number of wells to be used:







0.5 ml of HPJP diluent were added to a 5 ul vial of Streptavidin-HRP. Further dilutions
were made according to the number of wells required:






Dilution of Washing Buffer:
2 ml of washing buffer was diluted in 400 ml of distilled water.
195
IL-8 Assay Method:
A. Before use, all reagents were mixed thoroughly without making foam.
B. For each round of assay, the number of microwell strips required to test the
number of samples available was determined and removed from the pouch. The
appropriate number of wells needed for running blanks and standards was also
prepared. Every sample and every blank and standard and optional control
sample was assayed in duplicate.
C. lOOul of appropriate standard diluent were added to standard wells Bl, B2, CI,
C2, El, E2, Fl, and F2. A standard vial was reconstituted with the appropriate
volume as described above. 200ul of standard were pipetted into wells A1 and
A2. lOOul from A1 and A2 were transferred to Bl and B2 wells, respectively.
The contents were mixed by repeated aspirations and injections. This procedure
was repeated from the wells Bl, B2 to wells CI, C2 and from CI, C2 to Dl, D2
and so on creating two parallel rows of IL-8 standard dilutions ranging from
2000 to 62.5pg/ml. lOOul from the content of the last microwells used (Fl, F2)
were discarded.
D. lOOul of appropriate standard diluent were added to the blank wells (G1-G2).
E. lOOul of samples and lOOul of control were added to the sample wells and to the
control wells (HI, H2), respectively.
F. Biotinylated anti-IL-8 was prepared as above.
G. 50ul of diluted biotinylated anti-IL-8 were added to all wells.
H. The wells were covered with a plate cover and incubated for 1 hour at room
temperature.
I. The cover plate was removed and washed as follows:
1. The liquid was aspirated from each well
2. 0.3ml of washing solution was dispensed to each well
3. The contents of each well were aspirated again.
4. Steps 2 and 3 were repeated twice.
J. HRP solution was freshly prepared as above.
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K. lOOul of HRP solution were dispensed into all wells, including the blank wells.
The wells were covered with the cover plate.
L. The microwell strips were incubated at room temperature for 30 minutes.
M. The plate cover was removed and the wells emptied. The microwell strips were
washed according to point (I) above.
N. lOOul of ready-to-use TMB substrate solution were pipetted into all wells,
including the blank wells. The wells were then incubated in the dark, by
wrapping the plate in aluminium foil, for 12-15 minutes at room temperature.
O. The O.D. values of the plate were monitored and the substrate reaction stopped
before positive wells were no longer properly readable (maximum 20 minutes).
Incubation time of substrate solution is usually determined by the ELISA reader
performances: many ELISA readers record absorbance only up to 2.0 O.D.
P. The enzyme-substrate reaction was stopped by pipetting lOOul of 1.8 N sulphuric
acid into each well, including the blank wells, to completely and uniformly
inactivate the enzyme. Results were then read immediately after the addition of
sulphuric acid.
Q. The absorbance of each well was read on a spectrophotometer using 450nm as






1 2 3 4 5 6 7 8 9 10 11 1
A 2000 2000 C5 C23 C38/75 C47 C57/75
B 1000 1000 C6 C24 C29 C50 C58/75
C 500 500 C7/75 C27 C40 C52 C59/75
D 250 250 C8/75 C23 C41 C52 C66
E 125 125 C5/75 C33 C41 C53/75
C67
F 62.5 62.5 C20 C34/75 C43 C54/75 C68/75
G Blank Blank C21 C36 C44 C55 C74/75
H Ctrl Ctrl C22 C37 C45/75 C56 C80
Data analysis:
A linear standard curve was generated as for IL-6 and the amount of IL-8 in each
sample was determined by extrapolating OD values to IL-8 concentrations usng the
standard curve.
Limitations of the Procedure:
These were the same as for IL-6 assay.
Performance characteristics
Sensitivity
The minimum detectable dose of IL-8 was less than 25 pg/ml. This has been
determined by adding 3 standard deviations to the mean optical density obtained when




Sample n Mean (pg/ml) SD CV% Sample n mean (pg/ml) SD CV%
A 8 1934 11.71 0.60 A 40 1977 39.21 1.96
B 8 267.3 5.35 2.0 B 40 249.9 15.34 6.13
Linearity of dilution
A human serum pool containing 1000 pg/ml of measured IL-8 was serially
diluted in standard buffer diluent over the range of the assay. Linear regression of
samples versus the expected concentration yielded a correlation coefficient of 0.99.
Normal serum values
The average concentration of IL-8 detected in 72 normal serum is 407±331
pg/ml, ranging from 0 to 1938 pg/ml (data provided by the manufacturer).
Recovery
Recovery of IL-8 added to normal serum was 100% (84 to 114%) for IL-8
concentration ranging from 2000 to 62.5 pg/ml (data provided by the manufacturer).
x. 3. slCAM-1 Assay
The principles of sICAM-1 assay were exactly the same as for IL-6 and IL-8.
Sensitivity
The minimum detectable dose of sICAM-1 for this assay was less than O.lng/ml. This
has been determined by adding 3 standard deviations to the mean optical density
obtained when the zero standard was assayed 32 times.
Precision:
Mean Mean
Sample n SD CV% Sample n SD CV%
(ng/ml) (ng/ml)
A 8 7.82 0.081 1.03 A 22 8.05 0.317 3.93
B 8 1.17 0.033 2.82 B 22 1.03 0.084 8.15
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Normal serum values
The average concentration of sICAM-1 detected in 77 normal human serum samples is





Patient Characteristics and Clinical Outcome
xi. l. Patient characteristics
The pilot study showed that a third of A&E attendants presented with an
infectious illness, and 42% of these were febrile. 41% of patients with infectious
illnesses were admitted to hospital and 56% of hospitalized children did not, in
retrospect, require treatment that was not administrable at home (Table 7 4).The height of
fever and uncertainty of diagnosis were prominent reasons for admission, whereas only
3% of the children were admitted for social reasons. Furthermore, clinical and
demographic determinants of hospitalization were not the same as those dictating
hospital-based treatment (data not shown).
From 1 September 1998 to 31 August 1999, a total of 9980 non-trauma cases
were seen at the emergency department of the Edinburgh Royal Hospital for Sick
Children. Of these, 6128 (60%) patients presented with an infectious illness. 618 patients
fulfilled the study criteria (age <5 years and temperature >38.5°C) and clinical and
laboratory data were prospectively collected from these patients (.Figure 6). Of the 618
febrile patients (with axillary temperature >38.5°C), 342 (55.3%) were males and 276
(44.7%) were females, p=0.009. The median age was 19.3 months, range 0.3-71.8
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months. The vast majority (77.3%) of the febrile patients were 36 months of age or
younger, and there were only three infants less than a month old (Table 15). Nearly half
(47.9%) were seen during the winter months (December to February) while less than 5%
presented during the summer months (June-Aug), (Figure 7). 346 (57.7%) patients were
seen out of working hours (between 17.00 and 09.00), and 254 (42.3%) came during
working hours (9.00-17.00). Time of presentation to ER was not recorded for 18
patients. Two hundred and twenty two patients (35.7%) were self referred, 320 (51.9%)
were referred by general practitioners, and 77 (12.5%) were brought in by ambulance.
The source of referral was not recorded for one patient. The majority of the patients
were initially attended by junior doctors; 433 (71%) were seen by a SHO, 101 (16.6%)
by a registrar and 74 (12.1%) by a staff grade. A consultant and a senior registrar saw
one each (0.2%). This information was not available for 8 patients (Figure 8). 289
patients (46.8%) had received an antipyretic before being assessed by a physician and 91
(14.7%) had received an antibiotic for the presenting illness. The median temperature
recorded at the emergency room was 39.0°C, range 38.5°C- 40.5° C. Only 15 patients
(2.4%) had temperatures higher than 40.0° C, and there was no case of hyperpyrexia
(>41.0°C).
xi. 2. Hospital admission
399 patients (64.6%) were admitted to the hospital and 219 patients (35.4%)
were discharged from the emergency department. Sixty four (16.2%) of the admissions
were to the high dependency or intensive care units. The median duration of hospital
stay was 2 days, however, the majority of patients (44.9%) were admitted for only one
day (Figure 9). 22 (5.6%) patients were discharged on the same day. The total patient-
days spent in hospital over the one year period was 980. Almost all admitted patients
(98%) had at least one laboratory, or radiographic, test done, compared to 82.2% of
those who were discharged from the emergency department. The majority of admitted
patients (85.2%) were investigated by a blood culture, while this test was done on an
ambulatory basis in less than half (48.4%) of the patients. 113 (28.3%) of the admitted
patients were treated with parenteral (usually intravenous) antibiotics, while this mode
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of therapy was administered on an ambulatory basis on only two (0.9%) occasions. A
third (33.3%) of hospitalized patients did not receive any antibiotics, while the
remaining third (38.3%) were prescribed oral antibiotics.
Hospitalized patients were significantly younger than those who were discharged
from the emergency department: median age 17.1 and 24.7 months, respectively
(p=0.001). Equal proportions (64.3% vs 64.9%) of males and females were admitted
(p=0.892). Patients were equally likely to be admitted when they came during normal
working hours (66.5%) or out of hours (62.1%) (p=0.197). Patients were more likely to
be admitted when referred by their GP (74.7%) than when self-referred (44.1%), (LR
52.0, p=0.0001). Admitted patients had statistically, but not clinically, significant higher
temperatures than those who were discharged from the emergency room; median
temperature 39.1°C vs 39.0°C respectively, p=0.0001. Moreover, the presence of a high
fever (>40.0°C) did not influence the decision to admit, p=0.103. Admitted patients were
both subjectively and objectively more ill; they were more tachypnoeic (median
respiratory rate 40 vs 35), more tachycardic (median heart rate 160 vs 150), and scored
significantly higher (median score 7 vs 4) on the clinical assessment scale (p-values
>0.0001 for all parameters). Junior (SHO) doctors admitted similar proportions of
patients to middle grade doctors (registrars and staff-grades); 67.7% vs 59.3%, p=0.061
(X test with continuity correction).
xi. 3 Prevalence of serious bacterial infection
A total of 571 (92.4%) of febrile patients were investigated by one or more
laboratory or radiographic tests (Table 16). Virological tests were done in 142 (23%) of
the patients, 66 (46.5%) of these yielded a positive result (Table 17). 165 (26.7%)
patients had a serious bacterial infection. Table 18 shows the incidence of illnesses in the
study population. The incidence and types of serious bacterial infection are shown in
Figure 10 and table 21 and are detailed in the following sections. Some patients had
more than one illness classifiable as SBI therefore the cumulative proportions of SBI are
more than one.
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xi. 3. a. Bacteraemia
Of the 441 blood cultures taken, twelve (2.7%) grew pathogenic organisms
(Table 22). All cases of bacteraemia occurred in hospitalized patients. Seven (58.3%) of
the pathogenic isolates were streptococcus pneumoniae, two of these were identified as
serotype 23 & type 2, and the rest were not typified. A four month old baby had
pneumococcal meningitis and two older infants had uncomplicated pneumococcal
bacteraemia. In more than half (57%) of pneumococcal bateraemia the organism was not
detected at the time of discharge from the hospital. One had a potential source of fever
(otitis media) and two had specific viral infection (RSV+ve bronchiolitis and
chickenpox). The estimated attack rate of invasive pneumococcal disease was 28 per
100,000 for the under-five children in the population served by the Edinburgh Hospital
for Sick children. Two girls with E.coli septicaemia also had the same organism isolated
from urine. The patient with meningococcal septicaemia had classical clinical features of
this illness, purpuric rash, hypotension and thrombocytopenia. The patient with
streptococcus agalactae septicaemia did not have meningitis. The patient with blood
culture positive for staph, aureus was highly febrile and with peri-oral ulcers and
cervical adenopathy and was admitted as eczema herpeticum and received nine days of
parenteral antibiotic therapy in hospital. Twenty four (5.4%) of blood culture isolates
were of organisms considered contaminants in immuno-competent patients. There were
16 isolates of coagulase negative staphylococcus, two corynebacterium species, one
each of streptococcus mitis, strep, salvarius, and strep, sanguius. There were two more
isolates of unidentified streptococcus species.
xi. 3. b. Meningitis
Lumbar puncture and CSF examination and culture were done in 29 (4.7%)
patients. Three patients had meningitis; an incidence of 0.5%. The clinical details of
these patients are detailed in Tablel6. The five year old girl presented with clinical
features of meningitis with a purpuric rash and thrombocytopenia. Lumber puncture was
not done. The diagnosis was based on the clinical picture and she received 10 days of
hospital treatment.
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xi. 3. c. Urinary tract infection
Urine was collected from 343 (55.5%) of 618 patients fulfilling the age and
temperature criteria. Children who had urine obtained had higher median temperature
than those who did not have urine collected. This difference (39.1°C, vs 39.0°C) was
statistically (p=0.026), but not clinically, significant. They were more likely to be
admitted (p=0.0001), but did not look more ill, as judged by the median clinical score
(p=0.46) and the subjective assessment of the severity of illness (p=0.663). There was no
difference between those who did or did not have urine obtained for culture with regard
to, sex (p=0.267), median age (p=0.150), and the presence of a localizing sign
(p=0.234). Patients with a potential source of fever (otitis media, URTI, GE) were
equally likely to have urine obtained for culture as those who did not have an
identifiable cause of fever (p=0.249). A third of patients (13/42) with a specific viral
syndrome (bronchiolitis, croup, stomatitis, chickenpox), had urine obtained for culture.
It can therefore be concluded that the patients from whom urine was obtained are a
reasonably representative sample of the studied population of febrile children.
Girls and boys in different age categories (<12 months, 1-2 years >2 years) were
equally likely to be tested for UTI (Table 19). There were 39 positive urine culture
results. All were caused by E. coli. The majority of positive urine cultures (72%) were
associated with significant pyuria on microscopic examination. The vast majority
(82.1%) of patients with positive cultures were admitted to hospital. The majority
(74.3%) of these were treated with antibiotics before discharge, a third (34.5%) with
parenteral antibiotics. Follow up data were not available for those who were discharged
before culture results were available. Information about further isotopic confirmation of
pyelonephritis or urological anomaly was not sought.
The overall prevalence of urinary tract infection was 11.4% (95% CI, 8%-15%),
with higher rates in girls (18.1%) than in boys (5.5%). The highest prevalence (26.2%)
was in girls below one year of age (Table 19). UTI was equally common in patients with
or without a potential source of fever (13.6% vs 10.6%), p=0.426. Furthermore, patients
with specific viral syndromes (bronchiolitis, croup, stomatitis and chickenpox) were
equally likely to have UTI (7.7%) as those without a clinically identifiable viral illness
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(10.6%), p=0.741. Two infants (5.1%), 3.7 and 12.5 month old girls, were bacteraemic.
E. coli was grown from urine and blood of both patients. There was no significant
difference between patients with and those without UTI with regards to age,
temperature, and the degree of illness as judged by the clinical assessment score.
Conventional laboratory tests (WBC, ANC, CRP and ESR) were significantly higher in
patients with UTI, while there was no difference in cytokine levels between patients
with and without UTI, (Table 24).
xi. 3. d. Pneumonia
268 patients (43.4%) had a chest radiograph done. Boys and girls were equally
investigated by a chest radiograph, p=0.960. Patients who had chest radiography done
were younger, more febrile and more tachypnoeic. They also looked more ill, and were
more likely to be hospitalized. Patients were more likely to have CXR obtained when
they did not have a potential source of fever (Table 20). The vast majority (95%) of
patients with clinical signs suggestive of pneumonic consolidation had CXR obtained.
On the other hand, 40.3% of those who had CXR done did not have physical signs of
pneumonia. Clinical signs suggestive of pneumonic consolidation were; dullness to
percussion, crepitations, bronchial breathing and localized reduced air entry. Other
signs, such as aegophony and tactile fremitus, were not among the signs reported in the
case notes. Respiratory rate above the upper limit for age was considered a sign of
pneumonia. Wheezing was not considered indicative of pneumonia. Forty six (17.2%)
chest radiographs were reported normal, 113 (42.2%) had abnormalities other than
consolidation (infiltrates, peri-bronchial thickening, etc.) and 109 (40.7%) had
pneumonic consolidation. Thirty eight patients without physical signs of pneumonia had
radiographic evidence of pneumonia (focal consolidation). Only one of these tested
positive for RSV antigen. The proportion of patients with occult pneumonia was
therefore 14.2%>. Table 25 shows the characteristics of patients with radiography-
confirmed pneumonia. From the 268 patients who had a CXR done, 221 (82.5%)
underwent blood culturing. Of the 109 patients with pneumonia, 94 (86.2%) had blood
culture performed. Four of these blood cultures (4.3%) grew pathogenic organisms (2
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streptococcus pneumoniae and one each of N. meningiditis and E. coli). The majority
(78%) of the patients with pneumonia were hospitalized. Of all the patients, 35.8% were
treated with intravenous antibiotics, 56% with oral antibiotics, and nine patients (8.2%)
did not receive any antibiotics.
xi. 3. e. Bacterial enteritis
86 (13.9%) patients had stools taken for culture. Eleven (12.8%) yielded a
positive test. Seven patients tested positive for CI. difficile, two of these occurred in
association with other SBI (meningitis and pneumonia). The latter two infections
occurred during the winter months (November - January). The five others occurred in
spring (March and April) and were not related to other infections. There were two
infections with Campylobacter jejnei and one each of Salmonella group D and Shigella
sonnei.
XI. 3. f. Soft tissue infection
There were two cases of clinically diagnosed soft tissue infection usually
considered bacterial in origin; one with periorbital cellulitis, the other with cellulitis
complicating chickenpox. Blood cultures from both patients were negative. There were
no cases of septic arthritis or osteomyelitis.
XI. 4. Non-SBI
Patients who did not have microbiologic or radiographic evidence of any of the
above infections were considered to have non-serious bacterial illness. The 453 (73.3%)
such patients were a heterogeneous group, which included illnesses that were
microbiologically defined, such as respiratory syncytial virus positive bronchiolitis, and
rotavirus positive gastroenteritis. Others were defined by specific clinical presentation,
such as varicella and herpes simplex stomatitis, while the diagnosis in the majority was
based on clinical features and the failure to demonstrate a specific, viral or bacterial,
pathogen. The latter group included otitis media, tonsillitis (with or without a positive
throat swab culture), viral upper respiratory tract infection and non-specific viral illness.
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The clinical diagnosis of otitis media was made without any indication of the
causative organism because tympanocentesis was not in routine use. 52 (8.4%) patients
were discharged with a diagnosis of otitis media, 22 of these had been hospitalised. Six
patients discharged with a diagnosis of otitis media were reclassified as SBI according to
investigation results, probably not available at the time of discharge. Two had
pneumonic consolidation, two with UTI, and one with both pneumonia and UTI. The
sixth patient, an 11 month old boy, had Streptococcus pneumoniae grown from blood
culture. 222 (36%) of the patients had throat swabs taken for cultures. Seventeen of
these cultures (7.7%) were positive for group A (3 haemolytic streptococcus. 54 (8.8%)
of these patients were discharged with a diagnosis of tonsillitis. Although potentially
serious, these infections were not included in the SBI group, in-keeping with the
conventional definition of this type of infection. 138 (22.4%) were discharged with
upper respiratory tract infection, bronchiolitis, or lower respiratory tract and chest
infection as the diagnosis. 64 (10.4%) patients had nonspecific viral illness, with no
clinically identifiable focus of infection. 18 (2.9%) patients had a specific clinically
identifiable viral infection such as herpetic stomatitis, chickenpox or croup. A
miscellaneous group of diagnoses comprised 26 (4.2%) patients. These included
diseases such as allergy, arthralgia, Kawasaki disease, mesenteric adenitis and peticheal
rash. 58 patients (9.4%) were discharged with a diagnosis of fever of unidentified origin.
17 patients (2.8%) were discharged without a diagnosis. 96 patients (15.5%) had a
febrile convulsion during the course of their presenting illness. 19 (19.8%) of these had a
SBI distributed as follows; 10 UTI, 7 pneumonia, and one bacterial gastroenteritis. A
further 14.8 month old boy had pneumococcal bacteraemia and was discharged as febrile
convulsion due to viral illness.
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Table 14: Number of patients admitted with an infectious illness requiring hospital treatment*
Treatment Number of patients treated Percent (%)5
Intravenous fluids 102 16.1
Oxygen 98 15
Suctioning 61 9.6
Naso-gastric tube feeding 42 6.6
Intravenous antibiotics 102 16.1
Any of the above 276 43.5
None of the above 359 56.5
*: Data from the nine week pilot study
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Figure 8: a) source of referral and, b) grades of physicians first attending the patients at the
emergency department.
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number of hospital days
Figure 9: Length of hospital stay for hospitalized patients.
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Table 16: Investigations for infectious illness performed on the study population
Test Number (%)
Chest radiograph 268 (43.4)
Blood culture 441 (71.4)
Urine analysis/culture 343 (55.5)
Cerebrospinal fluid analysis/culture 29 (4.7%)
Stool analysis/culture 86(13.9)
Throat swab culture 224 (36.2)
Viral titre/culture/antigen test 142 (23%)





Table 17: Sources of positive virological tests
Source Number (%) positive
Nasopharyngeal aspirate 41 (62.1)
Mouth swab 1 (1.5)
Skin lesion 2(3)
Stools 13 (19.8)
Stools & CSF 1 (1.5)
Stools & throat 5 (7.6)
Urine 1 (1-5)
Serological titre 2(3)
Table 18: Types of infectious illnesses in the study population
Illness Number (%)
Bacteraemia 12 (1.9)
Bacterial meningitis 3 (0.5%)
Pneumonia 109 (17.6)
Urinary tract infection 39 (6.3)
Bacterial gastroenteritis 11 (1.8)
Bacterial soft tissue infection 2 (0.3)
Non-serious bacterial infection 453 (73.3)
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Table 19: Incidence of UTI by age and sex
Age (years) <1 1-2 >2
Gender Male Female Male Female Male Female
Number of patients 96 70 108 88 138 118
Tested for UTI (%) 56.3 60 55.6 63.6 50 52.5























Figure 10: Proportions of patients with a) SBI and, b) non-SBI.
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Table 20: Clinical characteristics influencing the ordering of a chest radiograph
CXR obtained CXR not
obtained
p-value
% male 55.2 55.4 0.960
Admission to hospital 77.2 % 54.5 % 0.0001
Presence of potential source of fever 30.2 % 43.1 % 0.001
Presence of signs of pneumonic
consolidation §
35.8 % 1.4% 0.0001
Presence of signs of pneumonia* 59.7 30 0.0001
Looking ill 84.2 % 52.9 % 0.0001
SBI likely 78.4 % 40.8 % 0.0001
Median age (mo) 17.4 20.7 0.008
Median clinical score 7 5 0.0001
Median temperature (°C) 39.1 39.0 0.009





Table 21: Incidence of infectious illness across the age groups
Number (%) of patients in each age group
0-1 mo 1-3 months 3-36 months >36 months
Total number of patients 3 9 466 140
SBI 0 3(33) 128 (27.5) 34 (24.3)
Meningitis 0 0 2 (0.4) 1 (0.7)
Bacteraemia 0 1(11.1) 11(2.4) 0
Pneumonia 0 2 (22.2) 84(18) 23 (16.4)
Urinary tract infection 0 1(11.1) 30 (6.4) 8 (5.7)
Bacterial enteritis 0 0 11(2.4) 0





Predictors of Serious Bacterial Infection
xii. l. Clinical and conventional laboratory tests
There was no age or sex difference in the incidence of SBI. Patients referred by
their general practitioners were more likely to have a SBI than those who were self-
referred. Temperature, respiratory rate and heart rate and the clinical score were all
significantly higher in patients with SBI (Table 27).The incidence of SBI steadily rose
with the rise in temperature {Figure 14). 501(81.1%) of the patients were evaluated by a
white blood cell count; and 151 of these had SBI. The total WBC was significantly
higher in the patients with SBI (p=0.0001). Absolute neutrophil counts were
significantly higher in patients with SBI compared to those with non-SBI (p=0.0001)
{Figure 15). One hundred patients (16.2%) had ESR measured on presentation to the
emergency room, and 20 of these patients had SBI. ESR was significantly higher in
patients with SBI. CRP was done in 234 (38%) of the patients, and was significantly
higher in those with SBI {Table 32). The performance of the conventional tests in
predicting SBI are compared in Table 29.
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xii. 2. Cytokines
xii. 2. a. Cytokines in febrile patients and afebrile controls
Eighty-nine patients were recruited as the control group. These were children
who attended outpatient clinics during the study year. They were afebrile and did not
have an acute illness at the time of blood collection (see exclusion criteria above). 50
(56.2%) were males and 39 (43.8%) were females. The median age was 23.7 months,
range 0.1-57.9 months. From the 618 subjects, 342 (55.3%) were males, and their
median age (range) was 19.3 (0.3-71.8) months. There was no significant difference in
median age (p=0.247) or gender representation (p=0.882) between the controls and the
subjects.
Serum IL-6 was measured in 60 (67.4%) of the controls and was detectable in
four patients. IL-8 assay was done in 48 (54%) of the controls and was detectable in only
one patient; an infant who had cerebral palsy resulting from group B, (3-haemolytic
streptococcal meningitis and was having increasing seizure frequency, but was clinically
well at the time of blood collection (Table 26). Soluble ICAM-1 was detectable in the
sera of all the 67 (75%) controls from whom enough serum was available to measure
this cytokine. The cytokine was normally distributed (p=0.200, Kologrov-Smirnov test)
with a mean (SD) serum value of 895.68 (304.52) ng/ml (.Figure 11). The minimum and
maximum values were 108.00 ng/ml and 1600.00 ng/ml, respectively.
The 618 febrile patients who fulfilled the study criteria of age and temperature
are hereby referred to as subjects. 312 (50.5%) of these patients had serum IL-6
measured. Interleukin-6 was detectable in the majority (95.2%) of febrile patients. The
median serum IL-6 in these patients was 33.50 pg/1, range 00.00-5867.00 pg/ml, and
interquartile range 15.00-76.37 pg/ml. Serum IL-6 was not detectable in 15 (4.8%) of the
febrile patients. There was a significant difference in serum IL-6 between the afebrile
controls and the highly febrile patients, mean ranks 40.92 and 214.50, respectively
(p=0.0001). Serum IL-8 was measured in 264 (43.0%) febrile patients and was
detectable in 71 (26.7%). The median value in the study group was below detectable
level, with interquartile range 0.00-2.70 pg/1. The difference in serum levels between the
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febrile patients and the afebrile controls was significant (p= 0.0001). Serum sICAM-1
was detected in all of the 295 febrile patients tested (48% of all the patients). The
median value was 993.90 ng/ml, the minimum and maximum values, respectively, were
172.40 & 3949.90 ng/ml, with interquartile range 767.50 - 1232.80 ng/ml. Serum
ICAM-1 in febrile patients had a normal distribution, with a few outliers (Figure 12).
The difference in the serum sICAM-1 levels between controls and subjects was
significantly different, mean ranks 148.22 vs 189.06, respectively, p=0.004 (Figure 13).
xii. 2. b. SBI vs non-SBI
Serum IL-6 was measured in 312 patients and of these 115 had serious bacterial
infection. There was no significant difference in serum IL-6 between patients with and
without SBI, p=0.362. Serum from 264 patients was assayable for IL-8; eighty-six
patients had SBI. There was no significant difference in serum IL-8 between the two
groups (p=0.884). Of 295 patients whose serum sICAM-1 was measured, 95 had SBI.
Serum sICAM-1 was significantly higher in patients with SBI; p=0.005 (Table 30).
Standing alone, none of the three cytokines was useful in discriminating SBI from non-
SBI in a febrile child (Table 31).
Considering the twelve patients with a positive blood culture, there was no
significant difference in serum IL-6 between bacteraemic and non-bacteraemic patients;
median serum IL-6 (range) was 44.54 (0.00-5867.00 pg/ml) and 33.77 (0.00-1305.09
pg/ml) respectively, p=0.258. This was due to the wide overlap in the cytokine levels
between the two groups. Nevertheless, IL-6 was detected in all bacteraemic patients who
were tested for the cytokine, except the 19 months boy with meningococcal septicaemia
who had extremely elevated serum IL-8 and sICAM-1 levels (Table 22). IL-6 was also
highly elevated in all tested patients meningitis (Table 23). There was also no difference
in serum sICAM-1 between bacteraemic and non-bacteraemic patients; median levels
(range) being 1170.00 (662.20-3949.90 ng/ml) and 986.50 (189.40-3447.20 ng/ml)
respectively (p=0.150). However, bacteraemic patients had significantly higher serum
IL-8 values than non-bacteraemic patients; median (range) levels 101.70 (0.00-1652.00
pg/ml) vs. 0.00 (0.00-526.00 pg/ml) (p=0.0001). All the seven patients with either
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bacteraemia or meningitis, who had IL-8 measured, had detectable serum IL-8. A serum
IL-8 value of 20 pg/ml was 85.7% sensitive and 91.1% specific in detecting either
meningitis or bacteraemia, with a negative predictive value of 99.6%. Six of the seven
patients with either bacteraemia or meningitis who were tested for serum IL-8, had
levels above 20 pg/1, while only one of the 235 patients who did not have either of these
conditions had a serum level above this value.
xii. 3. Predictive model for serious bacterial infections among febrile young
children
Variables significantly associated with SBI in univariate analysis (Tables 32&33)
were sequentially entered in a logistic regression analysis to construct a model predictive
of serious bacterial infection. Respiratory rate, serum CRP and serum sICAM-1 were
identified as independent predictors of SBI. Hosmer-Lemeshow goodness-of-fit test
results were not significant (x2, 3.53, p=0.897), which statistically supports the
robustness of this prediction model;
{L = (log (p/l-p*) = {(0.04xRR) + (0.08XCRP) + (0.001 xsICAM)-4.0}.
P*: Probability of SBI.
The model was derived from 122 patients from whom all test parameters were
available. Thirty seven (30%) of these had SBI, and 26 (71%) were correctly identified
by the model. The model was 52% sensitive and 84.7% specific for SBI. The respective
positive and negative predictive values were 70.3% and 71.8%.
xii. 4. Correlations between infection parameters
Non-parametric (p) correlations between the infection markers are shown in
table 29. There was little or no correlation between the three cytokines (Table 34).
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4.1 M 16.8 12.8 14.6 5867.00 - -
Pneumococcal
meningitis
S. Pneumoniae 17.1 M 26.3 15.5 1.5 36.55 38.79 872.55
PUO, shivering
S. Pneumoniae 11.3 M 20.9 15.9 1.5 3005.40 102.22 2611.80 Otitis media
S. Pneumoniae
(type 2)




S. Pneumoniae 16.4 F 27.1 16.8 2.6 - - -
Pneumococcal
bacteraemia
S. Pneumoniae 24.5 M 38.2 32.1 18.0 - - -
Pneumococcal
septicaemia




19.3 M 21.8 16.4 1.5 0.00 1652.10 3949.90
Meningococcal
septicaemia
E. coli 3.7 F 56.3 50.7 - 50.14 4.18 1801.40
Pneumonia,
coliform sepsis
E. coli 12.5 F 41.4 37.4 14.5 - - -
UTI
Gr. B PHS 1.7 M 12.6 10.6 1.5 896.40 829.52 662.20
Gr. B pHS.
septicaemia











Source Blood & CSF Throat swab
Clinical meningococcal
meningitis
Age (mo) 4-1 17 66.5
Sex M F F
CSF cells (/pi) 6720 1500 -
WBC (/mm3) 16.8 12.6 26.8
ANC (/mm3) 12.9 9.2 25.2
CRP (mg/dl) 14.6 - -
IL-6 (pg/ml) 5867.00 737.99 1305.90
IL-8 (pg/ml) - 84.52 -
sICAM-1 (ng/ml) - 1227.10 3164.00
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Table 24: Clinical and laboratory characteristics of patients with UTI
Parameter (median) UTI No UTI p-value
Age (mo) 14.8 17.4 0.106
Temperature (°C) 39.0 39.1 0.333
Clinical score 5 6 0.406
WBC (xl03/l) 18.7 12.6 0.0001
ANC (xl03/l) 12.5 8.6 0.0001
ESR (mm/h) 52.5 23 0.041
CRP (mg/dl) 11.9 1.5 0.001
IL-6 (pg/ml) 27.87 34.84 0.840
IL-8 (pg/ml) 0.00 0.00 0.092
sICAM-1 (ng/ml) 1130.85 980.4 .071
 







Median age (m) 20.3 19.1 0.658
Temperature (°C) 39.1 39.0 0.129
Clinical score
7 5 0.0001
Respiratory rate (bpm) 46 36 0.0001
WBC (10J/mmJ) 14.7 13.2 0.112
ANC (107mmJ) 8.9 8.7 0.423
ESR (mm/h) 50 23 0.008
CRP (mg/dl) 3.4 1.5 0.032
IL-6 (pg/ml) 36.17 32.8 0.963
IL-8 (pglm/1) 0.00 0.00 0.925




Table 26: Cytokine levels in controls
Sex Age (months) IL-6 (pg/ml) IL-8 (pg/ml) Clinical details
Male 0.1 0.42 - Sibling of galactosaemia
Female 53.4 4.49 -
Listless, duplex kidneys, no
UTI
Female 14.1 5.89 - Galactosaemia
Female 22.9 25.41 -
Diarrhoea, milk fat
intolerance
Female 18.5 - 215.72
Increasing seizure





Figure 11: Distribution of serum slCAM-1 in controls
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Figure 13: Mean (95% CI) serum cytokines in febrile subjects and afebrile controls.
 















SBI 165 18.3 51.5 75.2 39.1 43 165 7
Non-SBI 453 19.6 56.5 60.2 39.0 36 156 5
p-value - 0.395 0.248 0.001 0.017 0.0001 0.034 0.0001
*Median values for continuous variables.
Table 28: Performance of selected range of clinical score in predicting SBI
Score Sensitivity Specificity PPV NPV LR (95% CI)
Post-test probability
of SBI
>4 85 30 33 83 1.2 (0.4-3.1) 33
>7 55 65 39 78 1.6 (0.8-1.9) 40
>10 17 92 40 73 2.1 (0.6-3.5) 46
>13 7 96 40 72 1.6 (0.6-2.3) 40























Total white cell count
Figure 15: Mean (95%CI) WBC and ANC in patients with and without serious bacterial infection.
 
Table 29: Performance of selected ranges of values of conventional tests in predicting
SBI.
























































































Table 30: Median (range) serum cytokine levels in patients with and without SBI
IL-6 (pg/ml) IL-8 (pg/ml) SICAM-1 (ng/ml)
SBI Non-SBI SBI Non-SBI SBI Non-SBI
Number 115 197 86 178 95 200
Median 36.52 31.62 0.00 0.00 1056.60 952.65
Range 0 -5867 0-671.64 0-1652 0 -526 323.90-3949.90 172.40-3062.80
p-value 0.362 0.884 0.005
Table 31: Performance of selected cut-off values of the cytokines in predicting SBI
Tpet Sensitivity Specificity PPV NPV LR+ Post-testJL CM
% % % % (95%CI) probability %
IL-6
(pg/ml)
>5 91 10 37 66 1.0(0.5-2.1) 33
>15 75 25 37 63 0.9(0.6-1.8) 31
>35 53 55 41 67 1.2 (0.3-3.8) 35
>75 30 76 42 65 1.2 (.4-3.4) 35
>200 13 90 44 64 1.3 (0.5-2.6) 49
IL-8
(pg/ml)
>5 22 79 34 68 1.0 (0.4-2.7) 27
>10 16 83 32 67 1.0(0.4-2.5) 27
>20 12 89 34 68 1.1 (0.5-2.2) 29
>40 10 91 36 68 1.1 (0.5-2.1) 29
>100 6 97 50 68 2.0(1.0-2.0) 44
sICAM-1
(ng/ml)
>600 97 13 35 90 1.1 (0.7-1.6) 34
>750 83 24 34 75 1.1 (0.4-2.7) 34
>1000 59 58 40 75 1.4 (0.3-3.7) 40
>1200 36 74 39 71 1.4 (0.4-3.7) 40
>1600 13 91 40 62 1.4 (0.8-1.7) 40
Pre-test probability = 27%
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Table 32: Clinical features and laboratory results of patients with and without SBI
Characteristic SBI Non-SBI p-value
n* n*
Median age (mo) 165 18.3 453 19.6 0.395
Sex (%male) 165 51.5 453 56.1 0.248
Referral (%GP-referred) 165 75.2 452 60.2 0.001
Temperature (%>39°C) 165 54.5 453 45.3 0.041
Median respiratory rate (bpm) 150 43 391 36 0.0001
Median heart rate (bpm) 160 165 427 156 0.011
Median clinical score 113 7 276 5 0.0001
Median total WBC (10lu /dl) 151 16.1 350 12.5 0.0001
Median absolute neutrophil count (1010 /dl) 151 10.6 350 7.9 0.0001
Median ESR (mm/hr) 20 47 80 22.5 0.007
Median CRP (mg/dl) 76 3.7 158 1.5 0.001
Median serum IL-6 (pg/ml) 115 36.52 197 31.62 0.362
Median serum IL-8 (pg/ml) 86 0.00 178 0.00 0.884
Median serum sICAM-1 (ng/ml) 95 1056.60 200 952.65 0.005
: number of patients for whom the test parameter was avai able.
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*: Pre-test probability = 27%




Table 34: Correlation matrix (p-value) between tested parameters of infection



































































xm. 1 Prevalence of SBI
As there is no standard case definition of serious bacterial infection, a definition
in common use was chosen as the primary outcome of the study. Most studies have
considered bacteraemia, meningitis, urinary tract infection, pneumonia, bacterial
gastroenteritis and osteomyelitis and soft tissue infection as SBI (see 1.2 chapter 1;
definition of SBI). However, the inclusion of illnesses with variable potential
aetiologies, such as pneumonia, could have affected the performance characteristics of
markers of bacterial infection. In studies such as this, classification bias is almost
inevitable because even in the face of positive culture results there is not enough
evidence to discriminate infection from colonization. Nevertheless, as a main objective
of the study was to find means of reducing uncertainty in evaluating a febrile child, and
where in real life scenarios a febrile young child with radiographic pneumonia would be
assumed to have a bacterial infection and treated as such, it was reasonable to include
pneumonia in the definition of SBI. Furthermore, the use of a-priori-defined protocol for
SBI diagnosis in a prospective study should have reduced the inherent ascertainment
bias that rises from varying definitions of illness. Based on these considerations, patients
with bacteraemia, bacterial meningitis, urinary tract infection, bacterial gastro-enteritis,
and pneumonia and soft tissue infection (regardless of the bacteriologic proof of the later
two groups of infections) were included in the SBI group.
Although mortality from infection has now substantially declined, infectious
illnesses consume a major proportion of resources allocated for health care, both in
hospital and primary care. Infection is the third commonest cause ofmortality
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considering all age groups and ranks tenth as a cause for hospitalization (Wilson D &
Bhopal R. 1998). In general practice, infectious diseases account for 40% of new illness
episodes, with the highest rates occurring in young children (Fleming et al, 2002).
Following the introduction of Hib vaccine, streptococcus pneumoniae emerged as the
commonest cause of SB1 in children, although occasional cases of invasive Hib infection
still occur due to failed or incomplete vaccination. The recently introduced heptavalent
pneumococcal vaccine is expected to further reduce SBI in young children. However, a
recent study in Scotland has shown that invasive pneumococcal disease is caused by 33
different serotypes, and only 48.4% of the isolates were serotypes included in the
currently licensed PCV-7 vaccine, which is expected to provide protection in 71.8% of
children below 5 years against serotypes in the vaccine (McChlery S, et al. 2005).
Furthermore, non-vaccine serogroups are recovered more frequently from children with
meningitis than those with other invasive pneumococcal disease (Ispahani P, et al.
2004). The quest for more protective measures and more accurate diagnostic and
surveillance methods therefore continues.
This study shows that a significant proportion of the young childhood population
is first seen at or referred to the only paediatric hospital in the region with a febrile
illness. Over 6% of non-trauma patients seen in the emergency department were febrile
young children. These patients accounted for two percent of the total 5-year-child-
population residing in the Lothian region served by the hospital. Lee and Harper
estimate that 8% of total paediatric emergency department visits are for young children
(< 36 months) with high (>39.0°C) temperatures {Lee & Harper. 1998). More than three
quarters (77.3%) of the current study patients were aged < 36 months. Half of the febrile
patients were between 12 and 36 months old, reflecting the higher incidence of acute
respiratory infections in this age group. This is partly due to the waning of maternally
acquired immunity and the increasing exposure of these children when they depart from
their protective homes to attend day care centres and nurseries. This was further
supported by the seasonal distribution of infectious illnesses whereby the great majority
of cases were seen during the cold months of the year. Half the patients were seen
between December and February, while less than 5% of the patients were seen in the
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summer months. The study spanned a complete calendar year to allow for the expected
seasonal variation in the incidence of different infectious illnesses. Neonates were
usually followed up and admitted to the regional neonatal unit situated not far from the
children's hospital. There was no SBI in the few neonates seen at the emergency
department. The prevalence of febrile illness in the studied population was
underestimated because historic fever (high temperature recorded at home) was not
taken into account. Extremes of fever (>40C) were rare, as has been observed in earlier
studies (McCarthy et al. 1976, McCarthy et al. 1977).
During the period of study, the majority (65%) of febrile patients were
hospitalised. Although a large proportion of the patients were admitted for only one day,
these patients collectively consumed a significant proportion of hospital days. Moreover,
patients hospitalized for acute illness were more likely to have more detailed
investigations. Almost all hospitalized patients were investigated for an infectious cause
or a marker of infection, while only a third of admitted children had parenteral
antibiotics. The findings from the pilot study agree with other studies which suggest that
a substantial proportion of child hospitalization may be unnecessary (Kemper et al.l988,
Perrin et al.l989, Gloor et al. 1993, McConnochie et al. 1997). This over-admission is
due to the uncertainty surrounding undifferentiated illness in children compounded by
the lack of consistency in the evaluative process of febrile children. Therefore, the
decision to admit may be made before a choice to treat or observe is made. Management
guidelines based on objective criteria and known priori probability of serious illness in
febrile children might alleviate this uncertainty and help implement a more rational and
cost-effective way of dealing with this problem. An encouraging sign, nonetheless, was
that nearly half of the patients who were discharged from the emergency room were
investigated with blood culture. Discharging patients in the face of suspected
bacteraemic illness demonstrates the growing awareness and utilization of the
ambulatory service, which has recently been established within the premises of the
emergency department. About half of the patients had already been seen by their GPs,
and these patients were more likely to be admitted and had a higher incidence of serious
bacterial infection. This is in-keeping with the findings of Duffy et al who studied
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hospitalization of adult patients in the same region (Duffy et al. 1998). These findings
further support the role of community-based management of young children considered
to be at low risk of SBI. This can be further facilitated by the knowledge of the
prevalence of infectious illnesses and the likelihood of serious bacterial infection in
young patients presenting with a high fever.
The incidence of serious bacterial infection in the studied population (27.6%)
was within the range of prevalence figures quoted by other authors. Nademi et al found
one out of three children referred with fever to have a SBI, with 42% of
microbiologically proven meningitis and/or sepsis caused by meningococci (Nademi Z,
et al, 2001). Using a definition of SBI similar to that used in our study, Bleeker et al
reported a 25% incidence in a group of 1-36 month old children (Bleeker et al, 2001).
Pulliam et al found 18% of their patients (1-36 months old) had a serious bacterial
infection. Bacterial gastroenteritis was not counted as a SBI and only patients without
clinically detectable infections were studied, accounting for the lower incidence
{Pulliam et al. 2001). Galetto-Lacour et al reported a 23% incidence of SBI in children
aged 7 days to 36 months. The commonest (68%) was UTI {Galetto-Lacour et al. 2001).
In a more recent study, the same authors studied children 7 days to 36 months old who
did not have a localising cause for their fever. Twenty-nine (29.3%) of 99 patients were
diagnosed with SBI {Galetto-Lacour et al. 2003). Gendrel et al studied 1500 children
aged 1 month to 15 years of age who were admitted with a fever >38.5°C. The
responsible infectious agent was identified in 360 patients, and 114 (31.7%) of these had
a serious bacterial infection. There were 5 cases of meningitis caused by H. influenzae
type b, in a population supposedly covered by the Hib vaccine. Among the other
bacterial infections were septicaemia caused by gram-negative organisms, such as E.
coli and Salmonella species {Gendrel et al. 1999). Lopez and colleagues identified 150
patients with invasive bacterial disease from a total of 445 (33.7%) febrile young
children {Lopez et al. 2003). Invasive bacterial illnesses included septicaemic enteritis,
acute pyelonephritis, sepsis and meningitis, arthritis and soft tissue infection, and
osteomyelitis. These children had higher probability of SBI as they were all hospitalized
and all underwent blood analysis to rule out the possibility of bacterial infection. Similar
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to our findings, they identified a heterogeneous group of organisms causing infections,
such as E. coli septicaemia, salmonella enteritis, meningococcal meningitis, and
staphylococcal arthritis, among others. These differences in the reported incidences of
bacterial illness are explained by differences in the study populations, physician's
criteria (temperature and age) for ordering cultures and other tests in febrile children,
interpretation of radiographic and laboratory test results and the coverage rates of Hib
and pneumococcal vaccines.
The majority (80%) of SBI in the current study occurred in children <36 months
of age, the group of patients most widely studied. All cases of bacteraemic illness and
bacterial gastroenteritis, and two of the three cases of meningitis, were in these younger
patients. The three febrile neonates (<1 months) did not have a SBI, but the only child in
the 1-2 months range had a bacteraemic SBI. This underscores the importance of careful
assessment and extensive evaluation of these young infants. Beyond this age the
incidence of SBI was similar across all age groups. An age related variation, albeit
differently, in the incidence of SBI was also noted by other workers. In the study by
Galetto-Lacour et al, infants <3 months had a 26% incidence compared to 20% in those
3-12 months old and 23% in 12-36 months old (Galetteo-Lacour et a. 2001). Bonsu and
Harper retrospectively studied consecutive febrile young infants (0-89 days old) and
reported a 1% rate of bacteraemia (Bonsu & Harper, 2004). Baker and Bell found that
the incidence (12.6%) and spectrum of causative organisms of SBI in febrile neonates
was similar to that observed in febrile infants 29 to 60 days old. However, the authors
demonstrated that infants younger than one month were different in that SBI was
unpredictable and concluded that protocols based on risk criteria are not applicable to
these young patients (Baker et al. 1999). In a commentary, De Angelis noted that febrile
infants younger than one month were different and suggested no changes should be
made to the current practice of extensive evaluation under broad spectrum antibiotic
cover {Baker et al. 1999).
xiii. i a. Bacteraemia
In the studied population, all positive blood cultures were in children younger
than three years of age. The incidence of bacteraemia appeared to be constant across the
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two year period (1998 and 1999) represented by the pilot study (2.5%) and definitive
study (2.7%), respectively. The prevalence of bacteraemia and the types of causative
organisms were comparable to that reported in other studies of febrile children.
Isaacman et al retrospectively studied young children (3-36 months) seen in a paediatric
emergency unit who had blood culture obtained for evaluation of fever. Two percent of
the cultures grew a pathogenic organism (.Isaacman et al. 2000). In a post-Hib vaccine
study, Lee and Harper reported a 1.6% incidence of bacteraemia in unselected 3-36
months old children with a high (>39.0°C) fever. The risk of bacteraemia was
significantly lower in the 3-6 months age group than in older age groups. Beyond six
months, there was no significant difference in the odds of bacteraemia between various
age categories {Lee and Harper, 1998). Our findings are different in that patients
younger than 6 months had a higher incidence of bacteraemia (7.1%) than older patients
(1.1%). There were more cases of gram negative bacteraemia, which tend to affect
younger age groups, in our patients. We witnessed no bacteraemic illness beyond 36
months of age.
Similar to most studies from Western countries, the absence of Haemophilus
influenzae type b was evident in our study. In the study by Lee and Harper ninety-two
percent of the isolates were pneumococci, and the others were Salmonella (5%), N
meningiditis (1%), and group A streptococcus (1%). Haemophilus influenzae type b was
not isolated from any of the children (Lee and Harper, 1998). Bandyopadhyay et al
found 37 (3%) of 1202 young children (2-36 months) with fever without source to have
a positive blood culture. Streptococcus pneumoniae was the most prevalent (84%)
organism, and only two patients (0.08%) developed serious bacterial infection
(.Bandyopadhyay et al. 2002).
In our population, the rate of positive culture in patients with no focus of
infection (occult bacteraemia) was 1.4%. The majority (71.4%) of isolated organisms
were streptococcus pneumoniae. The prevalence of occult bacteraemia has been further
reduced in populations covered with the conjugate pneumococcal vaccine (PCV7). Stoll
and Rubin studied young children (2-36 months) who had blood culture taken for
evaluation of fever and who were discharged from the emergency room. Three (0.91%)
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out of 329 cultures were positive, all streptococcus pneumoniae. The studied population
had received the heptavalent pneumococcal vaccine (PCV-7), so the authors suggested
that routine practice of obtaining blood cultures may no longer be indicated in
previously healthy, well-appearing, highly febrile young children who have received at
least 1 dose of PCV7 (Stoll et al. 2004, Rubin et al. 2004). Although in the majority of
children occult pneumococcal bacteraemia resolves without therapy (.Baraff, 2000),
untreated pneumococcal bacteraemia can result in complications, including persistent
bacteraemia and fever, pneumonia, cellulitis and meningitis (Jaffe et al. 1987). There is
an estimated 2.7% risk of meningitis from untreated pneumoccal bacteraemia (Rothrock
et al. 1997). Non-vaccine serotypes of streptococcus pneumoniae have been isolated
with increasing frequency in the years following the introduction of the heptavalent
vaccine. Furthermore, antibiotic resistance of these serotypes has increased (Farrell DJ,
2007). Other workers have reported a decrease in the carriage rate of penicillin resistant
pneumococci after the introduction of the 7-valent vaccine (Cohen R, 2006).
In our study population, the causative organisms of bacteraemic illness were
more heterogeneous. E. coli was isolated in two infants, both with concurrent urinary
tract infection. The baby with group B streptococcal septicaemia was less than two
months, an age that was not commonly included in other studies. A highly febrile infant
with infected eczema had Staph, aureus isolated from both skin swab and blood culture.
These organisms usually cause specific focal infections, and cause a more severe illness
when they invade the blood stream. They were therefore expected to be detected more
frequently in our study population, which included hospitalized children. In a population
of febrile infants (<1 year) at an African teaching hospital, Ayoola et al reported a 38.2%
incidence of bacteraemia, with E. coli and S. aureus each accounting for over a third of
cases {Ayoola et al. 2002). Meningococcal infections were particularly difficult to
ascertain. This organism was not recovered from the blood in patients with clinically
diagnosed meningococcaemia, and from those with clinical meningitis who had CSF
pleocytosis and meningococci isolated from throat swabs. This could be due to the
administration of antibiotics before referral, as is usually the practice upon clinical
suspicion of meningococcaemia. Many patients treated for meningococcaemia do not
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have this infection (Jaskiewicz et al. 1994), while it can pass undetected, clinically, in a
significant proportion of patients (.Dashefsky et al. 1983, Kuppermann et al. 1999).
Although occult meningococcal bacteraemia is rare, observed in only 0.06% of children
with fever without source in two multicentre studies (Jaffe et al. 1987, Bass et al. 1993),
the risk of serious sequelae is greater and includes purpura fulminans and meningitis.
Meningitis is said to occur in half of the patients with meningococcal bacteraemia who
are not treated with antibiotics (Kuppermann et al. 1999, Barraf. 2000). It is evident,
therefore, that the need for obtaining blood culture and rigorous evaluation of febrile
young children will continue regardless of the immunization status of the patient or
vaccination coverage in the population.
We have demonstrated that a significant proportion of serious bacterial infection,
including UTI and bacteraemia, occurred in children discharged with apparently less
serious diagnoses, such as otitis media or URTI. These patients were at risk of having
their underlying disease (UTI) going unchecked or developing more serious illness, such
as meningitis, from undetected bavteraemia. Other workers also have emphasised the
frequent occurrence of SBI in febrile children with seemingly benign illness. Isaacman
et al found that the proportion of patients with bacteraemia with a focal bacterial
infection was not dissimilar to that in patients without a focal bacterial infection
(.Isaacman et al. 2000). Schutzman et al noted a 3% incidence of bacteraemia in children
with otitis media, similar to those seen in children with no source of infection
(jSchutzman et al. 1991). In the study by Lee and Harper, 31% and 12.8% of positive
blood culture occurred, respectively, in patients discharged with a diagnosis of otitis
media and viral illness. The incidence of occult bacteraemia was the same in patients
with and without otitis media {Lee & Harper, 1998). Levine et al have shown that the
risk of SBI, particularly that of UTI, is appreciable in infants with RSV positive
bronchiolitis. Seven percent of RSV +ve patients, compared to 12.5% of RSV-ve
patients, had a SBI {Levine et al. 2004). There was a 1.1% rate of positive blood culture
in RSV+ve patients, compared to a 2.3% rate of bacteraemia in RSV-ve patients. The
occurrence of SBI was 10.1% in RSV+ve children <28 days and 5.5% (all UTI) in
children >28 days. The authors stated that a septic workup in infants <28 days is
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indicated even if an RSV infection is documented and that the presence of RSV does not
obviate the need for urine culture in infants >28 days (Levine et al. 2004). Titus and
Wright retrospectively analysed RSV+ve febrile infants and compared them with
matched infants who tested negative for RSV. Only 2 (1.2%) of the 174 RSV+ve
patients had SBI (both UTI), compared to 22 (12.6%) of the control group. Nonetheless,
the authors recommended that urine cultures be obtained in all febrile infants with RSV
infection (Titus and Wright. 2003).
On the other hand, patients with specific viral syndromes (croup, stomatitis and
varicella) are unlikely to have an underlying bacteraemia. Greens et al retrospectively
studied young children (3-36 months) with a recognizable viral syndrome (RVS) who
had a blood culture done. Two of 876 (0.2%) cultures were positive for pathogenic
bacteria. The authors concluded that highly febrile young children with uncomplicated
RVS have a very low rate of bacteraemia and need not have blood drawn for culture
(Greenes et al. 1999). It is perhaps prudent to consider and search for SBI in febrile
infants even when a diagnosis of respiratory infection was clinically made.
xiii. l. b. Meningitis
The incidence of meningitis in the study group was 0.5%. Streptococcus
pneumoniae was isolated from the blood of a 4 month old baby with typical clinical and
cytologic appearances of bacterial meningitis, and was thus considered pneumococcal
meningitis (Shackley F, 2000). The two other patients had clinical features of
meningococcal septicaemia and meningitis, but this organism was not isolated from
CSF. Around 15% of febrile patients with purpuric rash will have meningococcal
disease and, in the presence of meningeal signs, such patients are considered to have
meningococcal meningitis even if the organism is not isolated from CSF (Wells et al.
2001). However, viruses, such as enteroviruses and adenovirus, and bacteria other than
meningococci, also can cause a non-blanching rash (Neilsen et al. 2001). Likewise,
meningococci isolated from the throat of a patient showing clinical signs of meningitis
and CSF pleocytosis would be considered the causative agent of this disease in the
absence of other pathogenic bacteria grown from CSF. This low incidence of meningitis
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might allow for a less aggressive approach in evaluating young children showing no
signs of meningitis in whom the invasive lumber puncture can be omitted.
xiii. l. c. Urinary tract infection
During the study period results of urinalysis were provided in terms of white cell
numbers per high power field. Significant pyuria was quoted as wbc >40, although
counts higher than 100 were given in absolute numbers. Colony counts of >105/ml of a
single known urinary pathogen only were considered indicative of UTI, irrespective of
the result of urinalysis. This is a more conservative definition than those used in many
other studies. In spite of this, the overall prevalence of UTI in our population (11.4%)
was high, with exceptionally high rates in female infants. However, not all febrile
children were tested for UTI and therefore the high rates of UTI could be due to
selective testing of patients thought likely to have the illness. Furthermore, the high rates
in boys below one year (9.3%) could be explained by the almost non-existence of
circumcision in the studied population. Estimates of the prevalence of UTI in febrile
children vary among studies. This is due to the variation in the definition of UTI, method
of urine collection, and eligibility criteria with inherent selection bias. Roberts et al
reported an incidence of 4.1% from bag urine in children 0-2 years old with unexplained
fever. All infections were in girls, who had a 7.4% incidence. The lower reported rate
can be explained by the more stringent criteria used in testing for and defining UTI;
Infants with symptoms or signs attributable to other organ systems were excluded, a
colony count of >10s/ml of a single organism was not considered UTI unless it was
grown from two successive urine specimens, and isolated pyuria was not considered a
urinary infection (Roberts et al. 1983). Crain et al. reported a 7.5% incidence of UTI in
febrile infants younger than 8 weeks of age, and estimated that more than half of UTI
would have been missed if normal urinalysis (<5 WBC phpf) results were used to forgo
obtaining a urine culture (Crain et al. 1990). Buys et al studied 545 febrile children of
all ages with urine collected by suprapubic aspiration and found 44 (8%) children with
bacteruria. Two thirds of the bacteruric children had abnormalities of the urinary tract,
while radiological abnormalities were found in a third of children, mainly neonates, with
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sterile pyuria {Buys et al. 1994). Shaw et al obtained catheter urine culture from all
infants younger than 12 months and girls younger than 2 years with temperature
>38.5C° without a definite source for fever. The reported overall prevalence of UTI was
3.3% with higher rates in white girls (16.1%), uncircumcised boys (8%), and those with
a history of UTI (9.3%), malodorous urine (8.6%), and abdominal tenderness (13.2%)
{Shaw et al, 1998). Bauchner et al evaluated 664 children younger than 5 years of age
presenting with an acute febrile illness and no symptoms indicating UTI. Only 11 (1.7%)
had significant bacteruria. The authors concluded that searching for silent UTI is
unwarranted in the presence of another explanation for fever {Bauchner et al. 1987).
Febrile children with viral syndromes, such as bronchioilitis, and other identifiable
sources of fever outside the urinary tract may be at low risk for UTI {Kuppermann et al.
1998, Hoberman et al. 1993). However, the presence of less well-defined potential
sources of fever, such as upper respiratory tract infection, otitis media and gastro¬
enteritis, does not exclude urinary tract infection {Shaw et al. 1998).
The incidence of bacteraemic UTI (5.1%) was comparable to the 6% incidence
of bacteraemic UTI reported by Crain. None of the infants studied by Krober et al had
bacteraemia associated with UTI. These results are different from those reported by
McCracken and Ginsburg who found a 21% incidence of bacteraemia in infants 1-2
months old with UTI {Ginsburg et al. 1982). The patients in the latter study were sick
young infants many of whom were referred by other health facilities. In a more recent
study, Pitetti and Choi reported a 22.7% incidence of bacteraemia in infants younger
than two months and 3% in those aged 2-36 months of age with UTI {Pitetti & Choi,
2002). In febrile children, bacteraemic UTI is not clinically distinguishable from, and
has comparable outcome to non-bacteraemic UTI {Honkinen et al. 2000). The goals of
treatment of acute UTI- eliminating the acute infection, preventing sepsis, and reducing
the likelihood of renal damage- are all achievable by outpatient treatment. However,
since bacteraemia in itself is an indication for hospital treatment and observation,
hospitalization is necessary if the patient has clinical sepsis or is likely to have
bacteraemia based on clinical or laboratory evaluation.
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xm. l. d. Pneumonia
Because not all patients were investigated by chest radiography, the true
prevalence of pneumonia in the study population of febrile young children cannot be
determined with certainty. It would seem that patients considered at lower risk of
pneumonia did not have a chest radiograph ordered. Patients who had a chest radiograph
done were significantly younger, looked more ill, had a higher median temperature and
respiratory rate, and were more likely to be admitted. On the other hand, while a chest
radiograph was obtained in almost all patients who had clinical signs of pneumonia, a
third of those who did not have such signs were also investigated by chest radiography.
Furthermore, pneumonia was defined more stringently than in most of other studies in
that any radiographic findings short of focal consolidation in absolute terms, were not
considered pneumonia. The prevalence of pneumonia may have been underestimated by
considering all the patients with equivocal pneumonias, e.g. patchy infiltrates, and those
who did not have a radiograph as "no pneumonia" patients- the latter would have
specifically underestimated the occurrence of occult pneumonia. Assuming that those
who did not have CXR done did not have pneumonia, the incidence of pneumonia in this
population is 17.6%. This is comparable to the 19% incidence reported by Leventhal in
febrile children of all ages (Leventhal et al. 1982). Zukin et al reported a 14% incidence
of pneumonia in children up to the age of 17 years who were evaluated with a chest
radiograph (Zukin et al. 1986). Kramer et al studied younger (3-24 months) febrile
children with chest radiographs taken at their initial visit to the emergency department.
Twenty seven percent had radiographically diagnosed pneumonia (.Kramer et al, 1992).
Patterson examined febrile young children (<2 years) with and without symptoms and
signs of LRTI by chest radiography and found parenchymal opacification in 14% of the
patients {Patterson, et al. 1990).
The incidence of bacteraemic pneumonia in this study was 2.8%. This was
similar to the findings of Hickey et al who reported a 2.7% yield of pathogenic bacteria
in paediatric patients with radiographic evidence of pneumonia {Hickey et al 1996).
Ramsay et al reported a 2% rate of positive blood culture in children, of all ages, with
acute lower respiratory tract infection {Ramsey et al. 1986). Streptococcus pneumoniae
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was the causative organism of bacteraemic pneumonia in most of the previous studies.
In our study, pneumococci were responsible for only half of bacteraemia associated with
pneumonia. E.coli was grown from blood and urine of a 3.7 month girl who had chest
crepitations and 20 white cells/mm3 in the CSF. She was discharged with a diagnosis of
pneumonia and coliform sepsis. Gram negative bacteraemic pneumonia is a highly
specific subgroup of pneumonia that occurs mainly in infants and debilitated elderly
patients and has a high mortality. The most important organism is Klebsiella, which
causes Friedlander's pneumonia. Less commonly, E. coli, pseudomonas, and other
species are implicated. A nineteen month old boy was admitted with a purpuric rash and
had physical and radiographic evidence of pneumonia. N. meningiditis was grown from
blood obtained upon admission. Primary meningococcal pneumonia is a recognized
clinical entity that is associated with pleural effusion or empyema in 15% of cases
(Eastbrook et al. 1996). Blood culture is rarely positive in patients with radiographic
pneumonia and in clinical practice its use should be individualized to those who appear
ill.
Xlll. 2. Predictors of SBI
xiii. 2. a. Clinical assessment
Patients with SBI scored higher (median 7) on the clinical assessment scale than
those without SBI (median 5). However, the score was not clinically helpful in
identifying patients with SBI: only 17% of such patients scored more than 10, compared
with 8% of those without SBI. Thus, a score higher than 10 was 17% sensitive and 92%
specific in identifying SBI. A score of >10 increased the likelihood of SBI by only 19%
over that of the pre-assessment probability. The physician's subjective assessment was
equally unhelpful. The performance of the scale in our study mirrored that reported in
recent studies. Strait et al recorded the acute illness observation score for febrile children
(0-36 months old) without an apparent focus of infection. Patients with an occult
bacteraemia had a mean score of 9 (95% CI 8-11) compared to a mean of 8 (95% CI 7-
8) for children without bacteraemia. The difference, though statistically significant
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(p=0.03), was not of clinical use in distinguishing patients with occult bacteraemia
0Strait et al. 1999). Several recent studies have demonstrated the inaccuracy of the
observation scale in identifying patients with serious bacterial infection. Kuppermann et
al studied 100 febrile children aged 2 years or younger and found no difference in the
YOS between children with documented bacterial infection and those with laboratory-
documented respiratory viral infections (.Kuppermann et al. 1999). Pulliam et al
prospectively studied febrile children 1 to 36 months of age with clinically undetectable
SBI and found them indistinguishable from those without SBI in YOS (.Pulliam et al.
2001). Similarly, young children (7 days - 36 months) with and without SBI had
comparable YOS, as reported by Galetto-Lacour et al (Galetto-Lacour et al. 2001). In a
more recent study, the same authors reported a 23% sensitivity (95% CI 5-54%) and
82% specificity (95% CI 67-92%) for a YOS >10 in predicting SBI (Galetto-Lacour et
al. 2003). In our study, the clinical score has been recorded by different physicians with
varying levels of expertise. The resulting inter-observer variability is unquantifiable and
is likely to reduce the reliability of this measurement. Furthermore, the case mix in the
emergency department resulted in inclusion of patients with severe viral illness who
looked equally sick on the parameters measured on the scale. The antipyretic given to a
large proportion (47%) of patients before being evaluated also could have altered the
physical appearance of the child and, therefore, influenced the clinical assessment.
xm. 2. c. Traditional laboratory aids
Algorithms for evaluating febrile children have commonly included WBC
although studies have shown that it is not a reliable indicator of SBI (Barraf, 2000,
Bachur et al. 2001). In our population of febrile young children the white cell and
absolute neutrophil counts, although significantly higher in patients with SBI, were not
helpful in identifying these patients. Using the commonly used cut-off value of
"5 "7
15x10 /mm , WBC was only 56% sensitive and 66% specific in detecting SBI. Theses
values are comparable to those reported in the more recent studies evaluating blood
indices. Pulliam et al reported a sensitivity and specificity of 64% and 67%,
respectively, for a WBC at >15xl03/mm3, for predicting SBI in a 1-36 months child
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population (Pulliam et al. 2001). Ayoola et al studied one-year-old African children with
a high incidence (38.2%) of bacteraemia and concluded that a WBC at a cutoff of
15xl03/mm3 would have missed 79.5% of bacteraemic infants (Ayoola et al. 2002).
Studying children with fever and a rash, Carrol et al found that WBC was higher in
children without meningococcal disease (MCD) than those with meningococcal disease
(MCD) (Carrol et al. 2002). More recently, Galletto-Lacour also demonstrated a poor
sensitivity of 52% and only fair specificity of 74% for a WBC at a cutoff of 15xl03/mm3
(Galletto-Lacour et al. 2003).
We tried, as did other workers, using different cut-off values and combinations of
indices to work out clinically useful sensitivity and specificity trade-offs, but this was
not rewarding. Bonsu et al reported a sensitivity and specificity of 45% and 78%,
respectively, for WBC at a cutoff of 15xl03/mm3 in detecting bacteraemia in febrile
young infants (<90 days). Even at a much lower cutoff of 5xl03/mm3, WBC would have
missed 21% of patients with bacteraemia {Bonsu et al. 2003). At a cut-off of
3 3
17.1x10 /mm , WBC had a 69% sensitivity and 80% specificity for occult bacterial
infection (OBI) in the study of Isaacman. The addition of CRP to the blood cell count
added little diagnostic utility {Isaacman et al. 2002). Kuppermann et al found an ANC
value of >10xl03/mm3 to be a better discriminator of pneumococcal bacteraemia than a
WBC >15xl03/mm3 {Kuppermann et al. 1998). Lee and Harper, assessing the risk of
pneumococcal bacteraemia in the post-Hib immunization era, concluded that WBC at a
cutoff of >18xl03/mm3 could lead to a safe reduction in antibiotic use {Lee & Harper,
1998). In a cost-effectiveness analysis, Lee et al estimated that, at a 1.5% rate of
bacteraemia, taking blood culture and administering antibiotics selectively at a WBC
cut-off of 15xl03/mm3 prevents 48 cases of meningitis and saves 86 life-years per
100000 patients. Lowering the WBC cutoff to 10xl03/mm3 would incur significant extra
costs per life-year saved. However, if the rate of bacteraemia declined to 0.5%, then the
strategy of CBC testing loses its cost-effectiveness {Lee et al. 2001). Bonsu and Harper
found that the odds of bacteraemia were not decreased or substantially increased at
WBC values outside published norms. The authors concluded that WBC count is an
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inaccurate screen for bacteraemia in young children, and decisions to obtain blood
culture should not rely on this test (Bonsu et al. 2003).
CRP and ESR are widely used markers of infection and inflammation; ESR is
more commonly used in the USA, while CRP is favoured in Europe. In our study, only a
few patients were tested by CRP (38%) and/or ESR (16.2%) and therefore selection bias
was more likely with these tests. Two commonly quoted cut-off values of CRP; 5 mg/dl
and 15 mg/dl were compared. At a cut-off value of 5 mg/dl, CRP was only 43%
sensitive for SBI, with a negative predictive value of 73%. Increasing the threshold to 15
mg/dl dramatically reduced the sensitivity to 12%, with marginal gains in the positive
predictive value (from 45 to 56%), and increased the likelihood of SBI by 29%. The
poor performance of CRP in early detection of bacterial infection has been attributed to
the lag in the production of CRP following injury. The increase in CRP in response to
bacterial infection occurs about 12-36 hours after the onset of clinical signs. Therefore, a
negative CRP at the initial evaluation does not rule out serious infection and cannot be
relied upon in decision making (.Mathers et al. 1987, Pourcyrous et al. 1993). The low
sensitivity of CRP found in our study was therefore not surprising, because only CRP
values obtained at the initial presentation were considered. Had serial or second day
measurements been taken, we could have seen more favourable performance of this
time-honoured test. ESR across all the conventional ranges of values was more sensitive
but less specific than CRP and did not contribute much in reducing the uncertainty about
the presence of SBI. Studies vary widely in their findings regarding the usefulness of
CRP as a marker of bacterial infection. Fernandez-Lopez reported a sensitivity and
specificity of 63.4% and 84.2%, respectively, of CRP at an optimum cut-off value of
27.5 mg/1 in identifying invasive bacterial disease in febrile children 1-36 months old
(Fernandez-Lopez et al. 2003). Pulliam et al found that CRP, at a cutoff of 7 mg/dl, was
more powerful than WBC in predicting SBI, with a sensitivity and specificity of 79%
and 91%, respectively (.Pulliam et al. 2001). Their study population was a convenience
sample of 1-36 month old febrile children, 18% of whom had SBI. Galletto-Lacour et al
studied febrile children aged 7 days to 36 months with no localizing sign of infection
and reported a 29% incidence of SBI. Multilevel likelihood ratio revealed that CRP
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performed better than IL-6 and WBC indices in predicting SBI. CRP values of <40 mg/L
and >100 mg/L generated posttest probabilities for SBI of 9.7% and 86.5%, respectively.
The WBC indices only modestly changed SBI probabilities from pretest probabilities
(Galletto-Lacour et al. 2003). Gendrel et al reported a sensitivity of 98% for CRP at a
cutoff of 10 mg/1 to discriminate bacterial from viral infection. Because of the very low
cutoff, well below the mean for viral infections (19.5 mg/1), the reported specificity was
only 50%. IL-6 was more specific than CRP for bacterial infection (Gendrel et al. 1999).
Isaacman et al studied the utility of CRP for detection of occult bacterial infection in
febrile young (3-36 months) children in whom no focal abnormality was evident on
physical examination. 11.3% of 256 children had occult BI (6.6% pneumonia, 3.5%
UTI, and 1.2% with occult bacteraemia). The overall prevalence of bacteraemia was
2.1%. CRP, at an optimal cutoff of 4.4 mg/dl had a sensitivity of 63% and a specificity
of 81% for detection of occult bacteraemia. No significant difference was detected in the
distribution of CRP levels between patients presenting within 12 hours of illness onset
compared with later presentation (Isaacman et al. 2002). Fowlie and Schmidt
systematically reviewed diagnostic tests (mainly haematological indices and CRP) for
bacterial infection. The authors found enormous variation in the reported accuracy of the
tests and concluded that the current diagnostic tests, either singly or in combination,
were of limited value (Fowlie and Schmidt, 1998).
xiii. 2. d. The cytokines
Among the many cytokines tested, IL-6 and IL-8 were the most intensively
studied as markers of bacterial infection. IL-6 is widely acknowledged as an initiator of
the acute phase response, components of which (CRP and ESR) have long been used as
markers of bacterial infection. IL-8 is the most important chemoattractant to neutrophils
which were for long considered the wholemark of bacterial infection. These cytokines
rise at the onset of infection while CRP reaches the maximum concentration with a
noticeable delay. Patients suffering from SBI present to hospital after early
inflammatory events. The more proximal pro-inflammatory cytokines (TNF and IL-1)
were found elevated in septic patients mainly upon admission to the ICU, while IL-6 and
IL-8 concentrations were elevated throughout the inpatient period of recovery. It is
therefore not surprising that the latter were the most consistently detected cytokines in
septic patients. Furthermore, IL-6 assay is among the most sensitive cytokine assays,
with massive incremental changes observed in patients with proven bacterial infection. It
was therefore anticipated that these cytokines will more sensitively detect SBI at its
early stages, when it non-specifically presents as acute fever of unknown origin. ICAM-
1 plays a key role in trafficking neutrophils invited by invading bacteria and is therefore
expected to be elevated in bacterial infections. Soluble ICAM-1 has been shown to be a
good predictor of sepsis in neonates but its role in febrile children has not been proven.
ICAM-1 belongs to a different group of molecules involved in inflammation, is known
to have kinetics different from the pro-inflammatory cytokines and is a more distant
player in the cytokine cascade. Thus, a wider net is cast to capture markers of infection
by measuring it simultaneously with the pro-inflammatory cytokines. Conflicting
findings have been reported regarding the utility of these cytokines as markers of sepsis,
largely in severely ill patients admitted to intensive care units or in selected groups of
children with no identifiable source of an infection. Based on these considerations, IL-6,
IL-8 ans sICAM-1 were analysed in this study as predictors of SBI in an unselsected
group ofyoung febrile children.
To the limits of assay detection, IL-6 was absent in the serum of almost all
afebrile control patients. From the four controls with detectable IL-6, three probably had
some on-going inflammation, either from milk intolerance, tissue damage from
galactosaemia, or low grade kidney inflammation in the young girl with duplicated
kidneys. The presence of IL-6 in the sibling of a galactosaemic patient could not be
explained; this was possibly due to a subclinical infection. IL-6 was undetectable in the
serum of 15 (4.8%) of the febnle patients probably due to late presentation. Compared to
CRP, IL-6 is a rapidly responsive protein with a short half-life and may not remain
detectable long after the onset of infection (Panero et al. 1997, Harris et al. 1994). The
duration of fever could not be reliably ascertained in these patients. Serum IL-6 was not
useful in differentiating all SBI from more benign febrile infection and did not
significantly increase the projected probability of SBI, in general, among the studied
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population. There was no difference in serum IL-8 and IL-6 values between patients
with and without SBI. Compared to IL-6 and IL-8, serum sICAM-1 was significantly
raised in patients with SBI and independently predicted SBI in the multiple regression
model. On the other hand, both IL-6 and IL-8 were elevated in all patients with
bacteraemia and/or meningitis. It is possible that levels of IL-6 and IL-8 (in contrast to
ICAM-1, which is a more distal player in the inflammatory cytokine cascade) had waned
by the time blood was collected and persisted only in patients with pathogens circulating
in blood or localizing in the meninges after a period of bactraemia. It has been shown
that the majority of infected patients will have undetectable IL-6 concentrations 24 hours
later, and its sensitivity is therefore reduced 24 hours after the onset of infection (Ng et
al. 1997, Buck et al. 1994). Persistent elevation of ICAM-1 over a week has been
demonstrated in patients with sepsis (Sessler et al. 1995). This could be explained, in
part, by the slower kinetics and delayed shedding of the soluble adhesion molecule.
IL-6 was elevated in seven out of eight patients with bacteraemia who had the
test performed, and was highly elevated in all patients with meningitis. IL-8 was also
highly elevated in the only patient with meningitis who had the test done. IL-8, IL-6, or
both were highly elevated in all patients with bacteraemia and/or meningitis. Although
the numbers involved were too small to draw solid conclusions, it would seem that IL-6
and IL-8 are highly sensitive indicators for the more invasive forms (bacteraemia and
meningitis) of serious bacterial infections. Interestingly, these cytokines would have
detected the three bacteraemic patients discharged from the emergency room with minor
diagnoses, such as PUO with shivering, otitis media, and chickenpox. These patients
looked ill enough to have blood obtained for culture and other tests. Staph, aureus
bacteraemia in the child with infected eczema would also have been detected, with
implications for the immediate management of his condition. Obviously, the inclusion of
less well-defined illnesses, such as pneumonia, led to the overall poor performance of
these cytokines in singling out serious bacterial infections. Combining IL-8 with IL-6
could enhance the specifity of the tests for bacteraemia and meningitis. Since other
bacterial infections, such as UTI or pneumonia can be easily diagnosed by non-invasive
and easily available methods, future studies may usefully focus on the utility of these
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cytokines in the detection of bacteraemia and meningitis. By excluding equivocal
illnesses, the performance characteristics of the cytokine may be expected to improve
substantially.
Previous studies varied in the reported usefulness of these cytokines in various
situations. Among the cytokines, IL-6 is the most intensively studied new diagnostic
marker of infection, probably because of its acknowledged importance as an alarm
cytokine (Malik et al. 2003). Strait et al compared IL-6 with traditional clinical and
laboratory indicators of occult bacteraemia (2.5% incidence) in febrile non-toxic
appearing young children (0-36 months). At a cutoff of 65 pg/ml (determined from
ROC) the respective values of sensitivity, specificity, positive and negative predictive
values for IL-6 were, 88%, 70%, 7% and 99.6%. IL-6 was equivalent to ANC and
superior to WBC in predicting bacteraemia. However, there was a wide range and
overlap in IL-6 values between cases and controls evidenced by the wide confidence
interval (4.8-71.6) of the odds ratio (16.7) {Strait et al. 1999). In the study by Saladino et
al, none of 50 patients without signs of sepsis or occult bacteraemia had detectable IL-6,
whereas 10 of 11 patients with bacteriologically documented infections had detectable
IL-6, giving a sensitivity and specificity of 91% and 98% for invasive bacterial disease
{Saladino et al. 1992). Galetto-Lacour et al found IL-6 to be inferior to CRP in
predicting SBI in young febrile children without focal signs. The sensitivity and
specificity of IL-6 at a cut-off of 50 ng/L were 79% and 66%, compared to respective
values for CRJP (at a cut-off of 40 mg/1) of 89% and 75% {Galetto-Lacour et al. 2001).
In a more recent study, the same authors reported a 36% sensitivity and 80% specificity
for IL-6 >100 pg/ml in predicting SBI in a larger cohort of similar patients. The reported
sensitivity and specificity of CRP>40 mg/L were both 79% {Galetto-Lacour et al. 2003).
Gendrel et al reported 51% sensitivity and 85% specifcity for IL-6 at a cutoff oflOO
pg/ml in differentiating bacterial from viral infections. The respective values for CRP at
a cutoff of 20 mg/L were 83% and 71%. Although serum IL-6 levels were generally
lower in viral infections, some of the highest levels were in children with documented
viral infections {Gendrel et al. 1999). Other workers have found much higher levels of
serum IL-6 in certain viral infections (such as adenovirus) compared with others, such as
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RSV and influenza {Kawasaki et al. 2002). Franz et al demonstrated that IL-8 reduced
unnecessary antibiotic use in newborn infants suspected of early sepsis by 40% (Franz et
al. 2001). In the study by Galetto-Lacour et al, serum IL-8 values were comparable
between patients with and without SBI. IL-8 values were below detectable levels
(40 pg/ml) in 52% of patients with benign infection and in 25% of those with SBI
{Galetto-Lacour et al. 2001). Soluble ICAM-1 has been claimed to be a good marker for
sepsis in the neonate {Kuster et al. 1993). However, Bemer et al measured sICAM-1 in
cord blood and in plasma from babies with early onset infection and did not find any
difference from those found in healthy term babies. The poor sensitivity of sICAM-1
was explained by slower kinetics and delayed shedding of the soluble adhesion
molecule. Furthermore, plasma levels of sICAM-1 appear to be dependent on the
maturation of the immune system, because they are significantly lower in premature
infants {Berner et al. 1998).
Franz et al compared conventional and new markers of bacterial infections in
newborn infants. Different combinations of tests yielded only modest sensitivities (91%)
and specificities (73%) in predicting bacterial infection {Franz et al. 1999). Mehr et al
reviewed studies of cytokines as markers of bacterial sepsis in newborns and found that
cytokines needed to combine with CRP to offset the effects of short half-life of
cytokines and increase their accuracy. The authors concluded that data were too limited
to establish a clinical role for cytokines in neonates {Mehr et al. 2000). Hsiao and Baker
reviewed recent studies of markers of SBI in febrile children and concluded that
available data did not support the use of interleukin titres over other available indicators
of SBI {Hsiao et al. 2005). There are many factors that could affect the performance of
the cytokines and the discrepancies among studies reporting their use in predicting
invasive bacterial infection. The time course of changes among the cytokines is very
different and variable. The timing of presentation and blood collection in relation to the
onset of fever will therefore affect the serum levels of the cytokine. Antibiotics, which
are commonly prescribed and administered at the beginning of suspected infections,
have been shown to increase endotoxin and subsequently increase concentrations of
cytokines {Prins et al. 1995). The method of blood sampling itself can affect the serum
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cytokine concentrations (Mehr et al. 2000). Studies evaluating the use of cytokines as
markers of infection used a wide range of cut-off values which were unique to each
study. Furthermore, there was a wide variation in the limits of detection between assay
kits used by different studies. For instance, some studies used sensitive kits detecting
down to 0.35 pg/ml IL-6, while the limit of detection for other kits was over 50 pg/ml.
The range of reported test sensitivity (57-100%) and specificity (43-100%) was therefore
wide, with LRs ranging between 1.5 to oo (Table 35). The volume of blood required to
perform a cytokine assay (0.1-0.4 ml) does not pose a significant problem, but manual
immunoassay kits, with 2-4 hour turnover times, have so far been used thus hindering
the wide clinical application of the assays. Automated assays with fast turnaround times
are being introduced and this will greatly enhance the applicability of cytokine assays in
clinical practice. The rapidly evolving understanding of the molecular pathophysiology
of sepsis and the role of cytokines in this process coupled with technical advances in
biochemical testing, present the promise in future of more rapid and accurate diagnosis.
xiii. 2. e. The Predictive models
Currently, no single test fulfills the criteria of an ideal diagnostic investigation.
Therefore, constellations of tests are commonly used to identify bacterial infection. A
battery of laboratory tests can be ordered at the initial evaluation, either together or in a
step-wise manner. Combinations of test results are then used to make a judgment for
further management. Another approach is to construct and analyse models, derived from
clinical and laboratory data that can add to the diagnostic accuracy. Our model correctly
classified 70% of the patients to have either SBI or non-SBI illness. This leaves a third
of febrile children requiring other methods to decide upon their management. Bachur et
al constructed a model consisting of 4 clinical parameters; positive urinalysis,
WBC>20xl07mm3 or <4.1xl03/mm3, temperature >39.6°C, and age <13 days (Bachur
et al, 2001). The model had 82% sensitivity and 98.3% negative predictive value in
predicting SBI in young infants. Data were retrospectively collected (with all the
inherent bias) and sequentially entered into a decision-tree analysis. Furthermore, SBI
was strictly defined by positive culture of urine, blood, or CSF. Still, 18% of patients
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with SBI, including meningitis, were misclassified into the low risk group. Using
logistic regression on retrospectively collected data, Isaacman et al constructed a model
based on temperature, female gender, and ANC predictive of bacteraemia in febrile
children. The model marginally increased the sensitivity (by 4%) and specificity (by
15%) over those developed by the practice guidelines developed by Baraff et al.
However, the authors claim that the improvement in sensitivity and specificity represent
huge medical and economic gains when applied to the thousands of febrile children
evaluated yearly (Isaacman et al. 2000). In a more recent study, Bleeker et al found that
a prediction rule based on clinical data was insufficient in identifying SBI, and that
adding laboratory findings (WBC, CRP and urinalysis) only modestly improved the risk
estimate (Bleeker et al. 2007).
XIII. 2. f. Correlation between the parameters of SBI:
There was an insignificant negative correlation between serum IL-8 and all the
conventional indicators of bacterial infection, including temperature. This observation
has not been previously reported and has no plausible explanation. IL-6 had a moderate
positive correlation with CRP, the total WBC, and the absolute neutrophil count, and
poorly correlated with ESR. These parameters are part of the acute phase response, in
the induction of which IL-6 plays a major part. On the other hand; serum ICAM-1 had a
stronger correlation with ESR while poorly correlating with the other tests. This is
possibly due to the delayed rise of plasma fibrinogen which peaks in 24-48 hours and its
slow decline with a half line of 4-6 days, kinetics simialr to those of sICAM-1 explained
above.
xiii. 3. Strengths and limitations of the study
Not every eligible patient was enrolled. Therefore the study cannot be considered
a consecutive series for the purpose of studying the true prevalence and markers of
bacterial infection. Sampling bias may have occurred because well-appearing children
may have been discharged without performing any tests on them, while more ill-
appearing patients (who are presumably more likely to have SBI) were more likely to be
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investigated. It is not practical, or ethical, to subject all febrile children to the various
tests necessary to identify every possible cause of infection. Although illness outcome
was not part of the study, attendance at the only paediatric A&E in the region was
continuously monitored throughout the study period. Only one child, with three episodes
of pneuomococcal septicaemia and meningitis, was readmitted for a febrile illness (only
the first episode was included in the analysis). It was therefore unlikely that any serious
infection was not accounted for. Moreover, all patients fulfilling the study criteria were
traced and data available at the time of discharge collected, so the prevalence of febrile
illness is a true picture of the prevalence in the population. Factors that could potentially
affect infection rates in young children (perinatal history, underlying conditions, and
infectious exposures) were not considered in this study. These factors are usually
extracted from history and allowance made for the inherent higher pre-test probability of
SBI in evaluating these patients. There was a small number of patients with each type of
SBI, especially bateraemia and meningitis, lowering the power of the test and limiting
the ability to determine the utility of the cytokines in each type of infection. A positive
culture of normally sterile body fluids is the standard for diagnosing bacterial infection.
Obviously this is impractical to apply for every case, especially those with clinical
pneumonia. Culture can also be falsely negative either due to prior antibiotic use or
because of the low yield caused by insufficient sample volumes, especially blood. The
resultant misclassification of infected patients would markedly reduce the tests'
predictive values. It was attempted to obviate this problem by a definition of SBI that
encompassed both objective evidence of an infecting organism grown from pathological
specimens and radiographic and clinical evidence of bacterial infection. The current
study also used more strict criteria for the diagnosis of pneumonia, interpreted as
consolidation in clear terms, and UTI, which required pure growth of a pathogenic
organism. Otitis media and tonsillitis were not considered to be SBI.
In contrast to earlier studies, this study included all febrile young children regardless of
the presence or absence of a focus of infection. It has been shown that patients with focal
infection have similar incidence of SBI as those without a focus (Isaacman et al. 2000).
The study also determined the prevalence of all SBI, not limiting to occult bacteraemia.
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Furthermore, a wider age range, with different prevalence and special diagnostic
considerations and problems, was studied. The study population is therefore more
representative of real life scenarios and typical daily problems in a paediatric emergency
room. This study is the first of its kind that has determined the prevalence of SBI in a
defined population of young febrile children served by the only paediatric hospital in a
geographical region.
 
Table 35: Accuracy of Cytokines in detecting SBI in neonates and young infants*




Likelihood Ratio (95% CI)
Positive Negative
IL-6 level
Kallman et al, 1996 135 pg/ml 93 (70-99) 86 (69-94) 6.5 (2.9-16.5) 0.08 (0.01-0.35)
Messer et al, 1996 100 pg/ml 82 (52-95) 46 (39-52) 1.5 (0.95-1.86) 0.4 (0.11-1.06)
Bhatiya et al, 2000 133 pg/ml 81 (57-93) 96 (87-99) 21.5 (6.2-79.2) 0.19(0.07-0.4)
Panero et al, 1997 15 pg/ml 100 100 oo oo
Kuster et al, 1998 25 pg/ml 86 57 2 0.24
Silveira and
Procianoy, 1999
32 pg/ml 90 43 1.6 0.23




> 50 pg/ml 100 (57-100) 100 (96-100) oo oo
Franz et al, 1999 >70 ng/ml 69/80 91/87 7.7/6.2 0.34/0.23
>53 ng/ml 84/91 85/53 5.6/1.9 0.19/0.17
Franz et al, 1999 >70 ng/ml 83 76 3.5 0.22
sICAM
Kuster et al, 1998 425 ng/ml 82 79 3.9 0.23




The evaluation of febrile young children is an ever-lasting diagnostic
challenge for the clinician in a paediatric emergency room, with a great deal of
uncertainty and controversy surrounding the subsequent management of these
same children. This study has detailed the epidemiology of serious bacterial
infection in a defined population. A high rate of urinary tract infection in infants
and young children has been demonstrated. Some of these patients, and some with
bacteraemia, were considered to have minor illness at the time of discharge. Urine
testing should be part of the assessment of febrile children under two years
irrespective of their clinical diagnosis. Children with clinical diagnosis of upper
respiratory tract infection, including otitis media, should be carefully evaluated
and followed up for evidence of more serious illness. Pathogenic organisms not
covered by currently available vaccines cause a significant proportion of SBL,
including bacteraemia. These should always be considered when evaluating a
young febrile child. A high hospitalization rate for young febrile children was
demonstrated, with the potential for many unnecessary admissions. There is a
requirement for more accurate markers of serious infection to direct the cost-
effective management of these numerous patients. IL-6 and IL-8 appear to be
sensitive markers for meningitis and the potentially serious bacteraemia. High
serum DL-8 in particular is closely associated with bacteraemia and meningitis and
its absence may be considered a negative predictor. The specificity for these two
illnesses may be enhanced by the simultaneous measurement of IL-8 & DL-8.
Future larger studies may usefully focus on the utility of these cytokines in the




Appendix 1: The Acute Infant Illness Scale (Yale Observation Scale).
Observation item 1 (no/mild impairment) 3 (moderate impairment) 5 (severe impairment)
Quality of cry
Strong with normal tone
OR













Cries briefly then stops
OR
Content and not crying


























































Appendix 2: Waskerwitz bacteraemia scoring system- classification of illness.
Score Severity of illness
1 Child critically ill with localized illness
2 Child critically ill without localized illness
3 Child is sick - if sepsis work up is negative the patient can be discharged
4 Child is ill - may or may not have a localised infection and bacteraemia is
suspected
5 Child is febrile - may or may not have a localised infection, but looks well
and does not have bacteraemia
Appendix 3: Toxicity scoring in febrile children used by Schwartz et al.
Toxicity score Clinical presentation
4+
Child looks seriously ill: severe lethargy, inactivity, inattentiveness,
anorexia, apathy, weak cry.
3+
Child looks moderately ill during entire period of observation:
moderate lethargy or irritability, poor eye-to-eye contact,
diminished activity and playfulness, decreased appetite, attenuated
cry, diminished resistance to performance of painful parts of
physical examination.
2+
Child looks somewhat ill: some discernible and persistent lethargy
and irritability, diminished activity and playfulness, decreased
appetite.
1 +
Child looks mildly ill at times but has intermittent periods of
alertness, playfulness, interest in other people, and enough strength
to resist otoscopic and intraoral examination.
0
Child generally alert, active, playful, interested in other people,




Appendix 4: The study protocol
Prediction of Serious Bacterial Infection Study: Protocol.
Subjects:
Children aged 5 years or younger who present to the accident and emergency department
with a temperature of 38.5°C or more will be included in the study. The patients will be
managed in the usual way according to the discretion of the physician attending the
patient. Informed written consent will be collected from the parents.
The following data will be collected on specially designed forms:
• Date of birth and sex
• Date and time of attendance
• Source of referral
• Presenting complaint and other symptoms
• Clinical assessment score {on a specialform)
• History of chronic illness (including perinatal complications)
• Current medication (e.g. steroids or non-steroidal antiinflammatory drugs)
• Recent antibiotic treatment (within the last 48 hours)
• Recent immunization (within the last 48 hours)
• Temperature (axillary) and vital signs
• Physical examination findings
• Provisional (working) diagnosis
• Investigations requested and their results
• Type of infection (bacterial/non-bacterial)
• Antibiotic treatment administered
• Disposition and follow up arranged
The following investigations will be performed, at the discretion of the physician or as
per existing A&E policy, on all eligible consenting patients:




• An extra ml of blood will be collected to be processed for later determination of
serum cytokines levels.
Control group:
This will consist of the children attending the out-patient department from whom blood
is being drawn for any reasons. Any child (but see attached exclusion criteria) can be
included and informed written consent should be obtained from the parents. 1-2 ml of
blood will be collected and processed as above.
The following investigations will be done:
• Interlekin-6 (IL-6)
• Interlekin-8 (IL-8)
• Soluble Intercellular Adhesion Molecule-1 (sICAM-1).
The following data will be gathered from this group:
• Date of birth
• Date of attendance
• Sex
• Reason for blood drawing (investigation performed)
• Medical condition (diagnosis)
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Appendix 5: The Clinical Assessment Form
Prediction of Serious Bacterial Infection Study
Clinical assessment form.
"Please fill in this form before you do systemic examination of the child"
Patient's name: RC Date / Time
Score (degree of impairment)
Normal Moderate Severe
History
Appetite Normal Not his/her usual Hardly eating or
drinking
Activity Normal Decreased Inactive/refuses to
play
Easiness to console Normal Responds intermittently Inconsolable
Observation
Quality of cry/vocalisation Strong/content & not
crying
Weak Moaning/high pitched
Irritability Not irritable Irritable on handling Irritable
Social response/eye
contact/smile
Smiles/alerts Brief smile or response No smile/dull,
anxious face
Physical examination
Colour/peripheral perfusion Pink Pale extremities Pale/mottled/cyanosed






Severity of illness Mild Moderate Severe
Possibility of SBI Unlikely Equivocal Strong
* Feel free to use your discretion in assigning scores according to the age and
developmental stage of the child.
* Please also note that some historical and observational parameters are inter¬
changeable.
* Serious Bacterial Infection (SBI) is bacteraemia or septicaemia, UTI, pneumonia,
osteomyelitis or arthritis, meningitis or gastro-enteritis of bacterial aetiology.
Designation of the examining physician: SHO ( 1 ) Reg (2 ) Staff Grade ( 3 )
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